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Abstract 
 
Human trypanosomiasis is a group of neglected tropical diseases caused by 
protozoan parasites of the genus Trypanosoma. Trypanosoma brucei is responsible for 
sleeping sickness, also called African trypanosomiasis, while Trypanosoma cruzi causes 
Chagas disease, or American trypanosomiasis. Together, they are responsible for 
significant mortality, morbidity and lost productivity in the endemic regions. There are no 
vaccines for these diseases, and treatments rely on drugs with limited efficacy, high cost, 
serious side effects and long administration periods. Since these diseases affect mostly the 
poor, there is no economic interest in the development of new drugs by pharmaceutical 
companies, and hopes for new treatments rely on public initiatives, public-private 
partnerships or philanthropic programs. 
The first steps in the discovery of new drugs involve the identification of active 
molecules as starting points for further development, by either employing whole cells or 
specific molecular targets screenings. This thesis sought to exploit both strategies in the 
search for new molecules for trypanosomiasis drug discovery, with a focus on Chagas 
disease, one of the most neglected tropical diseases in the world. 
Employing a phenotypic-based high-content approach on T. cruzi parasites infecting 
mammalian cells, it was possible to identify active and selective compounds among a 
chemical library composed of 4000 kinase/phosphatase-like inhibitors. Besides, a 
phenotypic profiling assay allowed the identification of a set of molecules able to interfere 
with the intracellular development of T. cruzi parasites. Using this phenotypic approach, it 
was also evaluated whether the efficacy of the racemic nifurtimox mixture could be 
improved by the separation of individual R- and S-enantiomers with different potency, 
toxicity or pharmacokinetic properties in various lineages of T. cruzi. However, no 
differences were found between isomers. 
Silent information regulator 2 (Sir2) proteins, also called sirtuins, are a class of 
NAD+-dependent deacetylases conserved through evolution and present in all domains of 
life, from archaea to mammals. They are involved in many important functions such as gene 
silencing, DNA repair, longevity, metabolism, and others. Two homologues have been 
described in T. cruzi: a cytosolic Sir2 related protein 1 (TcSir2rp1) and a mitochondrial Sir2 
related protein 3 (TcSir2rp3). A target-based drug discovery strategy was employed to 
characterize and evaluate the potential of TcSir2rp1 inhibitors as novel drugs for Chagas 
disease. It was found that T. cruzi Sir2rp1 has NAD+-dependent deacetylase activity. This 
activity was inhibited by nicotinamide, a classic sirtuins inhibitor. In addition, some 
bisnaphthalimidopropyl (BNIP) derivatives previously shown to inhibit the Leishmania 
Abstract 
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infantum orthologue (LiSir2rp1) also inhibited TcSir2rp1. Besides, they were active against 
intracellular amastigotes. The strongest inhibitor and most selective compound, BNIPSpd, 
was tested in an in vivo mouse model for Chagas disease but was ineffective in controlling 
the infection. 
The potential of BNIPs as active molecules against T. brucei was also evaluated. 
One of the derivatives, BNIPDabut, is a potent inhibitor of in vitro growth of T. brucei 
bloodstream forms, although this activity is unlikely to be mediated by T. brucei Sir2rp1 
inhibition, as demonstrated by biochemical assays. BNIPDabut had a strong in vivo 
antiparasitic activity in a mouse model of African trypanosomiasis, but without achieving 
cure. Nevertheless, BNIPDabut should be considered a scaffold for further development.  
 
 
 
 
 
Keywords: Trypanosoma cruzi, Trypanosoma brucei, drug discovery, Sir2, 
bisnaphthalimidopropyl derivatives.
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Resumo 
 
A tripanossomíase Humana é um grupo de doenças tropicais negligenciadas 
causada por parasitas protozoários do género Trypanosoma. O Trypanosoma brucei é 
responsável pela doença do sono, também chamada tripanossomíase Africana, enquanto 
o Trypanosoma cruzi causa a doença de Chagas, ou tripanossomíase Americana. 
Conjuntamente, são responsáveis por uma mortalidade e morbilidade significativa e por 
uma perda de produtividade nas regiões endémicas. Não existem vacinas para estas 
doenças, e o seu tratamento depende de fármacos com eficácia limitada, custo elevado, 
graves efeitos secundários e longos períodos de administração. Uma vez que estas 
doenças afetam maioritariamente populações pobres, não existe interesse económico das 
companhias farmacêuticas em desenvolver novos fármacos, e a esperança de novos 
tratamentos recaem em iniciativas públicas, parcerias público-privadas ou programas 
filantrópicos. 
 As etapas iniciais na descoberta de novos fármacos envolvem a identificação de 
moléculas ativas como base de desenvolvimento adicional, seja pela seleção contra células 
totais, ou contra alvos moleculares específicos. Esta tese procurou explorar ambas as 
estratégias na procura de moléculas para a descoberta de fármacos para a 
tripanossomíase, com foco na doença de Chagas, uma das mais negligenciadas doenças 
tropicais. 
A abordagem fenotípica baseada em células mamíferas infetadas pelo parasita T. 
cruzi levou à identificação de compostos ativos e seletivos originários de uma biblioteca de 
compostos químicos constituída por inibidores de enzimas cínase e fosfatase. 
Adicionalmente, um ensaio de caracterização fenotípica permitiu a identificação de um 
conjunto de moléculas capazes de interferir com o desenvolvimento intracelular do parasita 
T. cruzi. Usando esta abordagem fenotípica foi também avaliado se a eficácia da mistura 
racémica do nifurtimox poderia ser melhorada através da separação individual dos R- e S-
enantiómeros possuindo diferente potência, toxicidade ou características farmacocinéticas 
em diferentes linhagens de T. cruzi. Contudo, não foram verificadas diferenças entre os 
isómeros. 
As proteínas pertencentes à família “Silent information regulator 2” (Sir2), também 
chamadas sirtuínas, são uma classe de enzimas com atividade desacetilase dependente 
de NAD+ conservadas ao longo da evolução e presentes em todos os domínios da vida, 
desde as archaea até aos mamíferos. Estão envolvidas em várias funções importantes 
como o silenciamento genético, a reparação de DNA, longevidade, metabolismo, entre 
outras. Duas proteínas homólogas foram descritas em T. cruzi: a Sir2 “related protein 1” 
Resumo 
xvi 
(TcSir2rp1) citosólica e a Sir2 “related protein 3” (TcSir2rp3) mitocondrial. Uma estratégia 
de descoberta de fármacos baseada em alvos moleculares foi aplicada para caracterizar e 
avaliar o potencial de inibidores da TcSir2rp1 como novos fármacos para a doença de 
Chagas. Foi demonstrado que a Sir2rp1 de T. cruzi possui atividade desacetilase 
dependente do NAD+. Esta atividade foi inibida pela nicotinamida, um inibidor clássico das 
sirtuinas. Adicionalmente, alguns derivados do bisnaftalimidopropilo 
(bisnaphthalimidopropyl, BNIP) anteriormente caracterizados como inibidores da proteína 
ortóloga de Leishmania infantum (LiSir2rp1), também inibiram a proteína TcSir2rp1. Para 
além disso, os derivados foram ativos contra a amastigotas intracelulares. O inibidor mais 
potente contra a enzima e seletivo contra amastigotas, o BNIPSpd, foi testado num modelo 
in vivo de doença de Chagas em ratinho, mas foi ineficiente no controlo da infeção. 
 O potencial dos BNIPs como moléculas ativas contra T. brucei também foi avaliado. 
Um dos derivados, o BNIPDabut, demonstrou ser um potente inibidor do crescimento in 
vitro das formas sanguíneas do T. brucei apesar de esta atividade não ser mediada pela 
inibição da atividade enzimática da Sir2rp1 do parasita. O BNIPDabut possuiu forte 
atividade antiparasitária in vivo num modelo animal de ratinho de tripanossomíase Africana, 
mas sem cura total. Contudo, o BNIPDabut deverá ser considerado uma estrutura química 
líder para desenvolvimento adicional. 
 
 
 
 
 
Palavras-chave: Trypanosoma cruzi, Trypanosoma brucei, descoberta de fármacos, Sir2, 
derivados do bisnaftalimidopropilo.
Table of contents 
xvii 
Table of contents 
 
Author’s declaration.......................................................................................................... vii 
Acknowledgments .............................................................................................................xi 
Abstract ........................................................................................................................... xiii 
Resumo............................................................................................................................xv 
Index of Figures .............................................................................................................. xxi 
Abbreviations List .......................................................................................................... xxiii 
 
PART I – Trypanosoma cruzi and Chagas disease ........................................................... 1 
1.1. History and discovery ................................................................................................. 3 
1.2. The species of Trypanosoma cruzi ............................................................................. 5 
1.3. Trypanosoma cruzi biology and unusual features ....................................................... 6 
1.3.1. Genome and gene expression ................................................................................. 6 
1.3.2. Kinetoplast .............................................................................................................. 7 
1.3.3. Glycosome .............................................................................................................. 8 
1.3.4. Trypanothione metabolism ...................................................................................... 9 
1.3.5. Additional biologic features ...................................................................................... 9 
1.4. Life cycle .................................................................................................................. 10 
1.5. Epidemiology ............................................................................................................ 12 
1.6. Transmission of Chagas disease .............................................................................. 13 
1.6.1. Routes of infection ................................................................................................. 13 
1.6.2. Vectors .................................................................................................................. 14 
1.6.3. Reservoirs ............................................................................................................. 15 
1.7. Clinical manifestations .............................................................................................. 16 
1.8. Host-parasite interactions ......................................................................................... 18 
1.8.1. Innate and adaptive immunity in T. cruzi infection ................................................. 18 
1.8.2. Evasion of the immune response........................................................................... 19 
1.9. Diagnosis ................................................................................................................. 20 
 
PART II – Control of Chagas disease .............................................................................. 23 
2.1. Vectorial control........................................................................................................ 25 
2.2. Therapies for Chagas disease .................................................................................. 26 
Table of contents 
xviii 
PART III  – Sirtuins: novel targets for parasitic diseases? ............................................... 47 
3.1. Histone deacetylases and the class of sirtuins ......................................................... 49 
3.2. Enzymatic activity of sirtuins .................................................................................... 50 
3.2.1. NAD+-dependent deacetylase activity ................................................................... 50 
3.2.2. ADP-ribosylation activity ........................................................................................ 50 
3.2.3. Other functions ...................................................................................................... 51 
3.3. Structural features .................................................................................................... 51 
3.4. Known members of the sirtuin family ........................................................................ 53 
3.4.1. Yeast Sir2 ............................................................................................................. 53 
3.4.2. Mammalian sirtuins ............................................................................................... 53 
3.4.3. Protozoan sirtuins ................................................................................................. 57 
3.4.3.1. Plasmodium spp. ................................................................................................ 57 
3.4.3.2. Leishmania spp. ................................................................................................. 58 
3.4.3.3. Trypanosoma brucei........................................................................................... 59 
3.4.3.4. Trypanosoma cruzi ............................................................................................. 60 
3.5. Modulation of sirtuin activity ..................................................................................... 61 
 
PART IV – Objectives and results ................................................................................... 65 
4.1. Scope of the thesis................................................................................................... 67 
4.2. Results ..................................................................................................................... 69 
4.2.1. Phenotypic drug discovery .................................................................................... 69 
4.2.1.1. High-content screening assays for Chagas disease drug discovery ................... 69 
4.2.1.2. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma cruzi 
activity, toxicity, or pharmacokinetic properties ............................................................... 93 
4.2.1.3. Synthesis of new 7-aryltioetherthieno[3,2-b]pyridines bearing arylamides or 1,2,3-
triazoles 1,4-disubstituted and evaluation of their antiparasitic activity against Leishmania 
infantum, Trypanosoma brucei and Trypanosoma cruzi .................................................. 97 
4.2.1.4. Exploiting the antiparasitic activity of naphthalimides derivatives.......................107 
4.2.2. Target-based drug discovery ................................................................................113 
4.2.2.1. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs against 
Chagas disease .............................................................................................................113 
4.2.2.2. Activity of bisnaphthalimidopropyl derivatives against Trypanosoma brucei ......155 
 
PART V – Discussion and conclusions ..........................................................................177 
5.1. Trypanosomiasis disease control: the missing piece ...............................................179 
Table of contents 
xix 
5.2. Phenotypic-based drug discovery: a viable approach ............................................. 180 
5.3. Target-based drug discovery: is Sir2 a potential drug target in Trypanosoma cruzi?
 ...................................................................................................................................... 183 
5.4. Naphthalimide derivatives: sirtuin inhibitors with trypanocidal activity ..................... 186 
5.5. Phenotypic drug discovery versus target-based drug discovery: which strategy comes 
ahead? .......................................................................................................................... 189 
 
PART VI – Annexes ...................................................................................................... 195 
6.1. Generation of molecular tools for essentiality evaluation of Sir2 related protein 1 from 
Trypanosoma cruzi ........................................................................................................ 197 
 
PART VII – References ................................................................................................. 203 
 
 xx 
 
 
 
 
Index of figures 
xxi 
Index of Figures 
 
Figure 1. Historical features of Chagas disease. A) Dr. Carlos Chagas, the discoverer of 
the disease. B) Etiologic agent of Chagas disease, Trypanosoma cruzi. C) Natural 
transmission vector of the parasite, triatomines. D) Brazilian 10,000 cruzados bank note in 
honor of Carlos Chagas. [Adapted from [10-12]]. .............................................................. 4 
 
Figure 2. Phylogenetic tree of trypanosomes based on simple sequence repeats DNA 
showing the geographical distribution and variety of hosts trypanosomes parasitize. 
[Adapted from [12]]. ........................................................................................................... 6 
 
Figure 3. Schematic representation of Trypanosoma cruzi life cycle stages. A) 
Epimastigotes. B) Trypomastigote. C) Amastigote. [Adapted from [31]]. ............................ 8 
 
Figure 4. Representation of Trypanosoma cruzi digenetic life cycle between a triatomine 
and a human host. [Adapted from [64]]............................................................................ 11 
 
Figure 5. Global geographic distribution of Chagas disease. [Adapted from [75]]. .......... 13 
 
Figure 6. Correlation between parasite load and disease severity over time in Chagas 
disease. [Adapted from [108]]. ......................................................................................... 17 
 
Figure 7. Ribbon representation of the yeast Sir2 in complex with an acetyl-ribosyl-ADP-
intermediate. The zinc binding site is represented in light blue and the NAD+-binding 
Rossman fold in orange. [Adapted from [215]]. ................................................................ 52 
 
Figure 8. Molecular mechanism of sirtuin NAD+-dependent deacetylation. [Adapted from 
[220]]. .............................................................................................................................. 53 
 
Figure 9. Representation of the seven mammalian sirtuins regarding their sub-cellular 
localization and attributed biological roles. [Adapted from [294]]...................................... 57 
 
Figure 10. Chemical structures of sirtuin modulators: A) Resveratrol; B) SRT1720; C) 
Sirtinol; D) Salermide; E) Sambinol; F) Splitomycin; G) Suramin. .................................... 63 
 
 xxii 
 
 
 
 
 
Abbreviations List 
xxiii 
Abbreviations List 
 
ADP – Adenosine Diphosphate 
BNIP – BisNaphthalImidoPropyl 
BSA – Bovine Serum Albumin 
cDNA – complementary DNA 
CDS – Coding Sequence 
DALY - Disability-Adjusted Life Year 
DNA – DeoxyriboNucleic Acid 
DNDi – Drugs for Neglected Diseases initiative 
DTU – Discreet Typing Unit 
ELISA - Enzyme-Linked ImmunoSorbent Assay 
FDA – Food and Drug Administration (American) 
GPI – GlycosylPhosphatidylInositol 
HAT – Human African Trypanosomiasis 
HDAC – Histone DeACetylase 
HTS – High-Throughput Screening 
HYG – HYGromycin phosphotransferase 
IFA – ImmunoFluorescent Antibody assay 
Ig – Immunoglobulin 
IGF-1 – Insulin-like Growth Factor-1 
KAT – Lysine AceTyltransferase 
kb – kilobase 
KDAC – Lysine DeACetylase 
kDNA – kinetoplast DNA 
LaSir2rp1 – Leishmania amazonensis Sir2 related protein 1 
LiSir2rp1 – Leishmania infantum Sir2 related protein 1 
LIT – Liver Infusion Tryptose 
LmSir2rp1 – Leishmania major Sir2 related protein 1 
MHC – Major Histocompatibility Complex 
MMS – Methyl MethaneSulfonate 
mRNA – messenger RNA 
mTORC1 – mammalian Target Of Rapamycin Complex 1 
NAD+ - Nicotinamide Adenine Dinucleotide 
NADP – Nicotinamide Adenine Dinucleotide Phosphate 
NEO – Neomycin phosphotransferase 
Abbreviations List 
xxiv 
NES – Nuclear Export Signals 
NK – Natural Killer 
NLS – Nuclear Localization Signals 
NO – Nitric Oxide 
NOAEL – No Observed Adverse Effect Level 
OAADPr – 2’-O-acetyl-ADP-ribose 
PAC – Puromycin N-ACetyltransferase 
PAHO – Pan American Health Organization 
PCR – Polymerase Chain Reaction 
PfEMP1 – Plasmodium falciparum Erythrocyte Membrane Protein 1 
PfSir2A – Plasmodium falciparum Sir2 A 
PfSir2B – Plasmodium falciparum Sir2 B 
PTM – Post-Translational Modification 
rDNA – ribosomal DNA 
RNA – RiboNucleic acid 
RNAi – RNA interference 
ROS – Reactive Oxygen Species 
rRNA – ribosomal RNA 
Sir2 – Silent information regulator 2 
SM – Selection Marker 
T(SH)2 – dihydrotrypanothione 
TbSir2rp1 – Trypanosoma brucei Sir2 related protein 1 
TbSir2rp2 – Trypanosoma brucei Sir2 related protein 2 
TbSir2rp3 – Trypanosoma brucei Sir2 related protein 3 
TcSir2rp1 – Trypanosoma cruzi Sir2 related protein 1 
TcSir2rp3 – Trypanosoma cruzi Sir2 related protein 3 
TCT – Tissue Culture Trypomastigotes 
TS – Trans-Sialidase 
TS2 – trypanothione disulfide 
TSA – TrichoStatin A 
UTR – UnTranslated Region 
WHO – World Health Organization 
wt – wild type 
 
 1 
 
 
 
 
 
 
 
PART I 
– Trypanosoma cruzi and Chagas disease 
 
 
  
 2 
 
 
 
 
Part I – Trypanosoma cruzi and Chagas disease 
3 
1.1. History and discovery 
 
Paleoparasitological studies on mummies found in the north of Chile and southern 
Peru have proven that infection of humans by Trypanosoma cruzi goes back at least 9000 
years [1]. The presence of the parasite itself largely pre-dates the arrival of humans to the 
American continent, some 15,000 years ago [2]. It is thought that the contact with humans 
first occurred when the early American nomadic people living a hunter-gathering lifestyle 
settled in valley and coastal regions of what is today the Atacama desert. The Chinchorros, 
as this people are known, probably perturbed the long established local sylvatic cycle of T. 
cruzi and thus were in the origin of human-vector transmission responsible for domestic 
cycle observed to our day. Deoxyribonucleic acid (DNA) analysis in more recent mummies 
and also in human remains from the Columbian era indicates that Chagas disease has been 
affecting human beings since then [1]. Probably the first clinical description of the disease 
was done by modern time physicians practicing in South America, like the Portuguese Luís 
Gomes Ferreira who described in 1735 the “bicho” disease characterized by an enlarged 
rectum, or the “mal de engasgo” (swallowing malady) in which patients had difficulties 
swallowing food [3]. These are probably accounts of the symptoms caused by the 
megavisceras characteristic of the chronic infection with T. cruzi. Charles Darwin, who has 
travelled to South America in 1835 describes a famous encounter with what was, at the time 
unknown for him, a vector species of the parasite. The journal entry for the episode reads: 
“The night I experienced an attack (for it deserves no less a name) of the Benchuca (a 
species of Reduvius) the great black bug of the Pampas. It is most disgusting to feel soft 
wingless insects, about an inch long, crawling over one’s body. Before sucking, they are 
quite thin, but afterwards became round and bloated with blood, and in this state they are 
easily crushed. One which I caught at Iquique was very empty. When placed on a table, 
and though surrounded by people, if a finger was presented, the bold insect would 
immediately draw its sucker, make a charge, and if allowed, draw blood. No pain was 
caused by the wound. It was curious to watch its body during the act of sucking, as it 
changed in less than ten minutes, from being as flat as a wafer to a globular form” [4]. 
It was not, however, until the pioneering work of Carlos Chagas (Figure 1 A) that the 
disease was fully characterized and understood [5]. The discovery happened in 1909 when 
Carlos Chagas, was sent on a campaign to provide aid as a malariologist to the workers 
constructing a new railroad in Lassance, Minas Gerais, Brazil. There one of the workers 
presented him with bugs that were biting them during the night, sucking blood, preferably in 
the area of the face. While examining one of these insects he detected trypanosome-like 
flagellated microorganisms, which he called Trypanosoma cruzi in honor of his mentor, 
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Oswaldo Cruz [5]. He then sent some of these insects to a research institute in Manguinhos, 
Rio de Janeiro, where they were allowed to bite monkeys. After about 30 days, the animals 
developed disease and had trypanosomes in their blood [5]. Carlos Chagas then returned 
to Lassance and started examining children with febrile symptoms. In one of them he found 
circulating trypanosomes with similar morphology to the ones in the blood of the monkeys, 
thus confirming the parasite was causing disease. Besides, he also describes finding 
circulating trypanosomes in a cat, suggesting they could be acting as domestic reservoirs 
[5]. 
Carlos Chagas was a brilliant physician and scientist. All by himself, he discovered 
the etiological agent (Figure 1 B), the transmitting vector (Figure 1 C), described the full life 
cycle and the main disease characteristics, as we know them today, in a period of just 5 
months. In contrast, other parasitic diseases took years or decades to be completely 
elucidated, as well as more than one personality [6-8]. Although Carlos Chagas notable 
work was not awarded a Noble Prize (he was nominated two times) like some of his 
contemporary parasitologists, the Brazilians decided to honor him by printing bills with his 
image and his work, in one of those rare occasions where a biologist appears in a bank 
note (Fig. 1 D). Other names have been since then associated with the disease due to 
important discoveries, like Salvador Mazza that described the first case and the incidence 
of Chagas disease in Argentina [9], or his disciple Cecilio Romaña that gives the name to 
the characteristic Romaña sign but also many others that contributed to the present 
knowledge of T. cruzi and Chagas disease. 
 
 
Figure 1. Historical features of Chagas disease. A) Dr. Carlos Chagas, the discoverer of the 
disease. B) Etiologic agent of Chagas disease, Trypanosoma cruzi. C) Natural transmission 
vector of the parasite, triatomines. D) Brazilian 10,000 cruzados bank note in honor of Carlos 
Chagas. [Adapted from [10-12]]. 
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1.2. The species of Trypanosoma cruzi 
 
Trypanosomes are early branching eukaryotes from the order Kinetoplastida, family 
Trypanosomatidae. They developed a very successful parasitism of all vertebrate animals, 
including fish, amphibians, birds, reptiles and mammals [13]. Moreover, they can be found 
in all the geographic areas of the globe [13] (Figure 2). All trypanosomes have a 
characteristic morphology in the vertebrate host bloodstream and their characteristic 
corkscrew-like motion was in the origin of their name, from the Greek trypano (drill, borer) 
and soma (body). The vast majority of trypanosomes are transmitted by arthropods, mostly 
insects [14].  
The evolutionary origin of T. cruzi in particular, has been a topic of much debate. 
The first major theory, and the one widely accepted until recently, was the supercontinent 
theory. According to this hypothesis, the T. cruzi clade evolved separately from other African 
trypanosome (like the T. brucei clade) when the supercontinent formed by present day 
Antarctica, South America and Australia separated from Africa. Like many species in this 
continent, for example, primates, trypanosomes then began a distinct evolutionary process. 
This theory was supported by studies analyzing 18S ribosomal RNA (rRNA) suggesting that 
the clade to which T. cruzi belongs, the stercorarian trypanosomes (i.e. those transmitted 
by fecal contamination) has separated from salivarian Trypanosomes (i.e. those transmitted 
by bites, like the T. brucei clade) around 100 million years ago [15]. However, some 
discoveries have challenged this hypothesis. One of them is the apparent low diversity of 
species that does not seem to reflect at least 40 million years of independent co-evolution. 
In fact, no bona fide species of T. cruzi clade has been described to date. Another fact has 
been the detection of trypanosomes belonging to the clade of T. cruzi in the African 
continent [16]. Both pieces of evidence have questioned the validity of the continent 
isolation theory. 
The hypothesis that is currently accepted is called the “bat seeding theory”. It 
considers that the common ancestor of the parasites belonging the T. cruzi clade was a bat 
trypanosome that diversified and spread geographically. Some of these trypanosomes 
subsequently switched from bats to terrestrial mammals, probably facilitated by an 
invertebrate vector that would feed on both hosts, and in one of these switches the T. cruzi 
species evolved. The theory is supported by the fact that the closest species of T. cruzi is 
Trypanosoma marinkellei found in South American bats [13] followed by Trypanosoma 
erneyi recently described in Mozambique, Africa [17] and by Trypanosoma dionisii found in 
bats both in the New and the Old World [18]. 
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Figure 2. Phylogenetic tree of trypanosomes based on simple sequence repeats DNA showing the 
geographical distribution and variety of hosts trypanosomes parasitize. [Adapted from [13]]. 
 
1.3. Trypanosoma cruzi biology and unusual features 
 
1.3.1. Genome and gene expression 
 
Although some characteristics had already been elucidated in the pre-genomic 
years, only after the completion of genomes sequencing of T. cruzi, T. brucei and 
Leishmania major, it was possible to characterize the full extent the particularities of the 
genomes of trypanosomatids [19-21]. The sequenced strain of T. cruzi (CL Brener), has a 
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diploid genome size of about 110 Mb, with an estimated haploid gene number of 12,000 
[19]. Because of the highly repetitive coding material of T. cruzi, accounting for about 50% 
of its genome, the chromosome assembly was not possible at the publication of the 
genome, and was later estimated to be 41 chromosomes [22].  
Gene expression in kinetoplastids is polycistronic, a reminiscence of bacterial 
operons. Most protein-coding genes are organized in unidirectional, densely packed 
regions separated by strand switch regions. Transcription results in long strands of 
ribonucleic acids (RNA) containing 20 or more protein-coding genes that are not necessarily 
related. These molecules are afterwards subject to trans-splicing and polyadenylation, the 
former being a mechanism originally discovered in trypanosomes [23, 24]. This process of 
trans-splicing involves adding the same 39 nucleotide cap to the 5’ end, called splice leader, 
to every mature messenger RNA (mRNA) in the cell. Unlike other eukaryotes, and because 
kinetoplastids do not possess introns, there is no cis-splicing, with the exception of four 
defined situations [21]. As a consequence of transcription’s nature, the lack of evidence for 
differential regulation of RNA polymerase II and no identifiable RNA polymerase II promoter 
consensus sequence, gene expression regulation in trypanosomes is thought to be post-
transcriptional [19]. The genes for most trypanosomal proteins are constitutively expressed 
in the different stages, nonetheless mRNA levels coming from the same polycistronic unit 
can vary significantly, suggesting an active control of mRNA half-life. Such a mechanism is 
essential to provide a fast adaptation, morphology modifications, surface composition and 
biochemical alterations necessary for the stage differentiations the parasite undergoes.  
 
 
1.3.2. Kinetoplast 
 
Kinetoplastidea have a single and highly ramified mitochondria containing a disk-
like structure known as the kinetoplast. This structure is formed by a giant network of 
interlocked kinetoplast DNA (kDNA) rings resembling medieval chainmail [25]. These kDNA 
rings are called minicircles, of about 0.5 to 2.5 kilobases (kb) in size, and maxicircles, of 
about 20 to 40 kb, and exist in numbers of several thousands and a few dozen, respectively. 
Genes codified by the minicircles in kDNA are involved in a process firstly described in 
trypanosomes called RNA-editing. In this process, minicircles encode for guide RNAs that 
modify the products transcribed by maxicircles into functional mRNAs, in a process that 
inserts or deletes uridilate nucleotides [26]. RNA editing was later found to be also present 
in higher eukaryotes [27]. Maxicircles encode for transcripts similar in structure and function 
to those of mitochondrial DNA of higher eukaryotes, like rRNA and subunits of the 
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respiratory complexes [26]. Although kDNA seems to be essential for the completion of the 
digenetic life cycle of trypanosomes, it is noteworthy, however, that dyskinetoplastic 
trypanosomes can be found naturally, like a small portion of Trypanosoma evansi 
populations [28], or can be produced in the lab by chemical [29] or genetic manipulation 
[30, 31].  
 
 
Figure 3. Schematic representation of Trypanosoma cruzi life cycle stages. A) Epimastigotes. B) 
Trypomastigote. C) Amastigote. [Adapted from [32]]. 
 
1.3.3. Glycosome 
 
The glycosome is a characteristic organelle of trypanosome that seems to be a 
specialized form of peroxisomes, with similar biogenesis mediated by peroxins, of which 
there are more than 20 proteins [33]. The organelle contains enzymes of the glycolytic 
pathway that are usually found in the cytosol [34]. Thus, glycolysis in trypanosomes is bi-
compartmentalized. The reason seems to be related with the fact that trypanosomes do not 
possess a mechanism of feedback inhibition by allosteric regulation like other eukaryotes, 
and must rely on the compartmentalization of relevant enzymes to prevent toxic 
accumulation of metabolic intermediates [35]. Additionally, it has been found that 
glycosomes possess many other enzymes required for other biosynthetic pathways, like 
peroxide metabolism, de novo pyrimidine biosynthesis and ergosterol biosynthesis [34]. 
Since the glycosome does not possess a genome, all the proteins it contains must be post-
translationally imported from the cytosol [36, 37]. Proper biogenesis of glycosomes as well 
as the correct importing of glycolytic enzymes is essential to parasite survival [38]. 
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1.3.4. Trypanothione metabolism 
 
In trypanosomes, like in any living organism, the homeostasis of redox equilibrium 
is affected by excessive reactive oxygen species (ROS) and nitrogen species coming from 
metabolism or the environment. The regulation of this intracellular redox state is mediated 
by thiol groups in proteins and low molecular mass compounds that act as redox buffers 
[39]. 
Whereas most organisms utilize glutathione and glutathione reductase as their 
major thiol-dependent mechanism, trypanosomes utilize a distinct system based on 
trypanothione and trypanothione reductase [40]. In T. cruzi, trypanothione is synthetized 
from one molecule of spermidine and two molecules of glutathione, in a reaction catalyzed 
by a single enzyme, trypanothione synthetase [41]. The active molecule 
dihydrotrypanothione T(SH)2 is a strong reducing agent, and upon reaction with oxidative 
species, is oxidized to trypanothione disulfide (TS2). Trypanothione reductase is responsible 
for reducing TS2 back to active T(SH)2 and thus maintaining an adequate pool of this 
antioxidant defense [42]. Although glutathione reductase and trypanothione reductase have 
a high protein homology, the latter is highly selective and is not able to use glutathione [43]. 
The intracellular role of trypanothione in trypanosomes is related with the delivery of 
electrons for the synthesis of DNA precursors in conjunction with the detoxification of 
hydroperoxides and is also important for other trypanothione dependent pathways [44]. 
Most of the enzymes in the trypanothione have been described as essential, and generated 
a high interest for the development of selective inhibitors as potential chemotherapeutics 
[45]. 
 
 
1.3.5. Additional biologic features 
 
Trypanosomes also possess acidocalcisomes, organelles that function as stores of 
calcium, magnesium, sodium, potassium, zinc, iron and also inorganic pyrophosphate and 
polyphosphate [46-48]. Additionally, they are also involved in pH homeostasis and 
osmoregulation of trypanosomes [48]. Originally discovered in trypanosomes, 
acidocalcisomes have also been described in other organisms and cells, including in the 
platelets [49-51]. 
The contractile vacuole is a structure that also plays a role in T. cruzi 
osmoregulation, by a mechanism of uptake or expelling of water in response to hipoosmotic 
and hyperosmotic stress, respectively [52]. 
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The main component of the cytoskeleton of trypanosomes is a structure of 
microtubules that span the entirety of the body [53]. T. cruzi codifies for an actin protein, but 
no actin filaments have ever been seen in the parasite, and this is probably due to 
differences of homology in regions associated with oligomerization and interaction with actin 
binding proteins [20]. 
The single flagellum of trypanosomatids is present in all life cycle stages, even in 
amastigotes where it is shrunk to a residual structure. Like other flagella in other organisms, 
it is composed by a set of nine pairs of microtubules arranged around a central pair. It is a 
multifunction organelle responsible for cell propulsion, control of cell morphogenesis, with 
a role in directing cytokinesis and adhesion to host tissues [54-56]. The paraflagellar rod is 
a complex trilaminar structure linked to the axonemal microtubules of the flagellum and 
seems to have important functions for cell viability and function [57]. Recently, the disruption 
of two core paraflagellar proteins, PFR1 and PFR2, in the T. cruzi genome proved to be 
disruptive of the correct attachment of the flagellum to the cell body of epimastigotes [58]. 
The flagellum originates in a structure called the flagellar pocket. This is the place 
where exocytosis and endocytosis occur in trypanosomes, although it has been 
demonstrated that in T. cruzi, the cytostomes seem to be the main structure involved in the 
process [59]. It has important roles in cell polarity, division, trafficking and virulence [60]. 
 
 
1.4. Life cycle 
 
T. cruzi has a complex digenetic life cycle alternating between a mammalian host 
and a hematophagous insect vector. Remarkably, most of the features of the life cycle were 
discovered by Carlos Chagas in his seminal work, but new insights and refinements have 
been added in recent years [5] (summarized in Figure 4). Human infection begins when an 
infected vector takes a blood meal and subsequently defecates near the bite site. The feces 
of the insect are laden with infective metacyclic trypomastigotes (Figure 3 B) forms. Since 
the parasites are not able to penetrate intact skin, they must gain access to a lesion in the 
skin and the host usually does this when he scratches the bite. Alternatively, the parasite is 
able to directly invade mucosal tissues, like the oral or conjunctive mucosa. When the 
parasites penetrate the first external barrier, they infect local cells, usually resident 
macrophages or dendritic cells, being able to invade practically any nucleated cell [61]. 
Trypomastigotes enter the cell by either a mechanism of lysosome recruiting to the cell 
membrane, membrane expansion by actin-dependent mechanisms or by a plasma 
membrane invagination, all of which culminate in the formation of a parasitophorous vacuole 
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[62]. This vacuole eventually breaks up and the parasite is released to the host cell 
cytoplasm where it transforms into the amastigote - the replicative form in the mammalian 
host (Figure 3 C). After a few rounds of division, the amastigotes start to differentiate back 
to infective trypomastigotes. The trypomastigotes then rupture the cell and are released into 
the extracellular environment where they enter the blood or lymph circulatory system. These 
parasites are called blood trypomastigotes and are only found in the mammalian host. 
Although metacyclic and bloodstream trypomastigotes seem to have similar biological 
characteristics, like the invasion and the capacity to transform into amastigotes, they have 
some important differences in surface antigens and in overall gene expression profile [63, 
64]. Through circulation, trypomastigotes gain access to other parts of the mammalian 
organism and re-infect a variety of cells. The parasite is transmitted to a vector by ingestion 
of blood with circulating blood trypomastigotes. In the midgut of the triatomines, the 
trypomastigotes differentiate into epimastigotes that are the non-infective and replicative 
form of the parasite in the vector (. After rounds of division, the epimastigotes migrate to the 
lower parts of the insect digestive track and in a new environment star differentiating to 
metacyclic trypomastigotes in a process called metacyclogenesis. These parasites are non-
replicative and infective, being released to the exterior when the parasite defecates again 
after a blood meal, and thus closing the cycle. 
 
 
Figure 4. Representation of Trypanosoma cruzi digenetic life cycle 
between a triatomine and a human host. [Adapted from [65]]. 
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1.5. Epidemiology 
 
Chagas disease is the most important parasitic infirmity in the Americas, even 
considering that the region is also endemic for malaria and leishmaniasis. Recent estimates 
report the number of affected people to be around 6 million [66]. There are about 40,000 
new cases every year, of which about one fourth are caused by congenital transmission, 
and the remaining by active vectorial transmission. Every year, Chagas disease claims 
more than 12,000 deaths [67, 68]. The population at risk is considered to be of 70 million 
people [66]. Disability-adjusted life years (DALYs) are an important measure of disease 
burden that expresses the number of years lost due to disability, poor health and early 
death. The number for DALYs for Chagas disease is a staggering 515 thousand years [69]. 
In fact, Chagas disease in the Americas is responsible for 8 to 10 times more DALYs than 
the aforementioned parasitosis malaria and leishmaniasis [69]. Considering that these 
people live already in underdeveloped regions, the affliction by the disease creates further 
hindrances to human development [70, 71]. The countries where the incidence is greater 
are Bolivia (6.1%) Argentina (3.6%), Paraguay (2.1%) and Ecuador (1.4) [66] (Figure 5). 
The reason for Bolivia to be the country most affected by Chagas disease is because there 
are more than a total of 8,000 new cases every year due to vectorial transmission alone. 
Mexico, despite having a lower rate of incidence of about 0.8%, still has more than 6000 of 
new cases every year. Brazil concentrates one of the largest numbers of infected 
individuals, of about 1.2 million people. This number has stabilized due to the interruption 
of the domestic vector transmission, and now the country only reports 46 new cases per 
year [66]. 
Although there are competent vectors and reservoir species of T. cruzi in the 
southernmost states of U.S.A., the incidence of the parasite in both vectors and reservoirs 
is very low. Coupled with high housing conditions in the country, vectorial transmission is 
almost inexistent. In fact, only 6 cases of vectorial transmission have ever been known to 
occur in USA [72]. Nonetheless, the country is home to about 300 thousand cases of 
Chagas disease due to the high number of people from endemic countries that has migrated 
and established there [73, 74]. Other non-endemic regions in the world also have imported 
cases of T. cruzi, most notably Canada, Europe, Japan and Australia (Figure 5). Spain, in 
particular, has a significant prevalence of T. cruzi because of the high number of Bolivian 
migrants living there [75]. 
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Figure 5. Global geographic distribution of Chagas disease. [Adapted from [76]]. 
 
1.6. Transmission of Chagas disease 
 
1.6.1. Routes of infection 
 
The T. cruzi infection can be acquired by different routes. Historically, vectorial 
transmission has been the most important mechanism, from the ages of the first contact of 
humans with the parasite, until the present day [77]. This kind of transmission requires a 
particular ecological unit composed of domestic or sylvatic mammals and triatomine vector 
species susceptible to parasite colonization. Because no humans are required for the 
maintenance of the cycle that has evolved for millions of years, Chagas disease is 
considered to be a zoonosis where humans are accidental hosts. 
The disease can also be transmitted from mother to son in a congenital manner. 
The incidence of congenital transmission is estimated to be around 1 to 10% of the newborn 
babies from mothers infected with Chagas disease [78, 79{Barona-Vilar, 2012 #351, 80]. 
The transmission is transplacental, in a mechanism thought to first require the invasion of 
trophoblastic cells, followed by infection of adjacent tissues and finally the fetus [81]. Little 
is known about the factors that potentiate congenital transmission, except a correlation 
between levels of parasitaemia of the mother and the risk of infection to the fetus [82]. 
Chagas disease can also be acquired through the use of blood products and 
transplantation of organs. Concerning the blood products, platelets seem to be associated 
with a higher risk of infection, followed by blood [83]. This seems to be because platelets 
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end up being in the same centrifugation fraction of trypomastigotes. Because of the 
acquisition of many cases of Chagas due to this route, screening campaigns have been 
implemented, not only in endemic countries, but also worldwide due to the migrations from 
endemic countries that integrate local blood donation programs [73, 84, 85]. In the case of 
organs transplants, tissues of chagasic patients containing dormant or actively replicating 
amastigotes, once in a new host may establish a new infection [86]. The risks associated 
to transplants are many times increased because of the use of immunosuppressants (to 
control organ rejection) enabling unchecked T. cruzi replication due to the loss of 
immunological pressure [87]. 
Oral transmission is another source of Chagas disease, with 138 reported outbreaks 
responsible for the appearance of 776 new cases in the period of 2000 – 2010. Oral infection 
is usually acquired through ingestion of food or beverages such as juices, water or soup 
contaminated with T. cruzi-infected triatomines or their feces. It is thought that 
contamination takes place when the bugs that usually hide in the cavities of edible 
vegetation (e.g. sugar cane or açaí berries) are accidentally poured during the preparation 
of these juices [88]. Some studies indicate that a very small inoculum is necessary to cause 
disease, because of the readiness with which laboratory animal become infected by this 
route [89]. Some reports have noted the increased aggressiveness of orally transmitted 
Chagas disease [90]. Early observations indicate that the mucin wall of particular strains of 
T. cruzi are physicochemically modified in vivo in way that the increases local gastric 
infectiveness [91]. 
 
 
1.6.2. Vectors 
 
Natural transmission of T. cruzi is mediated by an estimated number 140 species of 
bugs belonging to the Triatominae sub-family of the Reduviidae family. They are grouped 
into five tribes: Triatomini, Rhodiini, Alberproseniini, Bolboderini and Carvernicolini, with the 
first two being the most important in terms of epidemiology [92]. Triatomines, commonly 
called kissing bugs because of their preference for biting in the face, are native to the 
American continent and have distinct species specific geographic distribution. They can be 
found in both South and Central America but also in the southern parts of North America, 
although vectorial transmission in the U.S.A. is extremely rare [93]. While some vector 
species are predominantly domestic and feed on humans, others are more associated with 
the sylvatic cycle, and only seasonally or opportunistically invade homes. The species with 
the most epidemiologic importance for human transmission are Triatoma infestans, followed 
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Rhodnius prolixus and Triatoma dimidiata [94]. While Triatoma is usually found in mud-
walled houses or tiled roofs, Rhodnius is found in palm roofs. These distinct habitats seem 
to reflect the different evolution of these vectors and are also associated with the lineages 
of T. cruzi they predominantly are infected with: whereas T. cruzi lineage II has evolved with 
T. infestans in burrows and rocky grounds where edentates and ground dwelling marsupials 
co-habited, lineage I appears to have evolved with R. prolixus that inhabit palm trees where 
they feed on opossums [94]. 
Triatomines usually feed at night, when humans are physically inactive. They use a 
range of sensory systems to help them find their hosts, like CO2 gradient, odors, moisture, 
heat and airflow, besides a sensitive infra-red detection [95]. The CO2 of the breath is 
thought to be the reason why the bugs bite preferentially in the face. Sometime during or 
after the meal, they defecate the parasite laden fesses, in a time frame that varies from 
species to species, but is essential for effective transmission [96, 97]. Once they have taken 
the blood meal, they return to hide in the cavities and cervices during daytime, when hosts 
are physically active. 
 
 
1.6.3. Reservoirs 
 
Parasitic infection of the first mammalian hosts of T. cruzi are thought to have 
occurred about 80 million years ago [98]. The high diversity of hosts infected and the 
different environments where co-evolution occurred since then, allied with the many species 
of vectors aforementioned, are thought to be responsible for the heterogeneous nature of 
the different strains described to date. 
The “reservoir” of T. cruzi, the non-human organisms that are infected with the 
parasite and actively transmit the parasite to the triatomine vector, is usually divided in 
sylvatic and domestic. In the sylvatic habitat, there is an estimated quantity of some 150 
species and subspecies of animals that are infected with T. cruzi and can thus potentially 
act as reservoirs. Rodentia, Carnivora and Primates as well as orders of Marsupialia are 
among the many mammals described [99, 100]. The marsupial species and subspecies of 
Didelphis (common name opussums) whose ancestors are considered the first hosts of T. 
cruzi are also recognized as the most important reservoir because of its prolificacy, high 
adaptability and cohabitation with triatomines [101]. Interestingly, triatomines both feed on, 
and are part of the diet of opussums [100]. 
The domestic reservoir is formed by species that usually cohabit with human beings, 
either domesticated animals or undesired pests. Early reports have estimated the 
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percentage of T. cruzi-infected dogs and cats to be around 20 to 30% [102]. Recent studies 
have identified infected cats and dogs in all the Americas, even in the United States, and 
have estimated this prevalence to be 8-50%, much higher than the prevalence in the 
population [103, 104]. The actual contribution of infected cats and dogs in the dissemination 
of Chagas disease is however, still a topic of controversy. Another important peridomestic 
species is the common rat (Rattus rattus) with studies indicating presence of parasites in 
more than 30% of the animals evaluated [105]. Even if a distinction is made between sylvatic 
and domestic reservoir, it should be noted that both environments are dynamic and 
connected, since humans, infected animals and vectors can easily traverse them. 
Because T. cruzi has such a large reservoir, most of which not quantified, total 
eradication of the disease is considered to be impossible. 
 
 
1.7. Clinical manifestations 
 
Chagas disease is generally divided in three major clinically distinct manifestations. 
The first phase of the disease is called the acute phase and is considered to occur 8 to 10 
days after the infection by T. cruzi. It is accompanied by patent parasitaemia in blood and 
lasts for about 4 to 8 weeks. The big majority of the cases, more than 99%, are not 
diagnosed because of the absence of any symptoms, or the presence of mild, unspecific 
symptoms like fever or malaise (Figure 6). A rare sign of infection is the Romaña’s eyelid 
signal or the chagoma that are swellings of the zone where inoculation took place, in the 
eye mucosa or other skin locations, respectively [106]. Both of them are frequently 
accompanied with an increase in volume of local lymph nodes. Meningoencephalitis and 
myocarditis are very rare manifestations that occur in less than 1% of the cases and are 
associated with a risk of death. In the vast majority of the acute phase cases all clinical 
manifestations disappear after approximately 60 days. Parasitaemias also are not 
detectable after this time, even if no targeted chemotherapy has been initiated, and affected 
individuals enter the indeterminate form of the disease. Spontaneous cure of the disease 
has been described, although it is considered to be rare [107]. 
Some differences are, however, verified when other transmission routes give origin 
to acute phase Chagas disease. Congenital acute phase babies commonly display, in 
addition, anemia and may also have a low birth weight or more serious consequences like 
abortion or neonatal death [77]. Oral acute phases and transplantation are other particular 
situations that have been described above. In the case of transplantation, because of the 
immunosuppressive therapies that are many times recommended with the transplant may 
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cause a particular aggressive progression of the disease with more serious consequences 
like acute myocarditis. The same is verified for patients co-infected with human 
immunodeficiency virus (HIV) [108]. 
The indeterminate form is defined by a positive diagnosis by serological or 
parasitological tests, associated with a completely asymptomatic profile. Only about 25 to 
30% of these cases will eventually develop some of the chronic manifestations, while the 
remaining don’t have any sign of the disease for the rest of their lives [106]. 
Apart from rare occasions where acute phase directly progresses to a chronic 
phase, the chronic manifestations of Chagas disease only appear years to decades later 
(Figure 6). In fact, many people only discover they are infected many years after the initial 
infection event. The chronic manifestations of Chagas disease are divided into cardiac, 
digestive or cardiodigestive forms, the latter being a mixture of the first two. The digestive 
forms affect 10 to 15% of the chronic patients with manifestation like megaesophagus 
and/or megavisceras. Such conditions are not usually life threatening and seem to be 
confined to countries like Argentina, Brazil, Chile and Bolivia, most likely as a consequence 
of a local infective strain [77]. Cardiac manifestations are the most serious consequences 
of Chagas disease present in 20 to 30% of the patients. The common clinical findings are 
arrhythmias and cardiac failure. Sudden death is the most common cause of mortality 
among chronic patients, being responsible for about two thirds of the deaths in this group 
[106]. 
 
 
Figure 6. Correlation between parasite load and disease 
severity over time in Chagas disease. [Adapted from [109]]. 
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1.8. Host-parasite interactions 
 
1.8.1. Innate and adaptive immunity in T. cruzi infection 
 
One of the first lines of defense T. cruzi encounters upon penetrating the host 
organism is the complement system. Some antigens of T. cruzi, particularly trans-sialidases 
(TS), are recognized by complement elements, activating the complement cascade [110]. 
It has been demonstrated that trypomastigotes can activate the complement system by the 
lectin pathway and alternative pathway, whereas amastigotes are able to activate via non-
classical pathway [111-113]. 
Some of the molecules of the parasite are also able to activate Toll-Like Receptors 
(TLRs), a family of membrane proteins mainly expressed in different immune cells that 
trigger innate immune responses against foreign pathogens [114]. Some examples are the 
glycosylphosphatidilinositol (GPI) anchors of mucins and Tc52 that activate TLR2 [115, 
116], ceramide-containing GPI anchored molecules that activate TLR4 [117] and DNA from 
the parasite that activates TLR9 [118]. This last receptor has a central role in the control of 
acute infection, since mice knockout for Myd88 or TLR9 plus TLR2 fail to control the 
infection [119]. Moreover, the kinetics of TLR9 activation however, seem to be delayed 
[120], most likely because it takes time before DNA molecules originating from dead 
parasites are released. It is hypothesized that this lag period is enough for the parasite to 
establish a parasitaemia strong enough to avoid suppression by the immune system later 
on [120]. 
Neutrophils are the first cells to arrive to the parasite site of entry and uptake 
parasites that they kill by ROS and H2O2 [121]. 
Macrophages arrive later, but have a central role in the immune response to the 
parasite. They act both as host cells to T. cruzi, but also as antigen presenting cells. Some 
of the antigens currently known to activate primed macrophages are tGPI, ssp4 and AgC10 
[122-124]. The activation of macrophages also requires INF-γ, the most important cytokine 
for T. cruzi infection control [125]. This activation enables the exertion of their antiparasitic 
activity by Nitric Oxide (NO) production intracellularly to kill amastigotes, but also possibly 
other mechanism to fight extracellular trypomastigotes [126-128]. 
Finally, DCs are at the interface of innate and acquired immune response and are 
some of the first cells to be readily infected by T. cruzi. They are initiators of adaptive 
immune responses and are more efficient activating naïve T cells [129]. 
Natural Killer (NK) cells are also present in the first line of defenses against the 
invading parasite. They are rapidly activated by cytokines produced by dendritic cells, 
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monocytes and macrophages that have contacted with the parasites becoming cytotoxic 
cells. They also help shaping the innate and acquired immune responses by interacting with 
T cells, macrophages/monocytes and also DCs. Experiments where NK cells were depleted 
from mice led to high parasitaemia and increased mortality [130]. In mice, NK cells are the 
major innate source of innate INF-γ that macrophages recognize as a signal to produce NO 
and limit parasite replication during the acute phase [131]. 
T cell immunity also plays a role in the control of acute infection by both CD8+ and 
CD4+ mediated responses. In fact, knockouts for major histocompatibility complex (MHC) 
class II, CD8+ or CD4+ as well as anti CD8+ and CD4+ antibodies render mice highly 
susceptible to infection [132-134]. Whereas CD8+ are more associated with cytotoxic 
activities, CD4+ are responsible for INF-γ-mediated activation of macrophages, induction of 
CD8+ T cells, and stimulation of B cells to produce protective antibodies [135, 136]. 
As the disease progresses to a chronic phase, T cell immunity assumes the central 
role in keeping T. cruzi in check [137]. Some antigens of T. cruzi have already been 
characterized as being involved in acquired immune response stimulators, like the TS family 
[138], SA85-1.1 of TS [139], cruzipain [140] and KMP11 [141] through a MHCII mediated 
mechanism, and TSA1 [142], ASP 1 and 2 [143] and FL-160 [144] as MHCI-mediated. 
B cells also have a role in acquired immunity. T. cruzi infection stimulates both a 
parasite specific antibody (mostly immunoglobulin (Ig) A and IgM) production in acute phase 
and a polyclonal B cell activation in the chronic phase (IgG that is maintained for life) [145]. 
TS, cruzipain and other antigens are thought to be the target of this type of immunity, 
particularly the SAPA repeat in TS molecules [146]. Polyclonal activation in the chronic 
phase is responsible by the production of large amounts of IgG that lack parasite specificity, 
and allow the parasite to survive by avoiding a specific response [147]. 
 
 
1.8.2. Evasion of the immune response 
 
T. cruzi employs a range of mechanisms to evade the immune system and establish 
itself in the host organism as a silent pathogen. For this the parasites developed several 
strategies. One of them is the ability to escape the complement system. As described 
before, trypomastigote antigens are strong activators of the complement system, and thus 
the parasite needs to evade their deleterious effects. Some proteins have been described 
to be involved in the hindrance of complement activation by the alternative pathway, like 
gp160, gp58/68 and TDAF [148-150]. Also contributing to this inhibition is the presence of 
sialic acid on the parasite surface, harvested by the action of TS superfamily in host 
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molecules [151, 152]. T. cruzi is also know to shed C3b acceptors to the extracellular 
environment that also decrease complement activation at its surface. Both trypomastigotes 
and amastigotes have the capacity to resist complement lysis, however, epimastigotes do 
not [153]. 
The parasite is also able to escape from the action of antibodies. Cruzipain is a 
protease that is able to digest IgG molecules, both the Fab region in a lesser extent, and 
the Fc region in a major extent, thus disabling FcR binding [154]. 
When the parasites invade cells they must also protect from the intracellular 
aggressions of host cells. T. cruzi employs a range of antioxidant defenses like the 
trypanothione system, peroxidases and peroxiredoxins [155]. It has been demonstrated that 
stage differentiation from epimastigotes (insect stage) to metacyclic trypomastigotes 
(mammalian infective stage) is accompanied by an upregulation of antioxidant enzymes 
[156, 157]. Modulation of apoptotic responses has also been characterized in T. cruzi 
infected cells as a survival mechanism, namely the induction of early apoptosis by ceramide 
containing molecules of the parasite that assure premature and unharmed amastigote 
release [158]. In muscle cells, where T. cruzi is known to remain as a stealth parasite, it has 
been shown that there is less NO production and there are more polyamines that are 
thought to favor T. cruzi survival [159]. 
 
 
1.9. Diagnosis 
 
 The gold standard for Chagas disease diagnosis is the direct observation of 
parasites in blood smears [160]. However, because of the characteristic parasitaemia 
during disease progression, this method is mostly restricted to the acute phase, including 
congenital cases [161, 162]. Polymerase Chain Reaction (PCR) is also applicable to acute 
phase Chagas disease, however it is best suited for transplantation or accidental exposure 
situations [163]. 
Once the acute phase has run its course, the diagnostic tool that is most used is 
serology. Because parasites are, in most of the cases, not detected in the chronic phase, 
the most reliable diagnosis involves the detection of anti-T. cruzi antibodies, chiefly IgG. 
The serological tests available are Enzyme-Linked Immunosorbent Assay (ELISA), 
ImmunoFluorescent Antibody assay (IFA) and indirect haemagglutination [164, 165]. No 
single test is definitive, and confirmation should be obtained by two positive results, 
preferably with two different antigens (one from total parasite extracts and one recombinant 
antigen) [166-168]. Serology may be applied to diagnose children with acquired congenital 
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disease, but only after 9 months, time after which the mother antibodies disappear from the 
infant’s body [169]. 
PCR diagnosis is not usually recommended for chronic disease detection because 
a negative PCR is not indicative of T. cruzi absence. It is not suited for routine diagnosis 
because of the need of specific labs, poor standardization of protocols and also variable 
results between labs [170, 171]. This technique may be, nevertheless, useful for situations 
of inconclusive serodiagnosis and as a readout of treatment progression. In fact, 
quantitative PCR has been elected the major assessment tool for treatment efficacy in a 
recent clinical trial for Chagas disease [172, 173]. 
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2.1. Vectorial control 
 
Vectorial control has played a very important role in the reduction of cases of Chagas 
disease. Multinational efforts like the ones led by World Health Organization (WHO) and 
Pan American Health Organization (PAHO) aimed at the elimination of the domestic vector 
populations are thought to be responsible for the decrease in cases from 24 million in the 
1980s [174] to about 8 million cases in 2010 [66]. Today, countries like Brazil, Chile, 
Uruguay and Guatemala are considered to be free of the domestic vectorial transmission. 
The control and eradication of domestic triatomine populations from many 
households and even entire regions has been achieved because of the use of effective 
chemicals agents. There are many classes of insecticides, but the most used are 
pyrethroids like cypermethrin, cyfluthrin, deltamethrin and lambdacyhalothrin. These 
neuropoisons alter the permeability of neurons to sodium and potassium ions, irreversibly 
depolarizing the membranes of the cell, and thus causing paralysis [175]. Resistance 
pyrethroids has been found for Triatoma infestans [176] and it is thought that a suboptimal 
exposure to lethal pyrethroid concentrations selects eggs that are resistant to the insecticide 
and may display the resistance trait in the following developmental stages, including as 
adults [177]. A solution to this problem might be mixing or alternating the treatments with a 
different class insecticide. Other chemical-based strategies are the used of pyrethroid-
impregnated curtains and bed-nets [178, 179].  
 Non chemical control methods can also be applied and are considered to be 
essential for the long-term elimination of vector infestation. Some of the most common 
measures are related to housing conditions improvements, like the substitution of palm 
thatched roofs by metal sheets and plastered walls instead of simple mud walls that can 
have crack that harbor triatomines [180, 181]. Common in poor rural setting, these 
measures are a natural consequence of urbanization, where better construction and 
infrastructure planning are present. There have been reports, however, of cases where 
some triatomine species accompany the population and adapt to urban spaces, creating 
foci of Chagas disease transmission [182]. 
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2.2. Therapies for Chagas disease 
 
The contents of this section have been published in a review article: 
 
Gaspar L, Moraes CB, Freitas-Junior L, Ferrari S, Costantino L, Costi MP, Coron RP, Smith 
TK, Siqueira-Neto J, McKerrow J, Cordeiro-da-Silva A. (2015) Current and Future 
Chemotherapy for Chagas Disease, in Current Medicinal Chemistry, 22(37): 4293-4312.  
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3.1. Histone deacetylases and the class of sirtuins 
 
Post-Translational Modifications (PTMs) represent one of the major mechanisms in 
regulating protein function in all life forms. Through phosphorylation, acetylation, 
methylation, glycosylation and ubiquitylation, cells greatly extend the possibilities beyond 
the coding genome [183]. PTMs can change the enzymatic activity of a protein, change its 
subcellular localization, interfere with interaction partners, increase or decrease its stability 
and induce DNA interaction [183, 184]. 
Discovered half a century ago and largely ignored for the following years, lysine 
acetylation has re-emerged in the last two decades as a highly important PTM. It has been 
placed by some authors in the same level of biological relevance as phosphorylation [185, 
186]. In fact, studies of the acetylome (the acetylated-proteome) of mammalian cells, 
revealed acetylation sites in 1,750 different proteins [187], a number close to the about 
2,000 proteins found to be phosphorylated [188]. 
The “acetyl code” is maintained by three different protein types: the “writers”, lysine 
acetyltransferases (KATs) that add acetyl groups to proteins, the “erasers”, lysine 
deacetylase (KDACs) that remove acetyl groups, and “readers”, proteins that specifically 
recognize and bind acetyllysine groups [189]. 
KDACs in particular have been the focus of great interest by the scientific community 
due to their many roles in cell function and disease. KDACs are interchangeable called 
histone deacetylases (HDACs) because the first reactions catalyzed by these proteins to 
be discovered were the removal of acetyl groups in histone tails [185, 190]. 
HDACs are separated in four different classes based on sequence homology (Class 
I, II, III and IV) and two different families: the histone deacetylase family and the sirtuin 
family, the latter being all class III HDACs. While the first family has a limited set of molecular 
targets mainly composed of histones, sirtuins have a variety of substrates ranging from 
metabolic enzymes to structural proteins as well as histones [191-193]. The sirtuin family 
seems to be ubiquitous throughout all kingdoms of life. The number of genes coding for 
sirtuins within an organism ranges from as little as one in bacteria to seven in vertebrates 
[194]. The sirtuin family is further classified in 5 subclasses (I, II, III, IV and U) [195]. 
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3.2. Enzymatic activity of sirtuins 
 
3.2.1. NAD+-dependent deacetylase activity  
 
 The most common reaction catalyzed by sirtuins is deacetylation. This reaction is of 
upmost biological importance as there is a clear relation between the acetylation status of 
several proteins and their cellular functions [196-198]. The deacetylase reaction requires 
(nicotinamide adenine dinucleotide) NAD+, an acetylated lysine residue and produces 
deacetylated lysine, nicotinamide and 2’-O-acetyl-ADP-ribose (OAADPr) [199]. Studies on 
the kinetics and biochemical properties of the enzymes revealed binding to the acetyl lysine 
substrate prior to NAD+. This is followed by nicotinamide cleavage from NAD+. that is the 
first product released, followed by deacetylated lysine and OAADPr [200]. All sirtuins are 
strictly NAD+ dependent, a distinct characteristic that distinguishes them from other 
deacetylases. In fact, SIRT6 is a sirtuin capable of tightly binding to NAD+ without the 
requirement of an acetylated substrate, indicating that it may function as a NAD+ sensor 
[201]. 
Besides being an endogenous product of the deacetylation reaction, nicotinamide is 
also a well-known inhibitor of sirtuins. Nicotinamide is an amide of nicotinic acid (vitamin 
B3) and is part of common enzyme co-factors like NAD+ (nicotinamide adenine dinucleotide) 
and NADP (nicotinamide adenine dinucleotide phosphate) [202]. Intracellular physiological 
levels of nicotinamide in some mammalian cells seem to be in the range similar to the IC50's 
of some sirtuins reinforcing the hypothesis that some sirtuins may act as NAD+ and 
nicotinamide sensors [203, 204]. 
O-acetyl-ADP-ribose is another product of the deacetylation reaction [205]. Early 
studies characterizing this molecule found that quantitative microinjection into starfish 
oocytes led to a blockage of oocyte maturation, indicating for the first time that OAADPr can 
evoke a biological activity [206]. There is now mounting evidence that OAADPR can elicit 
downstream responses that might synergize or antagonize the biological functions of sirtuin 
genes. So far, OAADPr has demonstrated to be related with functions in gene silencing, ion 
channel modulation and cell redox state maintenance [205]. 
 
 
3.2.2. ADP-ribosylation activity 
 
Another reaction catalyzed by sirtuins is ADP-ribosylation. Although sirtuins were 
firstly described as ADP-ribosyltransferases, their deacetylase activity has quickly 
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overshadowed this activity, and as a consequence the biological processes associated to 
this reaction remain poorly understood [207]. In truth, sirtuins may have just deacetylase 
activity, both, or be mostly ADP-ribosyltransferases. An example is SIRT4 that is an efficient 
in vitro ADP-ribosyltransferase of histones, that only recently was discovered to possess 
deacetylase activity [208, 209]. There is an active debate on whether ADP-ribosylation is in 
fact a biologically relevant function of sirtuins, or just an irrelevant side reaction/non-
enzymatic artifact [210]. Notwithstanding, some of the players in the dynamics of 
intracellular ADP-ribosylation have only been recently identified and it is becoming apparent 
that this PTM might be relevant for the modulation important cell processes and signaling 
pathways like signal transduction mechanisms, transcription and DNA repair [211]. 
 
 
3.2.3. Other functions 
 
Although (de)acetylation is the most common PTM (de)acylation, other groups can 
be targeted, like succinyl and malonyl groups. SIRT5 and SIRT6 are some examples of 
proteins that perform deacylations of lysines other than acetyl groups, and their activities 
are important regulators of cell functions [212-214]. 
 
 
3.3. Structural features 
 
There is a wealth of information regarding the structural features of sirtuins. To date, 
some 83 structures of sirtuins are available in the protein databank, many of them co-
crystalized with natural ligands or inhibitors. Though the available structures range from 
bacterial to mammalian sirtuins, the majority of the structures originate from the human 
genome. 
Although the sequence homology can vary significantly between sirtuins, especially 
between prokaryotic and eukaryotic proteins, there is a conserved catalytic core of about 
250 amino acids common to all members in the family [215]. The structure similarity of 
PfSir2A with mammalian SIRT5, despite a sequence homology of just 33% is a clear 
illustration [215]. This core contains a Rossman fold domain that is a NAD+ binding site, and 
a Zn2+ binding domain containing four highly conserved cysteine residues arranged in the 
motif (CX2CX20CX2). The catalytic site is located inside a hydrophobic channel formed at 
the interface of this two domains [215] (Figure 7). 
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Figure 7. Ribbon representation of the yeast Sir2 in complex with an acetyl-ribosyl-ADP-
intermediate. The zinc binding site is represented in light blue and the NAD+-binding Rossman fold 
in orange. [Adapted from [216]]. 
 
Whereas in HDACs from class I, II and IV Zn2+ is an active participant in catalysis 
by producing free acetate and deacetylated lysine, in sirtuins it does not participate in 
reaction. However, the metal is essential for structural integrity, as was elucidated by the 
reversible loss of activity in a P. falciparum sirtuin where the zinc ion was removed [217]. 
Interestingly, an exception to the conservation of the CX2CX20CX2 motif is found on some 
sirtuins of trypanosomatids, where one of the cysteines is not present [218]. However, 
deacetylase activity does not seem to be affected [219]. The molecular mechanism of 
deacetylation is still not completely elucidated, but it is generally accepted that the first step 
in the reaction involves the nucleophilic addition of the acetyl oxygen to nicotinamide ribose 
by a mechanism of SN2 substitution to produce O-alkylamine intermediate and nicotinamide. 
Then the acetyl group is transferred to ADP-ribose to form O-acetyl-ADP-ribose and 
deacetylated lysine [220] (Figure 8). 
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Figure 8. Molecular mechanism of sirtuin NAD+-dependent deacetylation. 
[Adapted from [221]]. 
 
3.4. Known members of the sirtuin family 
 
3.4.1. Yeast Sir2 
 
The founding member of the sirtuin family is Sir2 from the budding yeast and was 
initially identified as part of a protein complex necessary to silence the expression of the 
mating-type-loci [222, 223]. Subsequently, it was also implicated in transcriptional silencing 
at telomere proximal sites [224] and ribosomal repeats at the ribosomal DNA (rDNA) locus 
[225-227]. Sir2 can be associated in distinct protein complexes that vary according to target 
site. For instance, at telomeres and the mating-type-loci, Sir2 forms a complex with two 
other homologues, Sir3 and Sir4 [224], while at rDNA locus Sir2 associates with Net1 and 
Cdc14 to form the regulator of nucleolar silencing and telophase exit - RENT complex [228, 
229]. Yeast cells lacking Sir2 present a reduced lifespan that has been correlated with the 
accumulation of extrachromosomal ribosomal DNA circles originating from illegitimate 
recombination that are toxic to the cell and have been associated with aging [227, 230, 231]. 
 
 
3.4.2. Mammalian sirtuins 
 
SIRT1 is the most extensively studied member among the sirtuin family. The TATA 
box-binding protein-associated factor RNA polymerase I subunit B (TAFI68) was the first 
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substrate to be identified for SIRT1 in mouse cells. It is a transcription factor necessary for 
regulating the RNA polymerase I transcriptional complex, where it was shown that 
deacetylation inhibits transcriptional initiation in vitro [232]. Studies on p53, a non histone 
substrate, demonstrated that acetylation activates the DNA-binding activity and target gene 
expression, also increasing its stability [233]. Consistent with this proposed SIRT1 inhibition 
of p53 function, SIRT1 knockout mice exhibit p53 hyper-acetylation and increased radiation-
induced apoptosis, suggesting that SIRT1 can facilitate tumor growth by antagonism of p53 
[234]. Still, the fact that SIRT1 can be found either overexpressed or underexpressed in 
different tumor types, and the finding that it can also function as a tumor suppressor [235] 
has hindered the clarification of its role in tumorigenesis. SIRT1 also plays an important role 
in metabolism, and its relation with caloric restriction and life-span extension has received 
much attention (reviewed in [236-238]). The beneficial effects of caloric restriction have 
been focused on the insulin-like growth factor-1 (IGF-1) and the target of rapamycin (TOR) 
pathways [239, 240], but increasing evidence suggest a role of SIRT1 in caloric restriction 
in mammals as well. For instance, SIRT1 expression was found to be elevated in models 
of caloric restriction, like fasting mice, low calorie diet in rat, or humans on a 25% caloric 
restriction diet [241-243]. On the other hand, mice lacking SIRT1 lost the life-span extension 
benefits of a 40% reduced calorie diet [244]. Despite many studies, the exact molecular 
mechanisms of SIRT1 in caloric restriction are still to be unraveled. 
In vitro studies attribute a role to human SIRT2 in cell cycle regulation through the 
deacetylation of both tubulin and histone H4 [193, 245, 246]. In particular, it has been found 
that SIRT2 overexpressing cells were significantly delayed in cell cycle progression through 
mitosis [247]. Some links with age-related diseases have been described for SIRT2, such 
has neurodegenerative diseases [248-250], as well as cancer. Mice lacking SIRT2 are 
prone to the appearance of tumors, thought to be mediated by the negative regulation of 
the anaphase-promoting complex by SIRT2 [251]. SIRT2 has been demonstrated to have 
decreased expression in human gliomas, some of the most frequent malignant tumors in 
the brain [193, 252]. Indeed, the SIRT2 gene is located at a chromosomal region frequently 
deleted in human gliomas. In addition, it was found to be an effective demyristoylase with a 
catalytic efficiency slightly higher for myristoyl groups than acetyl groups, although no 
physiologic target or biological relevance of this acyl modification has been described yet 
[253]. 
SIRT3 is the major mitochondrial deacetylase and studies with double knockout 
mice have revealed high levels of acetylation in protein targets [254, 255]. In addition, it was 
observed that these mice have impaired production of ATP [254]. When fasting or fed a 
high-fat diet, the mice display atypical phenotypes that include cold intolerance and 
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decreased ketone body formation [256, 257]. This strengthened the link with thermogenesis 
that had been previously demonstrated [258, 259]. In fact, SIRT3 expression is induced in 
mice in both white and brown adipose tissue upon caloric restriction and exposure of brown 
adipose tissue to cold temperatures [260]. In addition, SIRT3 also has a role in the 
deacetylation and activation of fatty acid oxidation, amino acid metabolism, electron 
transport chain and antioxidant defenses [261, 262]. 
SIRT4 was originally thought to be an unusual sirtuin due to the lack of deacetylase 
activity [263]. However, it was shown to ADP-ribosylate and down-regulate glutamate 
dehydrogenase production of ATP and has been implicated in insulin regulation of β-cells 
[208, 263]. Moreover, SIRT4 has recently been attributed a tumor suppressive function due 
to its involvement in DNA damage protection mediated by inhibition of mitochondrial 
glutamine metabolism, suggesting it might have therapeutic potential for treating glutamine-
dependent cancers [264]. This mechanism has been shown to be repressed by mammalian 
target of rapamycin complex 1 (mTORC1) pathway [265]. SIRT4 also coordinates the 
balance between lipid synthesis and their catabolism by repressing malonyl-CoA 
decarboxylase, proving that it has, in fact, deacetylase activity [209]. 
SIRT5 is a NAD+-dependent protein lysine demalonylase and desuccinylase [266] 
and also has a deglutarylase activity [267]. It has a deacetylase activity [191], but has 
preference for acylcarboxyl negatively charged groups [266, 267]. Some of its functions are 
related to glycolysis modulation [214]. The succinilome of mammalian cells has revealed 
many points of succinilation that are probable targets of SIRT5, mostly concentrated on 
mitochondrial metabolism [213]. SIRT5 also promotes urea cycle function via the regulation 
of carbamoyl phosphate synthase [191, 196], and purine metabolism via urate oxidase 
[268]. Although a global protein hypersuccinylation and elevated serum ammonia during 
fasting were observed in SIRT5 knockout mouse model, the enzyme deficiency did not lead 
to any major metabolic abnormalities under either low or high fat diet conditions. These 
observations suggest that SIRT5 is likely dispensable metabolic homeostasis under the 
basal conditions. It remains to be evaluated the role of SIRT5 in extreme conditions [269]. 
While most mammalian sirtuins have been mostly implicated with metabolism, 
SIRT6 seems to be the only one with a direct link supporting a defined role in mammalian 
aging [270]. In fact, mice lacking SIRT6 gene develop a progeroid-like symptom with loss 
of subcutaneous fat, curved spine and lymphopenia. They develop normally for 2 weeks 
after birth, but then suffer from acute degeneration processes, ending up dying at 1 month 
of age [271]. At first considered to not possess deacetylase activity, but solely an ADP-
ribosyltransferase activity [272], it was later found that SIRT6 removes both acetyl and long 
chain fatty acyl groups from target molecules [212, 273]. It is localized in the nucleus, 
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associated with chromatin, where it promotes the specific NAD+-dependent deacetylation 
of H3K9 and H3K56 [273-275]. SIRT6 is involved in genome protection by assuring correct 
telomere maintenance [273, 274], as well as DNA repair by double-strand break repair 
machinery [276, 277]. Like other sirtuins it also has a role in metabolism by influencing both 
glycolysis and gluconeogenesis [278-280] and lipid metabolism by regulating triglyceride 
synthesis [270, 281]. Conditions like inflammation, heart disease and cancer all seem to be 
linked with SIRT6 function [282]. 
SIRT7 is the least studied sirtuin of all the mammalian sirtuins, but recent findings 
have established new functions and roles for this protein. It is a nucleolar sirtuin [283] and 
its localization is associated with the main process happening at this sub-nuclear structure, 
namely rDNA transcription [284]. SIRT7 does not possess a very strong deacetylate activity 
towards common synthetic and natural peptides [283], which is in agreement with the fact 
that SIRT7 depletion in mice did not change the global acetylation levels of either nucleus 
or nucleolus proteome [285], indicating that SIRT7 deacetylase activity is specific to a 
limited set of proteins. One example is specific deacetylation of H3K18 [192, 286] that 
underlies its role in chromatin remodeling. Also, SIRT7 has been found to be closely 
associated with B-WICH complex, a chromatin remodeling complex [287]. It also has a role 
in protein synthesis [285, 288] and contributes to cell survival, namely by protecting against 
genomic insult [289, 290], hypoxia [291] and low glucose induced stress [292]. All the 
functions described characterize SIRT7 as a pro-survival protein. Indeed, it is currently 
considered to be an oncogene in all the cancer types studied so far [288, 293, 294]. 
A schematic representation of the localization and major biologic functions of 
mammalian sirtuins is represented in Figure 9. 
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Figure 9. Representation of the seven mammalian sirtuins regarding their sub-cellular localization 
and attributed biological roles. [Adapted from [295]]. 
 
3.4.3. Protozoan sirtuins 
 
3.4.3.1. Plasmodium spp. 
 
Parasites of Plasmodium spp. have been characterized with two sirtuin orthologues, 
called Sir2A and Sir2B. Sir2A is the most extensively studied homologue, mainly located at 
the nucleus [296] although it can also shuttle to cytoplasm after posttranslational 
SUMOylation [297]. Sir2A has been characterized as a mediator of transcriptional silencing 
at the telomeric regions of chromosomes [296, 298]. The telomeres of P. falciparum are rich 
in gene families involved in antigenic variation such as the var family of genes. These genes 
are responsible for the expression of parasite-derived P. falciparum erythrocyte membrane 
protein, PfEMP1, responsible for immune evasion in humans [299]. The family of var genes 
is tightly regulated by sirtuins, with the expression of its members being mutually exclusive 
[300, 301]. The switch of active var is controlled exclusively at the epigenetic level [300, 
302]. 
PfSir2B is a larger homologue with a molecular weight more than four times the size 
of Sir2A and is involved in the transcriptional silencing of a complementary subset of var 
genes with distinct promoter types [303]. 
 
 
 
Part III – Sirtuins: novel targets for parasitic diseases 
58 
3.4.3.2. Leishmania spp. 
 
Sirtuins from Leishmania spp. parasites were among the first to be identified in 
trypanosomatids, when a complementary DNA (cDNA) isolated and sequenced from 
Leishmania major showed a high homology with yeast Sir2 [304]. Antibodies raised against 
this LmSir2 later showed to be reactive against different life cycle stages of Leishmania 
major, but also of Leishmania amazonensis and even the serum of a patient infected with 
Leishmania infantum [305]. Furthermore, the protein was found to be among the secreted 
material of L. major [305]. 
Overexpression of the orthologous protein in L. infantum, sharing 93% homology to 
the L. major protein, led to an increased survival of amastigotes under axenic conditions 
[306]. Also, when the overexpression was performed in mammalian fibroblasts, host cells 
became more permissive to infection by Leishmania infection in comparison with wild type 
cells, hinting at a modulation of host cell by the parasite [307]. Genetic knockouts in L. 
infantum Sir2rp1 gene also contributed the elucidation of the importance of this protein in 
the parasite. While single knockouts were readily obtainable, double deletion of the alleles 
was only possible after the rescue by an ectopical copy of the gene, suggesting an essential 
role for parasite survival [308]. When single-knockouts of L. infantum Sir2rp1 were used to 
infect a macrophage cell line, in vitro, it was noted that although they had the same invasive 
capacity than wild-type parasites, they showed a hindered replication rate leading to 
diminished infections over-time. Furthermore, the mutant parasite also failed to establish 
infection in an in vivo mouse model of leishmaniasis [308]. Cellular and biochemical studies 
later established LiSir2rp1 as NAD+-dependent deacetylase with ADP-ribosylation activity 
that co-localized to the cytoskeleton and potentially interacted with tubulin as well as with 
HSP83, an orthologue of mammalian HSP90 [309, 310]. The association with cytoskeleton 
is a characteristic feature of both SIRT2 and HDAC6 [193, 311]. In addition, an orthologous 
from L. amazonensis, LaSir2rp1 was found to be a glycosylated protein, but whether this is 
the case for other species remains to be seen [312]. Although the Sir2 related protein 1 has 
received much attention, no studies have been made for the other two proteins codified by 
the Leishmania species, rp2 and rp3. 
Recently, Sir2rp1 from L. donovani has been implicated in the resistance of 
amphotericin B, a reference drug in the treatment of visceral leishmaniasis. When clinical 
isolates were targeted for gene knockout of the protein, parasites showed a lower level of 
multi-drug resistant transporter MDR1, lower drug efflux, increased ROS production and 
increased sensitivity to amphotericin B [313]. On the contrary, overexpression led to a 
resistant phenotype, thereby suggesting Sir2 as a new resistant marker for visceral 
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leishmaniasis [313]. Comparative transcriptomic analysis also implicates Sir2 in resistance 
to miltefosine, another drug used to treat the disease [314]. 
In addition to its potential as a novel drug target, Sir2rp1 from Leishmania spp. has 
also been suggested as a vaccine [315, 316]. 
 
 
3.4.3.3. Trypanosoma brucei 
 
Trypanosoma brucei, like Leishmania spp., has 3 sirtuins annotated in its genome. 
The first enzyme to be characterized in the parasite was TbSir2rp1 [317]. The enzyme is 
localized mainly in the nucleus in association with chromosomes. The protein was shown 
to possess both deacetylase activity towards endogenous histones and also ADP-
ribosylation of calf thymus histones, and to a lesser extent, bovine serum albumin (BSA). 
Up to that time, no ADP-ribosylation had been detected in common members of the sirtuin 
family like yeast Sir2 or HST2, and TbSir2rp1 was one of the first enzymes to exhibit this 
dual activity [318-321]. Furthermore, mutation of a catalytic histidine essential for 
deacetylase activity also affected ADP-ribosylation activity, suggesting that the two activities 
were occurring simultaneously. Because of the increased or decreased resistance to DNA 
damage caused by the alkylating drug methyl methanesulfonate (MMS) in overexpressing 
or RNAi-induced knockdown T. brucei cell lines, respectively, TbSir2rp1 was also attributed 
a role in DNA repair in this organism [317]. 
A later study performed in bloodstream forms (as opposed to insect stage forms in 
the previous work) characterized TbSir2rp1 and also the other two sirtuins, TbSir2rp2 and 
TbSir2rp3 that both have a mitochondrial localization [322]. TbSir2rp1 confirmed to be a 
nuclear protein, but when overexpressed to high levels in T. brucei cells, it localizes to the 
cytoplasm, with toxic effects to the parasite [322]. Besides, the authors performed gene 
knockouts for the three proteins and observed no growth defect or impairment while cultured 
in standard conditions [322]. TbSir2rp1 mutants, however, did show an increased sensitivity 
to MMS damage, confirming the previous results performed with RNA interference (RNAi). 
The particular localization of TbSir2rp1 led to the investigation of Sir2 mediated telomere 
gene silencing like the one that occurs in yeast or Plasmodium spp. [323, 324]. Although 
TbSir2rp1 confirmed to be an active player in the latter role, it was not required for antigenic 
variation as described for Plasmodium Sir2 [296, 298]. 
TbSir2rp1 has also been studied as a model sirtuin with both deacetylase and ADP-
ribosylation activity. Biochemical studies revealed that ADP-ribosylation is 5-fold less active 
than the deacetylation reaction, and occurs only in the presence of an acetylated substrate 
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by two distinct biochemical mechanisms [325]. The latter claim has since been challenged 
by another research group that demonstrated that ADP-ribosylation can occur in arginine 
independent of the presence of an acetylated substrate, as supported by mass 
spectrometry and molecular dynamics simulations [326]. 
 
 
3.4.3.4. Trypanosoma cruzi 
 
Although the draft of the T. cruzi genome has been published a decade ago, it was 
not until recently that the first experimental studies involving the sirtuins of this parasite have 
been published [19]. Unlike Leishmania spp. and T. brucei that possess three Sir2-like 
proteins, T. cruzi only has two coding sequences annotated in its genome, TcSir2rp1 and 
TcSir2rp3. 
One study employing parasites overexpressing TcSir2rp1 and TcSir2rp3 by a 
tetracycline inducible vector characterized some of the features of both proteins [218]. 
Localization studies employing both wild type parasites and polyclonal sera raised against 
both proteins, as well as localization of tagged copies in the overexpression mutants with 
monoclonal antibodies, attributed a cytoplasmic localization to Tcsir2rp1 and a 
mitochondrial to TcSir2rp3 [218]. Both of the proteins’ levels are regulated throughout the 
life cycle of the parasite, with a significant decrease in both at the trypomastigote stage 
[218]. Overexpression of TcSir2rp1 was responsible for higher metacyclogenesis and 
higher infectivity of Vero cells. Since metacyclogenesis occurs under nutrient deprivation, it 
is hypothesized that TcSir2rp1 may function like sirtuins from other organisms that respond 
to starvation [263, 327, 328]. On the other hand, overexpression of TcSir2rp3 led to a 
decrease in epimastigote replication time, lower infectivity in Vero cells, increased 
amastigote replication and normal metacyclogenesis [218]. Because of the oxidizing 
environment in which amastigotes replicate, it has been suggested that TcSir2rp3 performs 
protecting functions against oxidative stress like SIRT3 [197]. Both of the overexpressing 
cell lines reduced the levels of acetylation for particular proteins as well as protected against 
the effect of specific sirtuin inhibitors [218]. 
Moretti and colleagues also independently characterized both of the sirtuins in a 
simultaneous study [219]. In their study, they show that salermide, a sirtuin inhibitor 
analogue of sirtinol found to be a strong anticancer molecule, is active against both in vitro 
cultures of epimastigotes, and against an in vivo model of infection by T. cruzi, albeit at 
moderate levels [219, 329]. Salermide was also found to be a strong inhibitor of TcSir2rp3 
recombinant protein [219]. The authors report the same localization for both proteins, as 
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well as the interference in epimastigote growth, metacyclogenesis, infectivity of host cells 
and amastigote replication in lines overexpressing the sirtuins, though with some 
differences to the previous study, probably due to the amount of overexpression achieved 
[219]. 
 
 
3.5. Modulation of sirtuin activity  
 
Because of the many roles sirtuins undertake in cells and the links between sirtuin 
deregulation and disease, active research on sirtuin modulators has been made in the 
search for molecules that would eventually be beneficial for human health. 
As described earlier, high SIRT1 activity has been found to be beneficial in a range 
of conditions. This has led to investigations in molecules that could positively increase 
SIRT1 function. Initially discovered to mimic caloric restriction by a mechanism of sirtuin 
stimulation [330, 331], resveratrol and derivatives are considered the central compounds 
capable of sirtuin activation [332]. This polyphenol demonstrated significant protection 
against neurodegeneration and has also improved general health in mice fed with a high 
calorie diet [333, 334]. Due to its poor bioavailability, resveratrol formulations have been 
developed, and tests in humans have demonstrated benefits in healthy obese men like 
decreasing hepatic lipid content, triglycerides and inflammation markers [335, 336]. Other 
molecules structurally unrelated to resveratrol like SRT1720 have also been reported to be 
beneficial for obesity related parameters and other conditions, but never demonstrated an 
increase of lifespan in animals fed without high fat diet [337-339]. 
High controversy has been generated involving the SIRT1 mediated mechanism of 
these inhibitors, as many of them seem to be only working in some types of deacetylation 
assays and fail to be active against endogenous protein-derived acetylated peptides [340, 
341], leading to the hypothesis that other mechanisms like activation of AMPK may be 
taking place [342, 343].  
Even though the positive modulation of SIRT1 activity favored the discovery and 
design of pharmacological activators of sirtuins, SIRT1 inhibitors can also be potentially 
useful as therapeutic agents because SIRT1 has been described to be up-regulated in 
cancer cell lines [235]. Furthermore, sirtuin inhibitors have also been proposed for the 
treatment of other age-related human diseases like Parkinson’s disease [250], and 
infectious diseases such as leishmaniosis [344], and HIV [345], and others. Additionally, 
SIRT3, SIRT4, and SIRT5 are located into the mitochondria, where they mediate 
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deacetylation of proteins that participate in processes important for energy metabolism and 
apoptosis that may be implicated in diseases like cancer and metabolic syndrome [346]. 
Sirtinol was discovered by phenotypic screens to be an inhibitor of both yeast Sir2 
and SIRT2, and has some anticancer potential in breast and lung cancer [347, 348]. 
Salermide is an analogue of sirtinol with a stronger in vitro inhibitory effect towards SIRT1 
and SIRT2 enzymes, and it is a strong inducer of p53-independent apoptosis in cancer cells 
[329]. Other inhibitors include suramin, an inhibitor with several biologic activities, including 
antitrypanosomal [349], although not by a mechanism of sirtuin inhibition; cambinol, a 
sirtinol analogue with proved antitumoral in vivo efficacy [349]; and splitomycin [350]. 
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Figure 10. Chemical structures of sirtuin modulators: A) Resveratrol; B) SRT1720; C) 
Sirtinol; D) Salermide; E) Sambinol; F) Splitomycin; G) Suramin. 
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4.1. Scope of the thesis 
 
Human trypanosomiasis constitutes one of the most neglected group of diseases in the 
world, affecting especially poor people in the African and American continent. Chagas 
disease in particular is caused by the protozoan parasite Trypanosoma cruzi and is 
responsible for significant mortality and morbidity in Latin America [351]. Disease control 
has relied heavily on vectorial eradication programs, but the high number of new and past 
cases of infection have left an estimate of 6 million people worldwide infected with T. cruzi 
[66]. Treatment for Chagas disease is limited to the use of chemotherapeutic agents that 
are decades old and have problems such as safety, efficacy and the need for long 
administration periods [352]. Some clinical trials launched in the last decade constitute a 
progress in drug development for the disease, but have, unfortunately, failed to deliver a 
new therapeutic [173, 353]. The need for alternative drugs is therefore an urgent need. 
The first steps in drug discovery start with screens for active small molecule inhibitors of 
either the whole parasite (phenotypic strategy) or a biochemical defined and purified 
molecular target (target-based strategy) [354]. The experimental work supporting this thesis 
employed both of the approaches in the search for new starting points that could be used 
in trypanosomiasis drug discovery. In the first part of the results section, the phenotypic 
approach is introduced by the development and validation of high-content screening (HCS) 
assays successfully employed in the discovery of active compounds originating from a 
targeted library of kinase/phosphatase-like inhibitors (section 4.2.1.1). Furthermore, the 
application and versatility of the technology is demonstrated in the evaluation of the 
enantiomers of nifurtimox against several T. cruzi lineages (4.2.1.2) and in the 
characterization of the antiparasitic activity of two families of synthetized compounds: 
naphthalimides (4.2.1.3) and 7-aryltioetherthieno[3,2-b]pyridines (4.2.1.4). The second part 
exploits the potential of Sir2rp1 inhibitors as novel drugs against T. cruzi (4.2.2.1) and T. 
brucei (4.2.2.2). 
 
In particular, the objectives of this thesis were: 
- Validation of a phenotypic HCS assay for T. cruzi with a focused library of 
kinase/phosphatase-like small molecule inhibitors; 
- Development of a phenotypic profiling assay capable of identifying compounds 
that interfere with the intracellular stages of T. cruzi life cycle; 
- Evaluate the potential of Sir2rp1 as a drug target in T. cruzi; 
- Evaluate the potential of BNIP derivatives against Sir2rp1 enzymes and whole 
parasites of T. brucei and T. cruzi. 
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4.2. Results 
 
4.2.1. Phenotypic drug discovery 
 
4.2.1.1. High-content screening assays for Chagas disease drug discovery 
 
Carolina B. Moraes, Luís Gaspar, Adalberto M. Araujo-Junior, Jair L. Siqueira-Neto, 
Dawoon Han, Nakyoung Lee, Anabela Cordeiro-da-Silva, Sergio Schenkman and Lucio 
Freitas-Junior. 
 
 
Manuscript in preparation 
 
 
Objectives of the study: 
 
The present study aimed at the development of a high-content drug screening assay 
for T. cruzi. The use of the clinically relevant amastigote stage, the adaptation to high 
throughput, the reproducibility and the use of non-genetically modified parasites and host 
cells were the main objectives. Furthermore, a phenotypic assay that allows the 
visualization of the life cycle stage being affected by drugs was also developed and used to 
characterize compounds that stopped parasite development at distinct points. 
 
 
Main results: 
 
→ A high-content drug screening assay against T. cruzi with a high statistical validity was 
established. 
 
→ Of a total of 4,000 compounds screened, 119 hits were confirmed to be active against 
the parasite, as assayed by dose response curve analysis. Furthermore, 11 compounds 
were at least 5 times more selective towards T. cruzi parasites than host cells. 
 
→ A secondary analysis revealed an additional subset of compounds that were able to 
interfere with the development of the intracellular life cycle stages of the parasite. With the 
aid of a newly developed high-content immunofluorescence that marks amastigotes and 
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trypomastigotes of T. cruzi, it was possible to determine the stage of differentiation being 
affected by the drugs. 
 
 
Conclusion: 
 
The present study reports the development of two HCS assays that could have a 
potential use in drug discovery for T. cruzi. The use of unmodified cells, the adaptability to 
384-well plates and the high statistic value of the assay represent significant advancements 
in the field of drug discovery for the parasite. In addition to classic drug discovery, the 
immunofluorescence assay here reported should present a valuable tool when evaluating 
the mechanism of action of approved and newly developed drugs. The nature of the library 
used (kinase/phosphatase-like inhibitors) highlight the possibility of exploiting trypanosomal 
kinases as new drug targets against Chagas disease. 
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ABSTRACT 
 
Chagas disease is caused by the protozoan parasite Trypanosoma cruzi and 
remains one of the most neglected tropical illnesses in the world. It is endemic to Latin 
American countries and is considered to be the parasitic infirmity with the biggest local 
social and economic burden. Benznidazole and nifurtimox, the only drugs available to treat 
the disease, were introduced more than four decades ago, with undesirable side effects 
and low efficacy on the chronic phase of infection. Although some drugs have entered 
clinical trials in recent years, no major approval added new treatment options for Chagas 
disease, maintaining the pressure for the discovery of new drugs.  
In this work we report a HCS of 4,000 kinase inhibitor-like compounds using an in 
vitro model of infection of U2OS cells with Y strain T. cruzi trypomastigotes. A primary 
analysis of the results focused on the identification of active compounds able to reduce the 
ratio of infected cells, with a custom software developed in-house. A secondary analysis 
aimed at identifying molecules that interfere with the parasite intracellular development by 
marking amastigotes and trypomastigotes with specific antibodies. 
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AUTHOR’S SUMMARY 
 
Trypanosoma cruzi is a protozoan parasite belonging to the Kinetoplastida class 
responsible for Chagas disease, a neglected tropical illness that affects an estimated 6 to 
8 million people in Latin America, with another 25 million in risk of acquiring the disease and 
a death toll of 12,000 every year. Commonly transmitted with the bite of the triatomine bugs, 
the disease is characterized by a nearly asymptomatically acute phase but a problematic 
chronic phase in which 20-30% of individuals develop serious cardiac and/or intestinal 
problems. The therapies actually used to treat the disease have been introduced more than 
forty years ago, have adverse effects and are mainly active in the acute phase. There is, 
therefore, an urgency to find better alternatives. The screening of small molecule libraries 
is a central starting point to the discovery of active compounds against the parasite. 
Here we report an image-based HCS of 4,000 compounds from an anti-kinase-like 
library using the Y strain of the parasite invading U2OS cells. From this screening, we 
discovered 2 promising clusters able to clear the parasite from infected cells with low toxicity 
as well as compounds able to interfere with the normal intracellular development of the 
microorganism. 
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INTRODUCTION 
 
Discovered more than 100 years ago, Chagas disease, also known as American 
trypanosomiasis, remains one of the most neglected tropical diseases in the world. It affects 
mostly the South and Central American continent, with estimates of 6-8 million cases, other 
70 million people in risk of acquiring the disease, and about 12,500 deaths every [1,2]. The 
etiologic agent is the protozoan parasite Trypanosoma cruzi, a kinetoplastid with a complex 
life cycle. The human transmission happens with the bite of an infected hematophagous 
triatomine insect vector that releases contaminated feces in the proximity of the skin lesion 
[3]. The infective form metacyclic trypomastigotes easily infects local cells and inside the 
cell changes into the replicative form amastigote. After 5 to 6 days, the amastigotes 
differentiate into bloodstream trypomastigotes that burst the host cell and migrate to other 
parts of the body through the blood and lymph, where they can freely invade other cells or 
be ingested by an insect vector. In the triatomine gut the parasite transforms once again 
into an insect-specific replicative stage called epimastigotes and after several divisions it 
migrates to the final portion of the intestine where it differentiates once again into metacyclic 
trypomastigotes, thus closing the cycle [4]. 
The vectorial transmission is still responsible for some 41,000 cases every year, but 
infection with the parasite can also happen through other routes such as transfusions [5], 
congenitally [6] and orally [7]. These transmission mechanisms coupled with migration flows 
have, in the past years, contributed to a worldwide spread of the disease out of its endemic 
zones, making it a global concern [8]. After infection, an acute phase follows, and is most 
of the times asymptomatic or presents unspecific signs for 4 to 8 weeks. Unless treated, the 
parasite remains in the host for his lifetime, but only 30-40% of the individuals will present 
the chronic phase of the disease, characterized by cardiac symptoms, gastrointestinal 
alterations, or both, usually 10 to 30 years after the first infection [9]. Benznidazole and 
nifurtimox, two drugs developed more than forty years ago, are the only treatments 
available. Severe side effects, lack of efficacy in the chronic phase and the long periods of 
treatment necessary to achieve cure make these drugs far from ideal [10]. The lack of 
alternatives has prompted an increase in the number of drugs entering clinical trials for 
Chagas disease in the last years, most notably the ergosterol biosynthesis inhibitor 
posaconazole and K777, a cysteine protease inhibitor that targets cruzain, the major 
proteolytic enzyme in T. cruzi [11]. There is, however, still a need for innovative drugs. 
Since the sequencing of T. cruzi genome, many putative targets that may be 
exploited to treat the disease have been suggested, with the parasite kinome attracting 
particular interest [12]. It is composed of 190 protein kinases, a number relatively high when 
Part IV – Objectives and results 
75 
compared to other intracellular protozoan parasites that transit diverse environments such 
as Plasmodium falciparum, hinting at an important role of such proteins in the parasite life 
cycle [13]. Kinases have been associated with parasite morphology, proliferation, 
differentiation and overall viability [14-16]. 
This paper describes the first HCS against T. cruzi using a targeted library of 4 000 
anti-kinase-like compounds and using a dual approach to the result analysis: a classic 
approach that identifies and characterizes compounds able to kill the parasite and clear the 
infection from host cells and a phenotypic analysis aiming at identifying compounds that 
interfere with the parasite intracellular development. 
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MATERIAL AND METHODS 
 
Cells and parasites 
U2OS and LLC-MK2 cells (ATCC, Manassas, VA) were cultured in DMEM high-
glucose medium (Wellgene LM001-05) supplemented with 10% fetal bovine serum (FBS, 
Gibco 16000), 100 U penicillin/mL and 100 µg/mL streptomycin (Gibco 15140) in a humid 
atmosphere of 5% CO2 at 37°C, with sub-cultures every 2-3 days or 3-5 days, respectively. 
U2OS are human osteosarcoma cells readily infected by T. cruzi and were used to screen 
the chemical library. They present a large cytoplasm that facilitates parasite detection and 
grow in monolayers, spread from each other, crucial features for software analysis. LLC-
MK2 are monkey kidney epithelial cells used to maintain in vitro culture of tissue culture-
derived trypomastigotes (TCTs) of T. cruzi Y strain. Parasites were collected from the 
supernatant of infected LLC-MK2 cultures maintained in DMEM low-glucose (Wellgene 
LM001-11) containing 2% FBS and 1% penicillin/streptomycin, five or six days after 
infection. Y strain belongs to the T. cruzi sub-group II and is considered ideal for primary 
screening [17,18]. 
 
Reference drug and compound library 
The anti-trypanocidal reference drug benznidazole was kindly provided by Epichem 
(EPL-BS63) and was dissolved in DMSO at a stock concentration of either 80 or 40 mM. 
An anti-kinase compound library of 4000 molecules from BioFocus at a stock concentration 
of 10 mM in DMSO was reformatted to 384-well plates at a concentration on 5 mM in DMSO 
and tested in singlet. 
 
High-content screening 
384-well black sterile plates with clear bottom wells were plated with 9.4 μL of DMED 
low-glucose media and 0.6 μL of compound from the library with a CyBi-Well 384-channel 
pipettor (CyBio AG) for a final concentration of 20 μM for compounds and 400 μM for 
reference drug (EC100). Trypsinized U2OS cells at a cell density of 2x105 cells/mL were 
infected with a parasite suspension at 1.2x107 parasites/mL in a ratio of 1:4 (vol/vol) 
corresponding to 15 parasites/cell. 50 μL/well of this suspension was then added to the 384-
well plates containing the compound with a WellMate (Thermo Scientific) liquid handler and 
the plates were centrifuged for 1 minute at 1000 rpm and incubated for 48 hours at 37°C, 
5% CO2. Confirmation of active hits was done with the compounds diluted in a two-fold 
scheme for 10 concentrations starting at 40 μM. 
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Fixation, nuclei staining and fluorescence microscopy 
After the incubation, all wells were treated with paraformaldehyde (final 
concentration 4%) in PBS (Wellgene LB001-02) and fixed for 15 minutes, after which the 
wells were aspirated with an EL406 microplate washer-dispenser (BioTek). The staining of 
cell nuclei and parasites was done with 5 μM Draq5 (Biostatus DR50200) paraformaldehyde 
4% in PBS for 2 hours and then washed 2 times with 50 μL/well of PBS. Four fluorescent 
images per well were acquired using an Operetta confocal automated microscope 
(PerkinElmer) with a 635 nm excitation filter and 20x lens magnification. 
 
Immunofluorescence assay 
for the selected phenotypic hits, a high-content immunofluorescence assay was 
developed with some differences to the screening protocol. DMSO concentration was 
lowered to 0.5%. Cells were seeded one day before compound addition and infection with 
parasite in order to mimic a more physiologic condition and at a lower dilution (5x104/mL) 
so the 72 hours time-point would not be overgrown with cells. Fixation was done similarly 
to the screening protocol followed by washing with PBS 3 times. Triton X-100 0.2% was 
used to permeabilize cells and a solution of 4% BSA (Sigma A3059) in PBS was used as 
blocking agent. mAb 2C2 (anti ssp-4) [19] and mAb 39 [20] (anti-trans-sialidase (TS), kindly 
provided by Sergio Schenkman) at 1:500 dilution were used as primary antibodies targeted 
at the amastigote and trypomastigotes stage, respectively. AlexaFluor® 488 donkey anti-
mouse (Invitrogen A-21202, 1:200 dilution) as a secondary antibody and Draq5 were 
incubated for 30 minutes at room temperature and washed 3 times with PBS between 
additions. Seven images per well were acquired with the microscope described above. 
 
Software development for image analysis 
A custom software for the analysis of the images was developed and is published in 
the following reference: [21].  
 
Data normalization and assay quality control 
The activity was calculated by normalization of the infection ratio (number of infected 
cells/total cells) values obtained by the software based on the controls benznidazole (EC100, 
effective concentration showing 100% activity, meaning minimum measured infection ratio) 
and 1% DMSO (vol/vol) (0% activity, meaning maximum measured infection ratio) following 
the formula: % infection = (measured IR – μBNZ EC100) / (μ1% DMSO – μBNZ EC100) x 100 in which 
μBNZ EC100 is the average infection ratio of the benznidazole EC100 control and μ1% DMSO is the 
averaged infection ratio of all 1% DMSO control wells. The Z’ value, defined by the formula 
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Z’ = 1 – [(3σBNZ EC100 + 3σ1% DMSO)/(μBNZ EC100 - μ1% DMSO) where σBNZ EC100 and σ1% DMSO are the 
standard deviations of both controls, is used to quantify the suitability of a particular high-
throughput/content screening as a measure of statistical effect size [22]. IC50 (inhibitory 
concentration) and CC50 (cytotoxic concentration) values were obtained with GraphPad 
Prism 5 (GraphPad Software, Inc.) for reference drug and confirmed compounds. 
 
 
RESULTS 
 
High-content screening assay development 
The screening was based on the infection of U2OS cells by TCTs. T. cruzi 
trypomastigotes have the ability to infect most, if not all, types of nucleated cells. U2OS are 
an osteosarcoma cell line considered optimal for high-content image-based screenings due 
to their growing in monolayers and spread over surfaces, without the need for coating. Also 
because of its large cytoplasm, it facilitates cell segmentation and accurate parasite 
detection. Staining with a nucleic acids dye reveals both host cells nuclei and amastigote 
nuclear and kinetoplast DNA, whose pictures were analyzed with a specifically developed 
in-house software (Fig. 1). The differences in the size of DNA material was exploited for 
algorithm development. Infection ratio (IR), defined as the coefficient of number of cells 
infected by at least one parasite by the number of total cells, was 0.83 ± 0.04 for the 1% 
DMSO control versus 0.06 ± 0.01 for the benznidazole EC100 (400 μM), resulting in a wide 
IR window that enables accurate analysis and the detection of slight variations in compound 
activity, an important improvement over other assays where the IR window is of just 30% 
[23]. These values are clearly visible by the separation of control wells IR values in Fig. 2A 
and translate into a robust Z’ value of 0.81, conferring a high statistical confidence in the 
assay. In terms of average number of parasites per infected cell (p/ic), 1% DMSO control 
had 14.5 ± 1.3 p/ic while EC100 and non-infected controls displayed 2.0 ± 0.1 and 2.2 ± 0.3 
p/ic respectively. These values in negative controls correspond to a limitation of the software 
that identifies small doted structures in the pictures as parasites, so for any analysis 
including the parameter p/ic we took this limitation into account. 
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Figure 1. Software developed in-house for image analysis. A) Interface for plate selection, levels 
adjustment and picture navigation B) Raw images acquired in Operetta automated microscope, 
showing DNA staining by Draq5 displayed as white color. C) Plugin window developed for T. cruzi 
analysis. D) Parameters data obtained from the image analysis: number of total cells, number of 
infected cells, infected cells/total cells, number of total parasites, average parasites/infected cells, 
standard deviation of parasites/infected cell. E) Image analyzed by the software, showing the 
detection of nuclei of infected cells (green), cytoplasmic membrane of infected cells (blue), parasites 
(red) and nuclei of non-infected cells (light blue). F) Plate map of the selected screening plate, with 
a color gradient representing the infection ratio (IR), with blue representing high IR and white 
representing low IR. 
 
Cell toxicity induced by compounds was quantified by the parameter cell ratio (CR) 
= compound total cell number / average 1% DMSO total cell number. Cell number is derived 
by total nuclei count by the software. Average CR for the negatives controls EC100 and 
non-infected were 1.53 ± 0.11 and 1.52 ± 0.13 respectively. The reported values are higher 
than 1 because T. cruzi infection delays cell division and causes cell death to some extent. 
The absence of infection either by the presence of an active drug or no addition of parasite 
contributes to cell preservation. In order to access variability overtime in the screening 
process, two plates with a dose-response curve (DRC) to benznidazole starting at 400 μM 
were screened before and after the BioFocus compound plates. The DRCs had IC50 values 
of 54.,72 and 65.40 μM (Fig. 2B), values in the range of previous screenings done in-house. 
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Drug library screen, active hits selection and confirmation 
The first selection aimed at identifying hits that were able to clear parasites from 
infected cells, thus reducing infection ratios. This analysis originated a set of compounds 
here called classic hits, since traditional drug discovery for intracellular organisms usually 
uses this parameter as a measure of compound activity. The criteria applied was normalized 
activity ≥ 70% and CR ≥ 0.5 and originated 119 primary hits. The secondary screening (i.e. 
DRC) confirmed 76 compounds. Only the compounds that reach at least 70% are 
considered confirmed hits. To account for assay variability, normalized activity higher than 
70% minus 1 standard deviation was considered as a cutoff. The confirmation ratio was 
calculated to be 64%, in agreement with other screenings carried in-house. Confirmed hits 
with a selectivity index (SI) ≥ 2, totaling 36 compounds, were clustered in order to access 
structure-activity relationship. 5 clusters and 2 singlets were grouped in distinct scaffolds 
(data not shown). The most active hits, selected based on SI ≥ 5, are shown in Table 1 and 
are characterized by low IC50 values (<10 μM) and most of them had no CC50 calculated, 
since no concentration of the drug reached 50% of cell viability. In those cases the CC50 
was represented by >40 μM, and the SI was calculated based on that value. 
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Figure 2. High-Content Screening. A) Plot of the infection ratio (Y-axis) for positive (benznidazole 
at 400 μM – red) and negative (1% DMSO – blue) control wells for all screening plates (X-axis); Z’-
factor of 0.81, demonstrating the high statistical confidence of the assay. B) Dose-response curves 
for reference compound benznidazole before (DRC1, IC50 = 54.72 μM) and after (DRC2, IC50 = 65.40 
μM) the screening of the compounds plates. C) Histogram of the primary screening, showing the 
distribution of compounds (Y-axis) by their normalized activity: yellow (library compounds), blue 
(negative control, 1% DMSO), red (positive control, EC100 benznidazole = 400 μM), green (non-
infected cells), light blue (classic hits) and magenta (phenotypic hits). 
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Selection of compounds interfering with 
parasite intracellular development 
A second hit selection was carried in 
order to identify compounds able to interfere 
with the parasite intracellular development. 
The parameter exploited was parasites per 
infected cell, and as a primary filter, we 
selected compounds that had only 3 to 6 
parasite, on average. This low number of 
parasites contrasts with the number of about 
14 found in the negative control 1% DMSO. 
After visual confirmation, 192 compounds 
were selected to be confirmed by 10-point 
DRC in the same conditions as the primary 
screening. Instead of plotting normalized 
activity and cell ratio versus concentration, 
normalized activity and p/ic versus 
concentration graphs were plotted. For 
reference drug and classic hits, as 
concentration increases the activity 
increases as well and there is a decrease in 
the number of p/ic. The profile sought were 
graphs in which the normalized activity stays 
relatively constant through concentrations 
but there is a decrease in the parasite 
numbers. In theory, this analysis would enrich for compounds that interfere with intracellular 
development. The analysis identified 35 such compounds, that were subsequently tested 
on the high-content immunofluorescence assay developed. 
Figure 3. Dose-response curves of the top hit 
compounds. The eleven most active 
compounds are represented with dose-response 
curves of normalized activity (black dots and line) 
and also of cell ratio (red triangles and line). Only 
confirmed compounds with IC50 ≤ 10 μM and 
selectivity index (S.I.) ≥ 5 were chosen. It was not 
possible to calculate a cytotoxic concentration 
(CC50) for the majority of the compounds 
(represented by CC50 ≥ 40 μM, the highest 
concentration tested). 
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Immunofluorescence assay development 
The monoclonal antibodies 2C2 and 39 were both used to study the intracellular 
cycle of the parasite by selectively binding to T. cruzi surface molecules of each parasite 
stage, amastigote and trypomastigote, respectively. At least 8 concentrations were tested 
for each compound, and 21 pictures per concentration per time point were visually 
analyzed. mAb 2C2 starts binding to amastigotes as early as 30 minutes after infection, and 
mAb 39 scarcely binds to parasites in the first moments of infections, an observation in 
agreement with previous studies that account for a fast differentiation to trypomastigotes 
once they enter the cell [24]. Most of the times where was possible to identify parasites 
positively marked with mAb 39, they had a round shape, indicating the coiling that 
immediately precedes amastigote differentiation. Several time-points were tested to access 
representative states of the intracellular cycle of T. cruzi, and 12, 24, 48 and 72 hours were 
chosen (Fig. 4 and 5). 0.5% DMSO was used as a negative control to access the normal 
development of the parasites. At 12 hours there are present a couple of parasites per cell, 
most of which are 2C2 marked and have a small round shape. At 24 hours, the amastigotes, 
now with a stronger 2C2 signal, have gone through 2 or 3 cycles of multiplication. No mAb 
39 is identified at this time-point nor at the following, 48 hours. By this time, amastigotes 
have replicated several times and count about 14-16 per cell. At 72 hours the amastigotes 
start to differentiate into trypomastigotes once again, and that is visible by the decreased 
levels of mAb 2C2 expression and the start of expression of mAb 39. As a positive control 
two concentrations of benznidazole were used, one equal to the EC100 (400 μM) and a sub-
lethal concentration (100 μM). In the first case, some of the parasites start to express 2C2 
in lower levels, but eventually are killed by the compound while many of them don’t even 
show any binding for 2C2, and after the 48 hours time-point, no Draq5 marking for the 
kinetoplast and parasite nucleus is visible. The 100 μM concentration allows the 
differentiation and hindered replication, but in a much lower rate than control. After 48 hours, 
there is a decrease in amastigote numbers, indicating a slower killing of the parasite by 
benznidazole. 
Compound K12 is a classic hit tested on the immunofluorescence assay. For this 
compound, also very few parasites express 2C2, and in much lower levels than the control. 
After 24 hours the parasites loose viability and only a residual 2C2 marking is visible, most 
of the times not accompanied by nuclear/kinetoplast Draq5 staining, indicating parasite 
death. 
Of all the 35 compounds tested in the immunofluorescence assay, 22 presented a 
distinct phenotype when compared to the controls used. We present three of those 
phenotypes. Compound 10 was characterized by amastigotes that are not able to multiply 
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and remain in constant numbers up until the last time point. Additionally, they are abnormally 
strong in 2C2 marking suggesting a continued expression and accumulation of ssp-4 at the 
parasite surface. This result may be a consequence of the blocking of some parasite 
differentiation factor not crucial for parasite viability but that enables survivability and 
persistence in the cell. 
 
Figure 4. Phenotypes found with the monoclonal antibody 2C2 (mAb 2C2) 
immunofluorescence assay. The images displayed in the panels represent the controls, reference 
drug and selected compounds for four time-points (12, 24, 48 and 72h) using monoclonal antibody 
2C2 against amastigote-specific antigen ssp4. 
 
Compound 31 presents very small amastigotes weakly marked by amastigote 
antibody throughout all the time-points, very similar in shape and size to the 12 hours 0.5% 
DMSO control parasites. This may hint at an inhibition of early factor(s) required for 
amastigote growth and differentiation. Once again, since the parasites are still marked at 
72 hours with 2C2, such inhibition is not enough to cause the elimination of the parasite. 
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Compound 17 was characterized by a total absence of 2C2 in all the time-points, but with 
indication of parasite presence by Draq5 staining of nuclear and kDNA. The mAb 39 
immunofluorescence revealed many DNA spots co-localized with trypomastigote-shaped 
and round-shaped forms, leading to the hypothesis that there is some sort of trypomastigote 
stage arrest, not allowing the parasites to differentiate into amastigotes. These 
trypomastigotes and round-shaped intermediate forms are present up to 48 hours, and are 
occasionally detected at 72 hours. 
 
 
Figure 5. mAb 39 immunofluorescence assay. The images displayed in the panels represent the 
controls, reference drug and compound 17 for four time-points (12, 24, 48 and 72h) using monoclonal 
antibody 39 against trypomastigote-specific antigen TS. 
 
DISCUSSION 
 
Target-based approaches have been traditionally used not only for parasitic 
diseases, but also for other diseases drug discovery. Attempts to find a new drug for Chagas 
disease have followed this trend, with all the current molecules on the pipeline targeting a 
specific and know parasite protein. One of them is cruzain, also called cruzipain, a target 
discovered two decades ago and that has been studied extensively ever since [25-28]. K-
777, a vinyl sulfone that inhibits this enzyme is currently in prep/clinical studies but other 
inhibitors are still actively pursued as well [11,29]. Another sought target is 14α-
demethylase, commonly called CYP51, whose similarity with that of pathogenic fungi has 
led to the repurposing of several anti-fungal azoles with three distinct molecules of this class 
making it to the pipeline for Chagas disease [10,30,31]. This target still attracts much 
research, as proven by a recent screening of 104,000 compounds that yielded a potent 
inhibitor [32]. 
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Although some success has been achieved with target-based approaches, it is 
considered that cell-based approaches constitute the most promising strategy when it 
comes to find drugs for parasitic diseases [33]. This is because they resemble the most 
what happens in vivo and ultimately provide the best hits, selected for their ability to 
selectively kill the parasite. The inhibition of an isolated, purified enzyme under well-defined 
and controlled conditions, that is the staple of target-based approaches, is far from the 
complexity of the parasite cellular system. Also, these assays require appropriate target 
validation by genetic or biochemical means. Because cellular permeability and intracellular 
metabolic effects are issues not initially addressed, as well as their inability to provide 
cytotoxic measurements, the attrition rates for target-based approaches are potentially 
higher. In cell-based assays like the described herein, the concomitant measure of activity 
and preliminary cytotoxicity evaluation is not only important for screening purposes but also 
allows for a more focused medicinal chemistry development phase, since only lead 
compounds with the desired potency and toxicity are prioritized. One potential disadvantage 
of such assays is the low throughput, but we have successfully screened up to 10,000 
compounds per week with minimal automation using the protocol described in this paper. 
Target deconvolution, although not mandatory, is usually recommended in later 
development phases for the drugs discovered by this strategy. 
Some attempts have been made to develop target-free assays for Chagas disease. 
One study by Engel et al. used bovine embryo skeletal muscle and Huh-7 cells infected with 
trypomastigotes and stained with DAPI to screen a known library of 909 FDA approved 
drugs [23]. Although it represents an advancement face to previous studies, the infection 
ratios acquired with this protocol did not surpass 30%, and is limited by a 96 well format 
that offers low throughput. A later study tried to improve host cell segmentation by 
transfecting mammalian cells with a GFP reporter gene that facilitates boundary 
identification but that adds a non-natural interference that may potentially affect the assay 
[34]. Similarly to the previous screening, infection ratios observed were also low and 
parasite detection was poor. 
The screening assay herein described is a considerable advancement over previous 
protocols because it uses both cells and parasites not genetically modified, uses only one 
fluorescence measurement and quantifies infection ratio. The statistical Z’ value of  0.81 is 
proof of the robustness of the screening assay. 
The screening of the anti-kinase/phosphatase library identified 33 compounds that 
could be grouped into 7 clusters (data not shown) of active compounds able to clear the 
infection. All the 33 molecules had a IC50 lower than 20 μM with 8 having an IC50 lower than 
5 μM. The most active compound found had an IC50 of 460 nM. The majority of the top 
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active compounds also had high CC50, with the highest concentration tested not reaching a 
CR of 0.5 and suggesting that selectivity indexes could be even higher. Altogether, none of 
the compounds presented a selectivity index bigger than 31, with only 11 compounds being 
bigger than 5. 
When we look at the core structures of the majority of the clusters (data not shown), 
we can clearly see the similarity between their constitutive heterocyclic backbone and the 
core of a purine, a component of ATP molecules that participate in kinase and phosphatase 
reactions. ATP-competitive inhibitors are one of the four main groups of kinase inhibitors, 
and although not the ideal (like activation inhibitors) they comprise the most common class 
actually in clinical trials [35]. 
As was previously stated, T. cruzi and other trypanosomatids have a comparatively 
big kinome. One possibility is that while in metazoa and yeast the ultimate targets of many 
signaling cascades are transcriptions factors which then trigger the expression of new sets 
of genes, in trypanosomes there is an indiscriminate transcription of most genes in large 
polycistronic units. Thus signaling cascades mediated by kinases may have a function in 
post-transcriptional regulation. 
Some trypanosomatid kinases have been proved to be essential for parasite 
viability, but the fact that the compounds may be targeting a host kinase shall not be 
discarded. For instance, a host cell kinase has been related with T. cruzi invasion [36]. It 
cannot be excluded that the compounds may be targeting host cell kinases responsible for 
normal cellular functions that the parasite may require. The compounds discovered in this 
study may be useful not only for T. cruzi but also for other trypanosomatids due to kinome 
identity [13]. 
Another major advantage of our assay and respective analysis software was the 
possibility to detect compounds that might be interfering with the parasite intracellular 
development by making use of all the data provided by the image analysis. Our phenotypic 
selection yield compounds that displayed distinct phenotypes in relation to stage of the 
intracellular cycle of T. cruzi being affected. The three exemplified compounds displayed 
specific phenotypes that, as far as we are aware, have not been previously described. 
Additionally, our results suggest that it may be possible to stop the parasite development in 
specific stages inside cells. Because T. cruzi biology is still poorly understood in comparison 
to other trypanosomatids, in part due to its complex genetics [37] and also because of 
absence of functional RNAi interference machinery [38], the finding of such chemical 
compounds may be useful as biological probes to study the parasite. Questions like what 
triggers the stage differentiation and the pathways involved, or what factors are associated 
with parasite intracellular persistence could be answered with the help of such compounds. 
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Also, the identification of new drug targets by chemical genomics is a possibility. Since 
many kinases are involved in cell cycle regulation in eukaryotic cells, these could present a 
theoretical target of our compounds. Other possible future application of such 
immunofluorescence assay could be the analysis of known and novel compounds active 
against the parasite, in order to elucidate their mechanism of action. A downside to the 
assay is the need to test the two antibodies in separate, since they are both monoclonal 
produced in the mouse. A future improvement can be the development of a high-content 
immunofluorescence able to simultaneously access amastigote and trypomastigotes stage, 
either by selecting a different antibody from other source or by differentially labeling of one 
of the monoclonal antibodies. 
 
 
CONCLUSION 
 
This work presented an advanced and optimized HCS assay for Chagas disease 
that is a step forward compared to previous studies in terms of simplicity, throughput, 
adaptability and quality of the results. A total of 7 clusters originated form an anti-kinase 
drug library is reported and should be further studied due to the potential of targeting this 
parasite kinome. Additionally, our analysis permitted the identification of compounds that 
were able to interfere with the normal development cycle of the parasite in its intracellular 
portion, and are then suggested as chemical tools to help elucidate parasite biology. 
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4.2.1.2. Enantiomers of nifurtimox do not exhibit stereoselective anti-Trypanosoma 
cruzi activity, toxicity, or pharmacokinetic properties 
 
 
Carolina B. Moraes, Karen L. White, Stéphanie Braillard, Catherine Perez, Junghyun Goo, 
Luis Gaspar, David M. Shackleford, Anabela Cordeiro-da-Silva, R. C. Andrew Thompson, 
Lucio Freitas-Junior, Susan A. Charman, Eric Chatelain. 
 
 
Published at Antimicrobial Agents and Chemotherapy 2015, volume 59, number 6, pages 
3645-3647. 
 
 
Objectives of the study: 
 
Nifurtimox is currently synthetized and administrated as a racemic mixture. To test 
whether one of the enantiomers of nifurtimox was more or less active, toxic or had more 
advantageous pharmacokinetic properties, a detailed study assessing those characteristics 
was undertaken. 
 
 
Main results: 
 
→ The separated enantiomers, R-nifurtimox and S-nifurtimox, did not show statistically 
significant different properties in what concerns antiparasitic activity, host cell toxicity, nor 
displayed distinct pharmacokinetic properties. 
 
 
Conclusion: 
 
The study did not support the use of nifurtimox as a separate enantiomer, since any 
of them had any advantage over the currently used racemic mixture. 
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4.2.1.3. Synthesis of new 7-aryltioetherthieno[3,2-b]pyridines bearing arylamides or 
1,2,3-triazoles 1,4-disubstituted and evaluation of their antiparasitic activity against 
Leishmania infantum, Trypanosoma brucei and Trypanosoma cruzi 
 
 
Joana F. Campos, Gabriela Cristo, Luís Gaspar, Agathe Begouin, Catarina P. Baptista, 
Maria-João R. P. Queiroz and Anabela Cordeiro-da-Silva 
 
Manuscript in preparation 
 
 
Objectives of the study: 
 
The present study focused on the synthesis of new 7-arylthioetherthieno[3,2-
b]pyridine derivatives and their evaluation as antiparasitic agents against L. infantum, T. 
brucei and T. cruzi, with the last parasite being assayed with an HCS protocol. 
 
 
Main results: 
 
→ Seven new chemical entities belonging to two different scaffolds were synthetized and 
evaluated against three trypanosomatids. The antiparasitic activity of the derivatives was 
superior for both Trypanosoma species, whereas no significant activity was found against 
L. infantum parasites.  
 
Conclusion: 
 
In conclusion, although the newly synthetized compounds display some antiparasitic 
activity, new derivatives with increased potency and higher selectivity should be pursued. 
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Abstract 
 
New 7-arylthioetherthieno[3,2-b]pyridines bearing arylamides or 1,2,3-triazoles 
were synthesized by  reaction of 3-(thieno[3,2-b]pyridin-7-ylthio)aniline either with benzoyl 
chlorides to give the first or, in one pot procedure via the corresponding azide by a Cu(I)-
catalyzed azide-alkyne cycloaddition (CuAAC) to give the latter.  The anti-parasitic activity 
of the compounds obtained was evaluated at 10 µM against Leishmania infantum, 
Trypanosoma brucei and Trypanosoma cruzi. The diarylamide with a NO2 group in the meta 
position relatively to the carbonyl of the amide presented anti-parasitic activity against both 
T. brucei and T. cruzi and a F atom in the para position resulted in high activity for T. brucei 
and L. infantum but only moderate for T. cruzi. When the amide linkage was replaced by a 
1,2,3-triazole 1,4-disubstituted moiety no activity for L. infantum was observed for the tested 
compounds; for the compound with a phenyl group in the triazole high activity was shown 
for T. cruzi  and only moderate was observed for T. brucei; the compound with a F atom in 
the meta position showed activity for both T. brucei and T. cruzi; the substitution with a 
pyridine or a thiophene,  resulted in a high activity for both T. brucei and T. cruzi only for 
the thiophene derivative. Nevertheless, at the tested concentration the compounds did not 
show toxicity using MTT assay in PMA-differentiated THP-1 cells. However NOAELs 
indicate that selectivity may be improved. 
 
Keywords: 7-arylthioetherthieno[3,2-b]pyridines, 1,2,3-triazoles, diarylamides, anti-
parasitic activity, cytotoxicity. 
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Parasitic diseases caused by trypanosomatids such as Leishmania spp., 
Trypanosoma cruzi and Trypanosoma brucei are a group of communicable diseases mostly 
affecting people in developing countries. These diseases are responsible for a major part 
of the global morbidity, mortality and poverty.1 There is still no vaccine available and 
chemotherapies are far from satisfactory due to the emergence of resistance, toxicity-
related side effects, and lack of efficacy. As a consequence, the development of new drugs 
to treat these diseases is an urgent need.2,3 
The thieno[3,2-b]pyridine derivatives have shown several biological activities.4 The 
amide and 1,2,3-triazoles 1,4-disubstituted linkages are also present in different bioactive 
compounds.5 Our research group has been interested in the synthesis of thieno[3,2-
b]pyridine derivatives, namely as antitumor6 and antiogenic compounds.7 Our previous 
results had led us to search for new molecules with trypanocidal activity. Here we present 
the synthesis of new di(hetero)arylthioethers in the thieno[3,2-b]pyridine series, all 
substituted in the meta position relative to the thioether by arylamides or 1,2,3-triazole 1,4-
disubstituted moieties. The anti-parasitic activity of the compounds was evaluated against 
Leishmania infantum, Trypanosoma brucei and Trypanosoma cruzi. 
From the 3-(thieno[3,2-b]pyridin-7-ylthio)aniline (1a), previously prepared by us,7 
arylamides 2a-2c and 1,2,3-triazoles 1,4-disubstituted 3a-3d were synthesized either by 
reaction with benzoyl chlorides in N-methylpyrrolidinone (NMP) at RT overnight8 to give the 
first in moderate to good yields (Scheme 1) or, in a two steps one pot procedure using the 
mild conditions described in 2007 by Moses et al.,9 with tert-butyl nitrite (t-BuONO) and 
azidotrimethylsilane (TMSN3) to form the corresponding azide intermediate, followed by the 
addition of CuSO4.5H2O, sodium ascorbate and (hetero)arylalkynes by a Cu(I)-catalyzed 
azide-alkyne cycloaddition (CuAAC),10 to give the latter in good to high yields (Scheme 2). 
The azide 1b was isolated once in excellent yield (92%) and was fully characterized. 
 
N
S
S NH2
Cl
O
NMP, rt, overnight
N
S
S
H
N
O
2a R1 = NO2 , R
2 = H, 45%
2b R1 = F , R2 = H, 60%
2c R1 = H, R2 = F, 55%
R1
R2
R1
R2
1a
 
Scheme 1 Synthesis of di(hetero)arylamide thieno[3,2-b]pyridine thioethers  2a-2c. 
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N
S
S N3
N
S
S N
NN
(Het)Ar
i
i: t-BuONO (1.5 equiv.), TMSN3 (1.2 equiv.), CH3CN, 0 ºC to rt, 5-6h. 
ii: (Hetero)arylalkyne (1.0 equiv.), CuSO4 (10 mol%), sodium ascorbate (2.0 equiv.), CH3CN, rt.
ii
3a
1b
1a
3b
N
3c
3d
F
S
,50%
,80%
,50%
,70%
Scheme 2 Synthesis of 1,4-disubstituted (hetero)aryl-1,2,3-triazole thieno[3,2-b]pyridine7-
arylthioethers  3a-3d. 
 
The Table 1 summarizes the results obtained for the anti-parasitic activity of 
compounds 2a-2c and 3a-3d at 10 μM concentration. From the results we can conclude 
that the diarylamide 2a with a nitro group in the meta position relatively to the carbonyl group 
presents a strong inhibitory activity for T. brucei (102±0% inhibition) and T. cruzi (95±3% 
inhibition) and no activity for L. infantum. When a F atom is placed in the same position of 
the nitro group in amide 2b, there was a decrease of the inhibitory activity for T. brucei 
(26±9% inhibition) and T. cruzi (52±10% inhibition). Similarly, 2b showed no activity against 
L. infantum. The change of the F atom to the para position in amide 2c, gave a high 
inhibitory activity for T. brucei (102±0% inhibition), an almost complete inhibition for L. 
infantum (81±5% inhibition), and a moderate activity for T. cruzi (52±10% inhibition). With 
respect to toxicity, these amides showed some cytotoxicity with NOAEL (no observed 
adverse effect level) > 12.5 μM for 2a, 2c and > 25 μM for 2b. 
When the amide linkage is replaced by a 1,2,3-triazole 1,4-disubstituted moiety, no 
anti-leishmanial activity was found for all the compounds. For compound 3a with a phenyl 
group at the 4-position of the triazole, a high inhibitory activity was found for T. cruzi (97±1% 
inhibition) and a moderate inhibitory activity was observed for T. brucei (64±0% inhibition). 
Compound 3b with a F atom in the meta position showed high inhibitory activity for T. brucei 
and for T. cruzi (98±0% and 81±4% inhibition, respectively). The substitution with a pyridine 
or a thiophene in their 3-positions, 3c and 3d, respectively, resulted in a high inhibitory 
activity for T. brucei and for T. cruzi (97±1% and 80±3% inhibition, respectively) only for 
compound 3d. Compound 3c showed a moderate activity against T. brucei (61±15% 
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inhibition) and a mild activity against T. cruzi (31±6% inhibition). With respect to toxicity, 
these triazoles show a clear tendency, with compound 3b with a F atom in the meta position 
showing high cytotoxicity with NOAEL > 12.5 μM, followed for compound 3d showing 
NOAEL > 25 μM, and compounds 3a and 3c that are less toxic with NOAEL > 50 μM and 
100 μM, respectively. 
 
Table 1. Anti-parasitic activity against Leishmania infantum intracellular amastigotes, Trypanosoma 
brucei bloodstream forms, Trypanosoma cruzi amastigotes and cytotoxicity against THP1-derived 
macrophages (NOAEL). 
Compound 
10 μM single dose testing (%activity ± SD) 
Toxicity 
NOAEL 
(μM) 
 Leishmania infantum 
intracellular 
amastigotes 
 
Trypanosoma 
brucei  
 
Trypanosoma 
cruzi  
 
 
 
N A 
 
102 ± 0 
 
95 ± 3 
 
> 12.5 
 
 
N .A 
 
26 ± 9 
 
52 ± 10 
 
> 25 
 
 
81 ± 5 
 
102 ± 0 
 
47 ± 1 
 
> 12.5 
 
 
N.A. 
 
64 ± 0 
 
97 ± 1 
 
> 50 
 
 
N.A. 
 
98 ± 0 
 
81 ± 4 
 
> 12.5 
 
 
N.A. 
 
61 ± 15 
 
31 ± 6 
 
> 100 
 
 
N.A. 
 
97 ± 1 
 
80 ± 3 
 
> 25 
Results show means activities of at least three independent assays. NOAEL= No-Observed Adverse Effect 
Level (MTT assay in PMA-differentiated THP-1 cells). N.A., No Activity. 
 
All the compounds that presented more than 50% of activity towards any of the 
parasites were additionally tested at 1 μM. None of the compounds tested at this lower 
concentration were active against any of the parasites (data not shown). These results 
suggest that the inhibitory activity is a consequence of nonspecific toxicity mechanisms. All 
the assays were controlled with a reference drug for each of the diseases as seen in Table 
2, miltefosine for Leishmania infantum, pentamidine for Trypanosoma brucei and 
benznidazole for Trypanosoma cruzi. 
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Table 2. In vitro activity of reference drugs for Leishmania infantum, Trypanosoma brucei, Trypanosoma cruzi 
and cytotoxicity against mammalian cells 
Compound 
IC50  
Cytotoxicity  Leishmania infantum 
intracellular 
amastigotes 
 
Trypanosoma 
brucei  
 
Trypanosoma 
cruzi  
 
 
Miltefosine 
 
 
2.9 ± 0.5 μM 
 
N. A. 
 
N. A. 
 
15.9 ± 1.2 μM* 
 
 
Pentamidine 
 
 
 
 
N. A. 
 
2.94 ±  0.74 nM 
 
N. A. 
 
47.8 ± 3.3 μM* 
  
Benzinidazole 
 
 
N. A. 
 
N. A. 
 
1.23 ± 0.30 μM 
 
> 100 μM† 
* THP-1 -derived macrophages; †C2C12 cardiomyocytes 
 
Conclusions 
 
In this paper we describe the synthesis of new 7-aryltioetherthieno[3,2-b]pyridines 
bearing arylamides or 1,2,3-triazoles 1,4-disubstituted moieties and their biological activity 
against important disease causing parasites, the trypanosomatids Leishmania infantum, 
Trypanosoma cruzi and Trypanosoma brucei. The compounds synthetized were generally 
active against the parasites at both extracellular and intracellular stages. However, some of 
the compounds had also a NOAEL close to the dose tested in the parasitic assays (10 μM), 
hinting at nonspecific toxicity mechanisms and low selectivity towards trypanosomes. More 
derivatives should be synthetized in order to increase potency, selectivity or both. 
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Supporting Information contains the experimental part for chemistry synthesis, including 
the reaction conditions and characterization of the compounds prepared as well as the 
description of the materials and methods used in biologic activity assays. 
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4.2.1.4. Exploiting the antiparasitic activity of naphthalimides derivatives 
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Objectives of the study: 
 
This work aimed at the characterization of the antiparasitic activity of a series of 
single naphthalimides against L. infantum, T. cruzi and T. brucei. The determination of the 
structure activity for the various derivatives was pursued. 
 
 
Main results: 
 
→ Most derivatives have low or no activity against both intracellular parasites L. infantum 
and T. cruzi. 
 
→ Overall, the derivatives were mostly active against bloodstream forms of T. brucei 
parasites, in particular the compounds containing primary alkylamines. Structure activity 
relationship was only observed for urea derivatives. 
 
 
Conclusion: 
 
The presence of just one naphthalimide group seems to drastically decrease the 
antiparasitic activity of the molecules, a fact particularly noted against T. brucei parasites. 
Among the single naphthalimides, the group of derivatives synthetized with primary 
alkylamines and un-substituted ureas seems to be the most promising against T. brucei.  
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ABSTRACT 
 
A set of 1,8-naphtalimides derivatives were synthesized and tested against three 
protozoans that cause important human diseases: Leishmania infantum, Trypanosoma 
brucei and Trypanosoma cruzi. Additionally, toxicity was determined by growth inhibition of 
THP-1 derived macrophages. The results suggest that chemical modifications in the carbon 
chain linking the naphthalimide and the substituting groups have different effects in the 
parasites. This work should provide new insights for the design and optimization of more 
potent and directed naphthalimide derivatives against these organisms. 
 
Keywords: Naphtalimides derivatives, antiparasitic activity, cytotoxicity. 
 
MAIN TEXT 
 
Parasitic diseases caused by trypanosomatids are still an important health problem, 
mainly in tropical and subtropical areas. In addition, temperate regions of our globe, 
including North America and the Asia-Pacific region are also affected by disease-causing 
protozoans like Leishmania spp., Trypanosoma cruzi and Trypanosoma brucei. These are 
the species of trypanosomatids most associated with human health, being responsible for 
high mortality and morbidity [1]. There are still no vaccines and the actual chemotherapies 
are far from satisfactory, owing to the emergence of resistances, serious side effects, and 
its limited efficacy. Therefore, it is imperative to continue the discovery of new drugs to treat 
these diseases [2]. 
Naphthalimides and bis-naphthalimides are classes of compounds bearing aromatic 
groups that have generated intense interest by scientists around the world because of their 
many reported biological activities. Special attention has been devoted to the high 
anticancer activity of naphthalimides, which is due to their interactions with DNA by a 
mechanism of intercalation [3-5]. In addition, recent studies showed that 1,8-naphthalimide 
derivatives also demonstrated other biological activities, such as antitrypanosomal [6]. In 
this context, this work proposes to study the relationship between the structure and the 
activity of a set of 1,8-naphtalimide derivatives with 2, 3 or 4 carbons linking the 
naphthalimide moiety to different functional groups (amine, imine, guanidine, urea, amide, 
and 1,2,3-triazole) against three trypanosomatids: Leishmania infantum, Trypanosoma 
brucei and Trypanosoma cruzi. These 1,8-naphtalimide derivatives compounds had been 
recently synthesized and include naphthalimidoalkylamines 1a,b, and its heterocyclic imine 
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derivatives 2a-l, heterocyclic amine derivatives 3f,g, guanidine derivatives 4a-c, urea 
derivatives 5a-l, amide derivatives 6a-l and triazol derivatives 7d-f [7, 8]. 
 
Figure 1 - Naphthamides compounds 1a,b, 2a-l, 3f,g, 4a-c, 5a-l, 6a-l, 7d-f used in trypanosomatids 
tests: Leishmania infantum, Trypanosoma brucei, and Trypanosoma cruzi. 
 
All the naphthalimides compounds stock solutions were prepared in DMSO in a 
concentration of 10 mM and stored at -20 °C. Anti T. cruzi (Y strain) activity was performed 
by high content screening (adapted from [9]); for T. brucei (L427 Wild Type) bloodstream 
forms and axenic amastigote of L. infantum (clone MHOM/MA671TMA-P263) activity was 
determined using the resazurin-based assay [10, 11]; intracellular amastigote activity of L. 
infantum was performed by luciferase assay (adapted from [12]). The cellular toxicity of the 
compounds was evaluated on THP-1 differentiated macrophages using the MTT assay [13]. 
The table summarizes the results obtained for the compounds with relevant antiparasitic 
activity at 10 μM concentration. Overall, our results show that the best activity was against 
T. brucei. The group of naphthalimidoalkylamines represented by compound 1a and 1b 
show strong inhibition at concentration 10 μM (101±1% inhibition); however compound 1a 
presents higher toxicity with NOAEL (no observed adverse effect level) > 25 μM in 
comparison with 1b NOAEL > 100 μM, suggesting that shorter a carbon chain (n = 2) 
increases the cytotoxicity. The group of heterocyclic imines compounds 2a-l generally 
reveals good activity against T. brucei. Within the imino furan subgroup, compounds 2b, 2f 
and 2j, only 2f with 3 carbon atoms chain shows to be active (101 ± 1% inhibition), and in 
the subgroup incorporating imidazole (2d, 2h and 2l) compound 2l, with 4 carbon atoms 
chain, is the least active. The toxicity for heterocyclic imines is lower with 3 and 4 carbon 
chains. The compound with the best balance activity-toxicity belongs to compound 2e, with 
a three carbon atom chain and a pyrrole unit. Heterocyclic amines compounds are also 
active against T. brucei, our results showing almost complete inhibition with compound 3f 
(99 ± 1% inhibition) and 3g (96 ± 3% inhibition). However, compound 3g shows lower 
cytotoxicity than 3f, with NOAEL > 50 μM and > 25 μM, respectively. Guanidine substituted 
compounds 4a-c also reveal some anti-T. brucei activity, with a clear tendency for toxicity 
to decrease with the increase of the carbon chain length. Within the urea-substituted 
compounds 5a-l the most active compounds against T. brucei, at the concentrations tested, 
is 5f and 5l both with 4 carbon atom chains. Within this group, when the carbon chain 
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increases up to four carbon atoms, so does the activity increase. Also the nature of the 
terminal groups in compounds 5a-l is also found to be important for activity. Comparing the 
cytotoxicity of the four carbon chain members in this group (5c, 5f, 5i and 5l), only 
compound 5c was found non toxic, suggesting that unsubstituted ureas are less toxic than 
substituted ureas against THP-1 cell line. In relation to the triazole group, only compound 
7f shows activity against T. brucei (90 ± 3% inhibition), with toxicity increasing when the 
triazole group is linked by a 3 carbon atoms chain. Regarding T. cruzi, amine 1a and 
guanidine 4a shows modest antiparasitic activity (34 ± 9 % inhibition and 45 ± 9% inhibition, 
respectively). Urea 5l bearing a 4 carbon atoms chain and a n-butyl group as substituent 
shows to be the most active compound of all tested against T. cruzi, (81 ± 8 % inhibition). 
However, all compounds that show some activity against T. cruzi are accompanied by an 
increase in cytotoxicity, suggesting a nonspecific mechanism. Previous studies conducted 
in our laboratory have shown that bisnaphthalimidopropyl (BNIP) derivatives compounds 
exert significant effects against L. infantum [14]. Surprisingly, no significant anti-leishmanial 
activity was found for all the groups studied; either against L. infantum intracellular and 
axenic amastigotes. A hypothesis is that the activity is dependent on a second 
naphthalimide group in the molecule. Overall, the toxicity of the synthesized compounds 
with a 2 carbon atoms linker presents the higher toxicity. An exception was observed with 
the substituted urea-derived group, where the 4 carbon atoms chain compounds are the 
most toxic, with the exception urea 5c. The group of amides 6a-l compounds does not 
present relevant antiparasitic activity (data not shown).  
In conclusion, naphthalimides bearing primary alkylamines and un-substituted ureas are the 
hits for further research in Trypanosome brucei, in combination with longer linkers, and O-, 
N-functionalized linkers. No interesting results have been found to the other two 
trypanosomatids studied. 
 
Table 
Antiparasitic activity against Leishmania infantum intracellular amastigotes and axenic amastigotes, 
Trypanosoma brucei, Trypanosoma cruzi and cytotoxicity in THP1-derived macrophages for the 
compounds tested. 
Functional groups: 
naphthalimidoalkylamines 
 10μM single dose testing (% activity ± SD)  
Toxicity 
NOAEL 
(μM) Compound 
Radical / 
Carbon 
number 
 
Leishmania 
infantum 
intracellular 
amastigotes 
 
Leishmania 
infantum 
axenic 
amastigotes 
 
Trypanosoma 
brucei 
 
Trypanosoma 
cruzi 
 
1a R=NH2 / n=2  23 ± 17  5 ± 5  101 ± 1  34 ± 9  > 25 
1b R=NH2 / n=3  N. A.  N. A.  101 ± 1  N. A.  > 100 
Functional group: 
Heterocyclic imine 
          
2a X=NH/Y=C/ n=2  N. A.  9 ± 7  101 ± 2  22 ± 13  > 25 
2b X=O/ Y=C/ n=2  N. A.  5 ± 0  17 ± 12  N. A.  > 25 
2c X=S/Y=C/ n=2  N. A.  1 ± 3  8 ± 5  N. A.  > 25 
2d X=NH/Y=N/ n=2  N. A.  2 ± 1  101 ± 1  25 ± 4  > 25 
2e X=NH/Y=C/ n=3  N. A.  N. A.  101 ± 1  N. A.  > 100 
2f X=O/Y=C/ n=3  N. A.  20 ± 21  101 ± 1  N. A.  > 50 
2g X=S/Y=C/ n=3  N. A.  N. A.  101 ± 1  N. A.  > 50 
2h X=NH/Y=N/n=3  6 ± 13  23 ± 16  99 ± 2  N. A.  > 50 
2i X=NH/Y=C/ n=4  4 ± 12  1 ± 12  53 ± 5  N. A.  > 50 
2j X=O/Y=C/ n=4  N. A.  19 ± 4  26 ± 10  N. A.  > 50 
2k X=S/Y=C/ n=4  N. A.  27 ± 3  94 ± 2  N. A.  > 50 
2l X=NH/Y=N/ n=4  N. A.  24 ± 12  24 ± 3  N. A.  > 100 
Functional group: 
Heterocyclic amine 
          
3f X=O/Y=C/N=3  N. A.  13 ± 1  99 ± 1  17 ± 15  > 25 
3g X=S/ Y=C/N=3  N. A.  9 ± 4  96 ± 3  25 ± 10  > 50 
Functional group: 
Guanidine 
          
4a R=H/ n=2  N. A.  4 ± 10  100 ± 1  45 ± 9  > 25 
4b R=H/ n=3  N. A.  22 ± 8  101 ± 1  N. A.  > 50 
4c R=H/ n=4  N. A.  10 ± 2  N. A.  N. A.  > 100 
Functional group: 
Ureas 
          
5a R=H/ n=2  N. A.  14 ±1 5  N. A.  N. A.  > 25 
5b R=H/ n=3  N. A.  27 ±1 2  15 ±16  3 ± 8  > 100 
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5c R=H/ n=4  N. A.  16 ± 5  75 ± 12  N. A.  > 100 
5d 
R=4-NO2C6H4/ 
n=2 
 N. A.  . 11 ± 17  37 ± 8  N. A.  > 25 
5e 
R=4-NO2C6H4/ 
n=3 
 N. A.  N. A.  38 ± 6  26 ± 1  > 25 
5f 
R=4-NO2C6H4/ 
n=4 
 N. A.  10 ± 10  94 ± 4  N. A.  > 10 
5g R=CH2Ph/ n=2  N. A.  30 ± 6  5 ± 4  N. A.  > 25 
5h R=CH2Ph/ n=3  N. A.  16 ± 0  26 ± 6  21 ± 17  > 10 
5i R=CH2Ph/ n=4  N. A.  12 ± 12  74 ± 2  5 ± 8  > 10 
5j 
R=(CH2)3CH3/ 
n=2 
 N. A.  14 ± 1  18 ± 10  N. A.  > 50 
5k 
R=(CH2)3CH3/ 
n=3 
 N. A.  17 ± 14  18 ± 3  20 ± 12  > 25 
5l 
R=(CH2)3CH3/ 
n=4 
 N. A.  12 ± 12  96 ± 2  81 ± 8  > 10 
Functional group: 
1,2,3–Triazole 
          
7e n=2  6 ±16  13 ± 2  12 ± 4  6 ±12  > 100 
7d n=3  N. A.  11 ± 4  16 ± 6  N. A.  > 50 
7f n=4  17 ± 2  N. A.  90 ± 3  22 ± 5  > 100 
Results show means activities of at least three independent assays. NOAEL= No-Observed Adverse Effect 
Level (MTT assay in PMA-differentiated THP-1 cells); N. A. = no activity.  
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4.2.2. Target-based drug discovery 
 
4.2.2.1. Inhibitors of Trypanosoma cruzi Sir2 related protein 1 as potential drugs 
against Chagas disease 
 
 
Luís Gaspar, David M. Costa, Begoña Pérez-Cabezas, Joana Tavares, Nuno Santarém, 
Alain Pruvost, Isbaal Ramos, Ian K. Pemberton, Paul K. Thoo-Lin, Celine Ronin, Paola 
Ciapetti and Anabela Cordeiro-da-Silva 
 
 
Manuscript in preparation 
 
 
Objectives of the study: 
 
In this work, it was aimed to characterize the biochemical activity of T. cruzi Sir2rp1 
(TcSir2rp1) and the determination of its kinetic constants. In addition, it was analyzed if the 
enzyme would have druggable properties as assessed by inhibition by nicotinamide and by 
a family of compounds known to inhibit trypanosomal sirtuins, the BNIP derivatives. Finally, 
the activity of the compounds against the whole parasite in an in vitro assay as well as an 
in vivo model of disease was also determined. 
 
 
Main results: 
 
→ T. cruzi Sir2rp1 is a canonical sirtuin with NAD+-dependent deacetylase activity.  
 
→ The enzyme showed to be druggable, as demonstrated by the inhibition by the small 
molecule compound, nicotinamide. 
 
→ Some BNIP derivatives are active against TcSir2rp1. 
 
→ The BNIP derivatives are also active against intracellular amastigotes, albeit with low 
selectivity for a majority of the compounds. 
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→ The most selective compound, BNIPSpd does not present any in vivo activity. 
 
 
Conclusion: 
 
T. cruzi Sir2rp1 is, from a biochemical standpoint, a potential target against the 
parasite. Its deacetylase activity is readily inhibited not only by classic inhibitors, but also 
by experimental compounds like the trypanosomal sirtuin inhibitors BNIP derivatives. The 
in vitro activity of these inhibitors highlights the possibility of the synthesis of more potent 
and selective compounds.  
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ABSTRACT 
 
Chagas disease remains one of the most neglected diseases in the world and is the 
most important parasitic disease in Latin America. The characteristic chronic manifestation 
of chagasic cardiomyopathy is a region’s leading cause of heart-related illness, causing 
significant mortality and morbidity. Due to the limited available therapeutic options, new 
drugs are an urgent need to control the disease. Sirtuins also called Silent information 
regulator 2 (Sir2) proteins have long been suggested as interesting targets to treat different 
diseases, including parasitic infections. Recent studies on Trypanosoma cruzi sirtuins have 
hinted at the possibility to exploit this enzyme as a possible drug target. In the present work, 
the T. cruzi Sir2 related protein 1 (TcSir2rp1) is biochemically characterized for its 
deacetylase activity and its inhibition by the classic sirtuins inhibitor nicotinamide as well as 
by bisnaphthalimidopropyl (BNIP) derivatives, a class of parasitic sirtuins inhibitors. BNIPs 
ability to inhibit TcSir2rp1 and antiparasitic activity against T. cruzi amastigotes in vitro were 
investigated. BNIPSpd was found to be the most potent inhibitor of TcSir2rp1. Moreover, 
this compound showed an anti-parasitic activity similar to the reference drug benznidazole 
and the highest selectivity index among the compounds tested. Unfortunately, BNIPSpd 
failed to treat a preclinical mice model of Chagas disease possibly due to its 
pharmacokinetic profile. Medicinal chemistry modifications of the compound, as well as 
alternative formulations may improve activity and pharmacokinetics. In conclusion, the 
search for TcSir2rp1 specific inhibitors may represent a valuable strategy for drug discovery 
against T. cruzi. 
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1. Introduction 
 
Chagas disease, caused by the protozoan Trypanosoma cruzi, remains one of the 
most prevalent and neglected diseases in the world [1] and is the parasitic infirmity with the 
highest socio-economic burden in Latin America [2, 3]. While the vast majority of the newly 
acquired cases are asymptomatic, about 20 to 30% of the cases lead to the development, 
usually decades later, of the characteristic chronic chagasic cardiomyopathy that is the 
leading cause of non-ischemic heart disease in the continent [4, 5]. 
The parasite has a complex life cycle, with two hosts and four different stages: the 
replicative epimastigotes and the infective, non-replicative metacyclic trypomastigotes in 
the triatomine insect vector and the intracellular, replicative amastigote and the infective, 
non-replicative bloodstream trypomastigote in the mammalian host. This host can be the 
Humans or another of the more than one hundred mammalian species that act as natural 
reservoirs [6]. Although vectorial transmission has been greatly reduced in recent years, 
other transmission mechanisms like congenital, oral and blood and organ transfusion 
transmission still contribute to about 40,000 new cases and 12,000 deaths every year [7]. 
What used to be a local concern, has become a worldwide problem due to human 
migrations to other parts of the world like North America, Europe and Japan [8]. 
There is no available vaccine for Chagas disease, and the therapy relies on two 
drugs introduced more 40 years ago: benznidazole and nifurtimox. These drugs are far from 
ideal because of the many toxic effects and the requirement to administer them for long 
periods of time [4, 9, 10]. Thus, new drugs are an urgent need. Very few drugs have 
populated the pipeline for Chagas disease in the last decade, with most of them acting by 
the same mechanism [11]. The recent failure of clinical trials for two of these drugs, 
posaconazole and E1224, has exposed the fragilities of the chemotherapeutic pipeline and 
reinforced the need for constant drug discovery efforts to find alternative therapies [12-14]. 
Sir2 (silent information regulator 2) or sirtuins are class III histone deacetylases that 
are evolutionary conserved and present across various kingdoms of life, from bacteria to 
humans [15, 16]. They catalyze the NAD+- dependent deacetylation of acetylated lysine 
residues in a polypeptide chain, according to the reaction: 
 
Acetylated Protein + NAD+ → Deacetylated Protein + 2’-O-AADPr + Nicotinamide 
 
Besides the deacetylated lysine, other products are formed in the reaction, like 
nicotinamide (an endogenous inhibitor) and 2’-O-acetyl-ADP-ribose (2’-O-AADPr), that has 
been suggested as a second messenger [17] and has a function in promoting the 
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association of the complex Sir3/Sir2/Sir4 involved in yeast gene silencing [18]. Some human 
sirtuins like SIRT4 and SIRT6 and the protozoan Sir2 related protein 1 (Sir2rp1) from T. 
brucei and L. infantum also display ADP-ribosyltransferase activity [19-22]. However, the 
biologic role of ADP-ribosylation by sirtuins has not been clearly demonstrated and is 
currently debated to be a nonspecific side reaction [23]. In addition, some sirtuins have also 
been characterized to perform deacylase reactions beyond deacetylation, as is the case of 
SIRT5 that possesses demalonylase, desuccinylase and deglutarylase activity [24, 25]. 
Sirtuins have been attributed many roles in different organisms, including life span 
regulation, cell cycle progression, gene transcription, apoptosis, DNA repair and 
metabolism [26-29]. The human genome, as well as other mammals’ genomes, codify 7 
distinct sirtuins (SIRT1-7) [30], whose proteins are distributed in different cell compartments: 
SIRT1, SIRT6 and SIRT7 are located in the nucleus, SIRT2 is cytoplasmic (but shuttles to 
the nucleus), whereas SIRT3, SIRT4 and SIRT5 are found in the mitochondria [31]. Their 
different localizations are related with their cellular functions, for instance: nuclear SIRT1, 6 
and 7 are involved in transcription regulation [32], DNA repair [33, 34] and chromatin 
remodeling [35, 36], respectively; SIRT2 is a tubulin deacetylase that co-localizes with the 
cytoskeleton but is imported to the nucleus where it participates in cell cycle regulation [37]; 
and mitochondrial sirtuins SIRT3, 4 and 5, participate in fatty acid metabolism [38], amino 
acid metabolism [19] and the urea cycle, respectively [39]. 
By contrast, parasitic protozoa have less sirtuin homologues but they have also 
been described as “pro-life” proteins due to their importance for the normal development 
and functioning of these cells. For instance, in the apicomplexan Plasmodium falciparum, 
Sir2A and B are involved in antigenic variation, an essential process for immune system 
evasion [40, 41]. Trypanosomatids have between two to three homologues (Sir2rp1-3) with 
some of the members varying in their functions and subcellular localizations. T. brucei 
Sir2rp1 is the most characterized of the three enzymes, is located in the nucleus and seems 
to be important for the protection against DNA damage [21, 42]. TbSir2rp2 and TbSir2rp3 
are localized in the mitochondria and little is known about their function, except that they 
are all not essential for parasite survival [42]; Leishmania species also encode for three 
enzymes, but most studies are focused on Sir2rp1, that has a cytoplasmic localization. 
LiSir2rp1 from L. infantum is required for the normal replication of amastigotes [43]. T. cruzi 
genomes sequenced so far only revealed two homologues, Sir2rp1 and Sir2rp3. Two recent 
reports describe their localization in the cytoplasm and the mitochondria, respectively [44, 
45]. Overexpression of TcSir2rp1 and TcSir2rp3 revealed to interfere with epimastigotes 
growth, differentiation into metacyclic trypomastigotes, infectivity of host cells and 
intracellular amastigotes replication [44, 45]. It should be noted that some contradictory 
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findings have been reported by both research groups, differences that are likely related with 
the strategy of overexpression (constitutive [44] versus inducible [45]). A clearer role of the 
participation of Sir2rp1 and Sir2rp3 in T. cruzi life cycle and infectivity should be elucidated 
by gene knockout studies. 
In this work, we characterized for the first time the enzymatic activity of TcSir2rp1 
and search for specific inhibitors among BNIPs derivatives with anti-trypanosomal activity 
[46]. We demonstrate that TcSir2rp1 is a NAD+-dependent deacetylase that is inhibited by 
classic inhibitors as well as by some BNIP derivatives. Furthermore, we demonstrate that 
these inhibitors are also active against T. cruzi amastigotes, suggesting that TcSir2rp1 may 
be a viable drug target to explore for the chemotherapeutic control of Chagas disease. In 
addition, the in vivo activity of the most potent inhibitor and selective compound towards T. 
cruzi was evaluated by whole mice bioluminescent imaging. 
 
 
2. Materials and methods 
 
2.1. Ethics statement 
All experiments involving animals were carried out in accordance with the 
IBMC.INEB Animal Ethics Committees and the Portuguese National Authorities for Animal 
Health guidelines, according to the statements on the directive 2010/63/EU of the European 
Parliament and of the Council. 
 
2.2. Cells and Parasites 
Mouse myoblast C2C12 cell line, green monkey kidney epithelial Vero cells were 
cultured with high glucose DMEM supplemented with 10% FBS, 25 mM HEPES, 2 mM 
glutamine, 100 U/mL penicillin, 100 U/mL streptomycin and maintained in a humid 5% CO2 
atmosphere at 37ªC. 
T. cruzi wt and Luc+ Y strain trypomastigotes were maintained by in vitro infection of 
a monolayer of Vero cells and harvested by collection of the supernatant after 5 to 7 days. 
The trypomastigotes were used for the in vitro screening and to re-infect new monolayers 
for up to 10 cycles, after which point the cultures were rejected and restarted from a new 
frozen stock. Luminescent Y strain parasites were obtained by transfection as previously 
described [47]. Briefly, 10 µg of the overexpression plasmid pTREX [48], containing the 
sequence for firefly luciferase, were transfected into logarithmic Y strain epimastigotes 
using AMAXA Nucleofector II device (program V-33) with the Human T-cell nucleofector kit 
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(Lonza). Twenty-four hours after transfection, 75 µg/mL of G418 was added to the culture 
and parasites were selected for 6 weeks. Epimastigotes cultures were allowed to enrich for 
metacyclic trypomastigotes for 3 weeks, after which the parasites were used to infect 
monolayers of Vero cells in the presence of G418. The Luc+ tissue culture trypomastigotes 
released were maintained in culture by cycles of re-infection of Vero cells. 
 
2.3. Cloning, expression and purification of TcSir2rp1 
The full coding sequence of TcSir2rp1 (accession number: XP_818420.1) was PCR 
amplified from T. cruzi, CL Brener strain genomic DNA using the primers 5’-
CCATGGGAATGAATCAAGATAACGCCAACTTT-3’ and 5’-
CTCGAGTTTTCGGTCTGTCTGTGTGTACATG-3’. The gene was cloned into pET-28a 
(Novagen) using the NcoI and XhoI restriction sites, resulting in a C-terminal 6xHis tagged 
fusion protein. The plasmid was transformed into BL21 (DE3) E. coli for inducible 
expression. Bacteria were grown at 37ºC to an O.D. of 0.6 prior to overnight induction with 
0.5 mM IPTG (isopropyl-β-D-thiogalactopyranoside) at 18ºC. Cells were then pelleted, 
resuspended in buffer containing 500 mM NaCl, 20 mM Tris, pH 7.6 and disrupted by 
sonication. The lysate was cleared by centrifugation, applied to a Ni2+-NTA resin column 
and eluted with solutions of increasing concentration of imidazole. The purest fractions were 
re-purified a second time by the same technique to remove remaining contaminants as 
visible by SDS-PAGE Coomassie blue staining. The purified protein solution was passed 
through a PD-10 desalting column (GE Healthcare) and the buffer exchanged to PBS. 
Protein concentration was determined by DC Protein Assay (Bio-Rad) and aliquots were 
stored at -70ºC. Protein was Western blotted using a rabbit polyclonal anti-HisTag antibody 
in a dilution of 1:1000. 
T. brucei Sir2rp1 tagged with a hexahistidine tail has been previously expressed and 
characterized [49]. In this study, a pT7 expression vector containing the sequence for 
TbSir2rp1 (accession number: AAX70528.1) was used. Due to poor protein solubility, the 
plasmid was transformed into pLys BL21 (DE3) E. coli instead. Bacteria logarithmic grown 
at 37ºC to an O.D. of 0.6 were subject to a physicochemical shock by incubation with 2% 
ethanol in a water/ice bath for 30 minutes. Expression induction with IPTG at 0.1 mM was 
immediately followed at 18ºC for 12 hours. Purification by affinity chromatography, buffer 
exchange, protein quantification and storage was performed similarly to TcSir2rp1. 
L. infantum Sir2rp1 was expressed and purified as previously described [22]. 
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2.4. Deacetylation assays 
The deacetylase activity was measured using the commercial SIRT1/Sir2 
Deacetylase Fluorometric Assay Kit from CycLex (Japan) according to the manufacturer’s 
recommendations. Briefly, an acetylated substrate peptide with an N-terminal fluorophore 
and a C-terminal fluorescence quencher is deacetylated by a deacetylation enzyme (e.g. 
sirtuin) and becomes the substrate for a lysylendopeptidase that breaks the substrate and 
emits fluorescence. Fluorescence was measured in a fluorimetric plate reader (Synergy HT, 
BioTek) with excitation and emission wavelengths set at 340 and 440 nm, respectively, 
every 30 seconds for 1 hour. The slope of the linear part of the reaction was calculated and 
used as readout of enzyme activity. 
Kinetic constants were determined with 0.5 µg of TcSir2rp1. For the determination 
of the peptide substrate constants, NAD+ concentration was fixed at an excess of 2000 µM 
while the peptide substrate concentration was varied between 0.63 and 40 µM. For the 
NAD+ constants, the peptide substrate concentration was kept in excess at 40 µM while 
NAD+ concentration was varied from 15.63 to 2000 µM. Initial velocities were measured 
between 4 and 6 minutes where steady state conditions were assumed. Data was analyzed 
with Graphpad Prism version 6.0 software using the built-in enzyme kinetics, Michaelis-
Menten equation regression for Km and vmax determinations. kcat was calculated using the 
formula:  
𝐾𝑐𝑎𝑡 =
𝑉𝑚𝑎𝑥
[𝐸]𝑖
 
 
2.5. Synthesis of BNIP derivatives 
The following compounds were synthesized as previously reported 1-11 [46,50], 6b 
and 9a [51], and 6c [52]. Compounds 1a-c, 6a, 7a 12, 13 were newly synthetized according 
to the conditions described bellow. All starting materials were purchased from Sigma-
Aldrich, were of research-grade quality and were used without further purification. Thin 
Layer Chromatography (TLC) was performed on silica gel 60 F254 aluminum plates (Merck) 
in dichloromethane/methanol (95:5). NMR was recorded on a Bruker 400 Ultrashield 
spectrometer at 400.1 MHz for 1H and 100.6 MHz for 13C. 
 
2.5.1. Synthesis of BNIPDmPP, 12 
In a round bottomed flask, 1, 4 bis(3-aminopropyl) piperazine (0.3g, 1.498 mmol) 
and 1, 8-Naphthalic anhydride (3.011 mmol, 0.539g, 2.01 x excess) was dissolved in DMF 
(7 mL) followed by the addition of DBU (1 mL). The solution was stirred for 2 hours at 70°C 
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and was monitored using TLC. When the reaction was complete, the solution was poured 
into 50 mL of icy water and stirred with a glass rod to form a precipitate. The precipitate was 
filtered off, washed thoroughly with water and dried under vacuum at 50°C for 2 hours. The 
product, Bisnaphthalimidopropyl-piperazine (87% yield), required no further purification for 
the next step. Bisnaphthalimidopropyl-piperazine was then methylated. In a round bottomed 
flask, bisnaphthalimidopropyl-piperazine (0.25 g, 0.4464 mmol) was dissolved in 25 mL of 
anhydrous DCM followed by the addition of methyl-iodide (2 mL). The solution was boiled 
under reflux overnight to yield a precipitate which was filtered off and washed with 20 mL of 
anhydrous DCM. The methyl-iodide quaternary salt of bisnaphthalimidopropyl-piperazine 
(BNIPDmPP) (69% yield) was dried under vacuo at 50°C overnight. 
1H (DMSO-d6): δ 8.46-8.38, 7.85-7.79 (aromatic protons), 4.08 (triplet, CH2), 4.00 (triplet, 
CH2), 3.46-3.41, 3.34-3.26 (multiplet, 2 x CH2), 2.93 (singlet, 3H, CH3), 2.76-2.72 (2H, CH2), 
2.57-2.54 (2H, CH2), 2.09-2.05 (multiplet, 2H, CH2), 1.74-1.71 (multiplet, 2H, CH2). 
HRMS (ESI): calculated for C35H35N4O4 I, 702.1703, found: 575.2653 [M-I]+. 
 
2.5.2. Synthesis of BCNIPP, 13 
In a round bottomed flask, (0.596 g, 3.01 mmol) of 4-chloro-1,8-naphthalic anhydride 
was dissolved in 7 ml of DMF. 0.3g (1.498mmol) of bis(3-aminopropyl)piperazine were then 
added to the solution, followed by 0.7 ml of DBU. The solution was left to stir at 70ºC for 48 
hours. When complete, the reaction solution was poured in cold water (100ml) while stirring 
to form a precipitate as the product. This precipitate was then filtered with a Buchner funnel 
and washed up with water. The solid obtained was dried under vacuo, to yield BCNIPP 
(68% yield). 
1H NMR (CDCl3): δ = 8.56-8.40; 7.76-7.73 (naphthalimido ring protons), 4.12 (triplet, CH2-
naphthalimide), 2.21 (triplet, CH2 piperazine ring and CH2-N), 1.77 (pentet, CH2). 13C NMR 
(CDCl3): δ = 163.5 (4-chloro-naphthalimide carbonyl), 138.97-121.75 (4-chloro-
naphthalimide carbons), 56.07 (CH2-naphthalimide), 53.01 (piperazine CH2), 39.06 (CH2-
piperazine), 24.89 (CH2). 
HRMS (ESI): calculated for C34H30Cl2N4O4: 629.1644 (M+H); found: 629.1716. 
 
2.5.3. Synthesis of cis BNIP-1,4-Dacychex, 1a, trans BNIP-1,4-Dacyhex, 1b, 
and BNIP-1,4-Dabenz, 1c 
All the above diamines were treated with mesitylchloride in pyridine to yield the 
corresponding bismesityl derivatives in quantitative yields. Subsequent reaction N-
alkylation with O-tosylpropylnaphthalimide [51] gave the corresponding protected 
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bisnaphthalimidopropyl derivatives which upon deprotection with HBr/g.acetic acid in 
dichloromethane [51] yielded 1a, 1b and 1c (Figure 1). 
 
 
Figure 1. Schematic representation of the synthesis of compounds: cis BNIP-1,4-Dacyhex (1a), trans 
BNIP-1,4-Dacyhex (1b) and BNIP-1,4-Babenz (1c). 
 
Cis BNIP-1,4-Dacyhex, 1a 
HRMS (ESI): calculated for C36H36N4O4 2HBr: 748.1261, 589.2809 ([M+H]+-2HBr), 
found: 589.2798 ([M+H]+-2HBr). 
 
Trans BNIP-1,4-Dacyhex, 1b 
After N-alkylation step, the crude was thoroughly dried in a vacuum oven. The pale 
brown solid was re-suspended in hot toluene. The latter was quickly filtered and washed 
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with hot toluene. The resulting precipitate was dried under vacuo and the solid obtained 
gave a single spot on TLC (64%) as the protected trans BNIP-1,4-Dacyhex. 
The dibromide salt was obtained in quantitative yield. 
1H NMR (400.1 MHz, DMSO-d6): δ 8.70-7.60 (m, aromatic naphthalimido ring protons), 4.20 
(t, 2 x CH2-N), 3.4 0(s, CH2-N), 3.10 (s, NH), 2.20-2.10 (m, CH2), 1.50 (t, CH). 13C NMR 
(DMSO): δ 164.26 (C=O), 134.92-122.64 (Aromatic protons from the Naphthlimido rings), 
55.06 (CH), 42.74 (CH2), 37.59 (CH2), 26.91 (CH2). 
HRMS (ESI): calculated for C36H36N4O4 2HBr: 748.1261, 589.2809 ([M+H]+-2HBr), found: 
589.2808 ([M+H]+-2HBr). 
 
BNIP-1,4-Dabenz, 1c 
p-phenylenediamine, 1, (1 g; 9.25 mmol) was dissolved in pyridine (20 mL) and the 
solution was stirred. Mesithylenesulphonyl (Mts) chloride (4.25 g; 19.425 mmol) (2.1 M 
excess) was then added and the reaction was left stirring for 4h at room temperature. After 
this time, pyridine was removed, the remaining liquid was poured in icy water (200 mL) and 
a precipitate was formed. The solution was filtered off and washed with water several times. 
The solid was dried in the vacuum oven overnight to afford N,N-bismesityldiaminobenzene 
in 93.3% yield. 
1H NMR (DMSO-d6): δ 9.9 (2H, NH), 6.9 (4H, s, Aromatic H), 6.8 (4H, s, aromatic H), 2.4 
(12H, s, 4 x CH3), 2.2 (6H, s, 2 x CH3). 13C NMR (DMSO-d6): δ 142.3-122.0 (aromatic 
carbons), 22.8 (CH2), 20.8 (CH2). 
N, N-bismesityldiaminobenzene (0.1 g) was dissolved in DMF (2.5 mL), followed by the 
addition of O-tosylpropylnaphthalimide (2.4 M excess) immediately followed by caesium 
carbonate (5 M excess). The solution was left stirring overnight at 70 °C. Reaction 
completion was monitored by thin layer chromatography. The solution was poured into icy 
water (80 mL) to form a precipitate. Precipitate was filtered off, washed thoroughly with 
water and dried in vacuo. Fully protected N,N-bismesityldiaminobenzene: 1H NMR (400.1 
MHz, CDCl3): δ 8.50-7.7o (m, aromatic protons), 7.30, 6.80 (d, mesityl aromatic protons), 
7.20 (s, diaminobenzene aromatic protons), 4.2 (t, CH2-N), 3.8 (t, CH2-N), 2.4 (s, Ar-CH3), 
2.2 (s, Ar-CH3), 1.9 ppm (t, CH2). 13C (100.6 MHz, CDCl3): δ 164.00 (C=O), 134.00-122.00 
(aromatic carbons), 143.00-132.00 (Mesityl aromatic carbons), 140.00-138.00 
(diaminobenzene aromatic carbons), 48.00, 38.00, 27.00 (3 x CH2), 23.00, 21.00 ppm 
(Mesityl-CH3).  
Protected BNIP-1,4-Dabenz (0.1 g; 0.106 mmol) was dissolved in DCM (5 mL) with heating 
up and stirring. HBr/CH3COOH solution (385 µL) was added and solution was left in the 
fume cupboard at room temperature four days to form very fine precipitate which was 
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centrifuged, washed with DCM and ether and centrifuged after each wash to give the final 
product BNIP-1,4-Dabenz 1c (23.% yield). 1H (DMSO-d6): 8.51-8.40, 7.89-7.84, 7.19-6.90 
(Aromatic protons from the naphthalimido and benzene rings, 4.15-4.10 (4H, 2xCH2), 3.22-
3.19 (4H, 2xCH2), 1.99-1.92 (4H, 2xCH2). 13C NMR (DMSO-d6): δ 164.10 (C=O), 134.80-
122.60 (aromatic carbons), 55.60 (CH2), 37.90 (CH2). 
LRMS for C36H30N4O4 was 742.09, 582.23 [M-2HBr]+, found: 582.20 [M-2HBr]+, 583.20 
([M+H]+) and 605.0 m/z ([M+Na]+). 
 
2.5.4. Synthesis of BNIPDPP salt, 6a 
In a round bottom flask (50 cm3), 1,3-bis-(4-piperidyl)propane (0.25 g, 1.19x10-3 
mol,) and toluenesulfonyloxypropylnaphtalamide (0.98 g, 2.39x10-3 mol) were dissolved in 
THF(6 mL). The reaction was refluxed at 50oC for 15 minutes followed by the addition of 
caesium carbonate (1 g, 3.069x10-3 mol), the reaction was left to stir overnight at 50oC. The 
resulting solution was poured into icy water (100 mL). A precipitate was formed and after 
vacuum filtration, the product was dried in a vacuum oven at 45oC overnight. The crude 
product (base of BNIPDPP) was recrystallized from ethanol (64.8%). 
1H-NMR (CDCl3): δH 8.52– 8.50 (2H, CH aromatic protons), 8.15– 8.11 (2H, CH aromatic 
protons), 7.70–7.65 (2H, CH aromatic protons), 4.17– 4.14 (2, CH2 protons), 2.84 – 2.82 
(2H, CH2 protons), 2.41 – 2.37 (2H, CH2 protons), 1.91-1.83 (2H, CH2 protons), 1.79-1.74 
(2H, CH2 protons), 1.51-1.48 (2H, CH2 protons), 1.71-1.09 (H, CH protons) ppm. 
In a round bottom flask (50 cm3), the free base BNIPDPP (1 g, 1.459x10-3 mol) was 
dissolved in DCM (20 mL) and HBr/CH3CO2H (2 mL) was added slowly. The reaction was 
stirred for 2 hours at room temperature to yield a precipitate. The latter was filtered off by 
and washed with DCM (30 mL) and ether (10 mL). The BNIPDPP salt was dried under 
vacuo at 45oC for 2 hours (yield 72.3%). 
1H-NMR (CDCl3): δH 8.53 – 8.51 (2H, CH aromatic protons), 8.14 – 8.12 (2H, CH aromatic 
protons), 7.70 – 7.66 (2H, CH aromatic protons), 4.69 (2H, CH2 protons), 4.17 – 4.14 (2H, 
CH2 protons), 2.84 – 2.82 (2H, CH2 protons), 2.41 – 2.37 (2H, CH2 protons), 1.91-1.83 (2H, 
CH2 protons), 1.79-1.74 (2H, CH2 protons), 1.51-1.48 (2H, CH2 protons), 1.71-1.09 (H, CH 
proton) ppm. 
HRMS (ESI): calculated for C43H48N4O4 [M+1]+ - 2Br: 685.3748, found: 685.3736. 
 
2.5.5. Synthesis of BNIPDapp, 7a 
Synthesis of N,N-dimesityl-aminopropylpiperazine. In a round bottomed flask, 1 g of 
1,4 bis(3-aminopropyl)piperazine (0.0499 mol) was dissolved in 10 mL of anhydrous 
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pyridine. The solution was stirred at 0°C (on ice) then mesitylenesulfonylchloride (Mts-Cl) 
(2.19 g, 0.01003 mol, 2.01 x excess) was added slowly, over 15 minutes. The reaction was 
stirred for 1 hour at 0°C (on ice) and monitored using TLC. When complete, the solution 
was poured into 50 mL of icy water while stirring with a glass rod and left to settle for 15 
minutes to form a precipitate. The latter was filtered off, washed thoroughly with water and 
dried under vacuo, followed by recrystallisation from ethanol (36%). In a round bottomed 
flask, N,N-dimesityl-aminopropylpiperazine (0.3 g, 0.5357 mmol) and O-
tosylpropylphthalimide (0.46 g, 1.125 mmol, 2.01 x excess) was dissolved in 6 mL of DMF. 
Once fully dissolved cesium carbonate (0.873 g, 2.6785 mmol) was added slowly. The 
solution was stirred overnight at 60°C. When complete, the solution was poured into 50 mL 
of icy water and stirred with a glass rod to yield a precipitate. The latter was filtered off, 
washed thoroughly with water and then dried under vacuum at 50°C. The crude product 
was recrystallized from ethanol to give BNIP-Di-Mts-aminopropylpiperazine (49% yield). In 
a round bottomed flask, 0.23 g of BNIP-Di-Mts-aminopropylpiperazine (0.222 mmol) was 
dissolved in 1 0mL of anhydrous dichloromethane (DCM) followed by the addition of 1 mL 
of hydrobromic acid in glacial acetic acid (HBr/gCH3CO2H). The solution was left stirring for 
24 hours at room temperature and monitored using TLC. When complete, the precipitate 
formed was filtered off and washed with 20 mL of anhydrous DCM and 5 mL of ether. The 
dihydro-bromic salt of bisnaphthalimidopropyl-diamino-propylpiperazine (BNIPDapp) (75% 
yield). 
BNIPDapp: 1H NMR (DMSO): δ 8.5-7.5 (aromatic protons), 4.1 (CH2-Naphth), 2.6 (CH2-NH, 
in chain), 2.5 (CH2-N, from ring), 2.0 (NH) and 1.5 (CH2). 13C NMR (DMSO): δ 165.0 (C=O), 
140.0–120.0 (aromatic carbons), 70.0 (CH2, from ring), 20.0-50.0 (CH2, from chain). HRMS 
(ESI): calculated for C40H48N6O4Br2, 833.1846 [M-2H-Br]+, found: 833.1844 [M-2H-Br]+ 
 
2.6. Screening of enzyme inhibitors 
A class of bisnaphthalimidopropyl (BNIPs) derivatives previously described [46] as 
well as the newly synthetized derivatives were evaluated as potential TcSir2rp1 inhibitors. 
The enzymatic reactions were performed in the presence of the various inhibitors, 200 µM 
NAD+ and 10 µM of peptide substrate. The inhibition is expressed in percentage and was 
calculated as the ratio of velocity for the linear portion of the reaction, normalized with a no 
drug control and a reference drug control (nicotinamide at 2 mM). 
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2.7. Anti-Trypanosoma cruzi activity assays 
For the evaluation of the activity against T. cruzi amastigotes an assay using high-
content screening (HCS) was designed. In summary, 100 µL of host C2C12 cells were 
seeded in clear bottom black plates at a density of 2.5x104 cells/mL (2.5 х 103 cells/well). 
After 24 hours, 50 µL of Y strain tissue culture-derived trypomastigotes were used to infect 
the host cells at a density of 7.5 x 105/mL (3.75 x 104 parasites/well). The parasites were 
allowed to infect for a 24 hour period, after which compounds were added in a volume of 50 
µL. Final concentration of DMSO in the assay did not exceeded 0.5%. After 72 hours of 
compound incubation, the wells were fixed with 4% paraformaldehyde for 15 to 30 minutes. 
The plates were then washed once with deionized water and stained with a solution of DAPI 
(3 µM) for 1 hour. Plates were imaged in an INCell 2000 (GE Healthcare) high-content 
analyzer by taking 16 pictures per well at 20X objective amplification. Images were analyzed 
with INCell Developer software (GE Healthcare) using the segmentation of host cell nuclei 
and parasite kinetoplast DNA (kDNA). The measurement output used was the average 
number of parasites per cell calculated by the ratio of host cell nuclei/parasite kDNA. 
 
2.8.  Evaluation of BNIPSpd potential toxicity in vitro 
To evaluate in vitro toxicity towards mammalian cells (hepatocytes, neurons and 
MDCK cells, a renal cell line from dogs), all the compounds were assayed with MTT [53]. 
Additionally, for cardiotoxicity evaluation another methodology was preferred as toxic 
effects in cardiomyocytes could be affecting their function before being lethal. Therefore, 
we performed a test that determines the function of the hERG channel in response to the 
test compound. The hERG assay was performed according to the manufacturer’s protocol 
Predictor hERG Fluorescence Polarization Assay (Invitrogen). Briefly, inhibition of hERG 
channel was analyzed by competition of BNIPSpd and a high-affinity red fluorescent hERG 
channel ligand. BNIPSpd was mixed with the ligand and membranes containing hERG 
channel, incubated for 2 hours at room temperature and the fluorescence polarization was 
measured using 530 nm/590 nm ex/em filters using the Synergy 2 plate reader (Biotek). 
A set of in vitro assays were also performed in primary cells (hepatocytes and neurons) to 
evaluate BNIPSpd potential toxicity: (a) host cell nuclei counting after HOECHST staining, 
(b) viability by measuring the metabolization of WST-8 probe, (c) apoptosis induction 
through caspase 3/7 activation, (d) evaluation of mitochondrial dysfunction by measuring 
the membrane potential using TMRM probe, (e) membrane integrity by measuring the 
extracellular LDH, (f) DNA damage by histone H2AX phosphorylation (exclusively in 
hepatocytes) and (g) imaging of neurite outgrowth (exclusively in neurons).  
Part IV – Objectives and results 
128 
The assays were performed 24 hours after cell collection and isolation. For 
apoptosis, TMRM, HOECHST and WST-8 assays, cells were seeded at a density of 5000 
cells/well in coated 96 well plates, incubated for 24 hours with the compound and then 
stained during 60 minutes with the following fluorescent probes: 5 µM CellEvent Caspase 
3/7 Green Detection Reagent (Invitrogen) for measuring caspase 3/7 activation, 50 µM 
tetramethyl rhodamine methyl ester (TMRM probe, Anaspec Inc.) for measuring 
mitochondrial depolarization related to transient cytosolic Ca2+ signals, 5 µg/mL of 
HOECHST (Sigma-Aldrich) for nuclei detection and 10 µL/well of WST-8 reagent (Sigma-
Aldrich) to detect viable cells. After 60 minutes, absorbance at 450 nm was measured in 
order to analyze cell viability (WST-8). After that, cells were washed three times and 
analyzed using the automatic fluorescence microscope BD Pathway 855. Pictures were 
taken using the a 20X objective and 488nm/515nm ex/em filters for CellEvent Caspase 3/7 
reagent, 555nm/645nm ex/em filters for TMRM and 380nm/460nm ex/em filters for 
HOECHST. Data were analyzed with AttoVision (Becton Dickinson). The LDH assay was 
performed according to the manufacturer's protocol, Cytotoxicity Detection Kit LDH 
(Roche). LDH release was measured in mU/L in culture media obtained from cells subjected 
to treatments for 24 hours. The release of LDH from cells with damaged plasma membrane 
into the culture medium is assayed by incubating the clarified culture medium with sodium 
pyruvate in the presence of NADH. Pyruvic acid is catalyzed into lactic acid by free LDH 
along with a simultaneous oxidation of NADH to NAD+. The rate of oxidation of NADH to 
NAD+ was measured at 490nm using Synergy 2 from BioTek. 
For the neurite outgrowth assay, samples were washed with PBS and fixed using 
methanol for 10 minutes at -20ºC. After fixation, the samples were washed three times with 
PBS and permeabilized with PBS-Triton 0.3% for 10 minutes. The samples were washed 
three times and then blocked with BSA 0.5% in PBS for 30 minutes. Anti-tubulin III antibody 
(Sigma-Aldrich) was added at 1/1000 dilution in blocking solution and incubated for 60 
minutes at room temperature. After three washing steps, a secondary antibody Alexa 488 
was added at 1/100 and incubated for 60 minutes. After washing three times with PBS, 
pictures were taken using the BD Pathway 855 automated fluorescent microscope at 
488nm/515nm ex/em. Neurite average length was calculated using the neurite outgrowth 
module of AttoVision software (Becton Dickinson). 
DNA damage was evaluated by washing cells with PBS and fixation using 
paraformaldehyde 3% in PBS for 15 minutes. After fixation, the samples were washed three 
times with PBS and permeabilized with PBS-Triton 0.3% for 10 minutes. After washing, the 
samples were blocked with PBS-BSA 0.5% for 30 minutes. H2AX antibody (Abcam) was 
added at 1/400 in PBS-BSA 2.5% and incubated for 60 minutes at room temperature. After 
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three washing steps, the secondary antibody Alexa 488 was added 1/100 and incubated for 
60 minutes. After washing three times with PBS, pictures were taken using the BD Pathway 
855 automated fluorescent microscope at 488nm/515nm ex/em filters. To determine the 
DNA damage, intensity in the nuclei was analyzed using AttoVision software (Becton 
Dickinson). 
Nimesulide (400 µM) was included as a positive toxicity control, and the vehicle as a 
negative control. The relative percentage of deviation from the negative control was 
quantified and assigned with a number from 0 to 5 according to the following criteria: 0 (0-
20% deviation), 1 (20-40%), 2 (40-60%), 3 (60-100%), 4 (100-1000%), or 5 (>1000% 
deviation). The sum of these values was further ranked to create a combined injury criteria 
that varied from no injury (0), low injury (1 to <5), moderate injury (≥5-to <12) to high injury 
(≥ 12).  
 
2.9. In vivo activity  
To evaluate BNIPSpd efficacy in vivo, five to six weeks old female BALB/c mice 
were obtained from Charles River and infected with T. cruzi trypomastigotes expressing 
luciferase. Parasites were collected from the supernatants of a monolayer of Vero infected 
cells, washed and resuspended in PBS-glucose 0.2%, and injected intraperitoneally in mice 
(1x104 per mouse). After 7 days of infection, mice were treated with drugs for 4 consecutive 
days by oral route (benznidazole in 20% Kolliphor) or intravenous route (BNIPSpd in 10% 
DMSO) at a dose of 100 and 5 mg/kg/day, respectively. Infection and treatments efficiency 
were evaluated following subcutaneous injection of 2.1 mg of luciferin and through whole 
animal live imaging using an IVIS Lumina LT (Perkin Elmer). Images of the animals were 
analyzed by LivingImage (Xenogen). 
 
2.10. Pharmacokinetics 
The pharmacokinetic profile of BNIPSpd was determined following intravenous 
injection of 5mg/kg in BALB/c mice. The blood was collected from the tail veins after 0 min, 
5 min, 15 min, 30 min, 45 min, 1 h, 3 h, 24 h, 48 h and 72 h of drug administration. Blood 
concentrations of the drug were analyzed by UHPLC-MS/MS ESI+. 
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3. Results 
 
3.1. TcSir2rp1 is a canonical sirtuin with NAD+-dependent deacetylase activity 
The sequence of the putative Sir2rp1 gene from the reference, sequenced CL 
Brener strain [54] was retrieved from the trypanosomes genome database (accession 
number: XP_818420.1). Because of the hybrid nature of the strain, two sequences are 
currently annotated. We cloned the Esmeraldo-like protein. Globally, there is a 3% 
difference to the non-Esmeraldo like protein at the amino acid level due to two additional 
aminoacids in the C-terminal. We PCR amplified the gene with primers designed taking the 
Esmeraldo-like sequence as a template. Sequencing of the cloned sequenced inserted into 
pGEM T-easy vector, had a 100% match with the Esmeraldo-like gene. 
The gene was then cloned into pET-28a in order to yield a C-terminal hexa-histidine 
tailed protein. E. coli BL21 (DE3) transformed with the resulting plasmid produced soluble 
protein in a range of conditions, with the highest quantity being produced when the bacteria 
were induced overnight at 18ºC with 0.5 mM of IPTG. Recombinant TcSir2rp1 was 
separated from other bacterial proteins by purification with an affinity chromatography and 
imidazole was removed by buffer exchanging to PBS. The purified protein was run on SDS-
PAGE gel stained with Coomassie blue and found to be of the appropriate size 
(approximately 40 kDa), and with only residual impurities observable when 10 µg of the 
protein were loaded (Fig. 2A). Additionally, protein Western blotting with an anti-HisTag 
antibody also revealed a single band with the expected molecular weight (Fig. 2A).  
 To detect deacetylase activity, we used a commercial kit, SIRT1/Sir2 Deacetylase 
Fluorometric Assay Kit (CycLex, Japan). The reaction principle involves the deacetylation 
of a synthetic peptide substrate (Ac-peptide) that in the deacetylated form becomes the 
substrate for a lysylendopeptidase that releases a quencher group from the molecule, 
allowing the fluorophore to emit fluorescence. Deacetylase activity was detected with 0.5 
µg of protein in the presence of 200 µM of NAD+ and 10 µM of acetylated peptide substrate 
(Fig. 2B). However, when NAD+ was excluded from the reaction, there was no increase in 
fluorescence, confirming TcSir2rp1 as a NAD+-dependent deacetylase (Fig. 2B). 
Furthermore, when incubated with the histone deacetylase class I and II inhibitor trichostatin 
A (TSA) at 1 µM, TcSir2rp1 still displayed 77±8 % of activity (Fig. 2B). TSA is a poor inhibitor 
of sirtuins (class III deacetylases), confirming the classification of the protein as a canonical 
Sir2. 
The kinetics of the deacetylase activity were determined by performing the reactions 
with one of the reactants fixed in an excess concentration, while the concentration of the 
other reactant was varied, in order to have steady state conditions. When NAD+ was fixed 
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at 2000 µM, acetylated peptide was varied from 0.63 to 40 µM, and when the latter was 
kept at 40 µM, NAD+ was varied from 15.63 to 2000 µM. The initial velocities represented 
as µM.s-1 were then plotted for each condition (Fig. 2C and D). The data was analyzed by 
curve fitting the Michaelis-Mentel model available in GraphPad Prism Software 6.0. Km, vmax, 
kcat and kcat/Km values calculated are shown in Table 1. The NAD+ kinetic data obtained for 
this enzyme is highly similar to the data obtained for T. brucei Sir2rp1 [49]. Furthermore, 
comparing with other characterized sirtuins like yeast Sir2 and the human SIRT2, TcSir2rp1 
also displays a high deacetylation activity as demonstrated by the catalytic efficiency 
(Km/kcat) constants calculated for the homologue enzymes [193, 200][55, 56]. Catalytic 
efficiencies are the most relevant constant in physiological conditions since they define the 
rate of the reaction when substrate concentrations are not at saturating levels, like what 
happens for most cellular enzymatic reaction [56]. 
 
Table 1 
Kinetic parameters determined for TcSir2rp1 
 Ac-Peptide NAD+ 
Km (µM) 14.23 ± 0.61 38.32 ± 9.64 
vmax (µM.s-1) 0.034 ± 0.003 0.018 ± 0.004 
kcat (s-1) 0.136 ± 0.013 0.075 ± 0.018 
kcat/Km (mM-1.s-1) 9.585 1.956 
 
Taking into account our results, we established a screening assay where reactants 
were fixed at 10 µM (Ac-peptide) and 200 µM (NAD+). 
Nicotinamide was tested in order to evaluate if small molecules could inhibit the 
enzymatic activity described. Nicotinamide is a classic non-competitive inhibitor of sirtuins 
that has been used to characterize several enzymes [22, 57]. A dose-response curve of 
nicotinamide inhibition of TcSir2rp1 indicates an IC50 of 456±44 µM (Fig. 2E). This value is 
significantly higher when compared to the IC50 determined for other sirtuins like the human 
SIRT1 (118.3±23.6 µM), the Plasmodium falciparum Sir2A (51.2±3.0 µM) or the LiSir2rp1 
(39.4±5.0 µM) previously described [46, 58]. When a concentration of 200 µM of 
nicotinamide was tested against TbSir2rp1, LiSir2rp1 and the human SIRT1, TcSir2rp1 only 
had a mild inhibition of 34±1% whereas the inhibition was 70±5%, 82±0%, 66±10% for 
TbSir2rp1, LiSir2rp1 and human SIRT1, respectively (Fig. 2F). Some studies have 
previously reported the antiparasitic activity of nicotinamide on T. cruzi, but, to our best 
knowledge, this is the first report that proves the molecular inhibition of the parasite sirtuin 
by nicotinamide [45, 59]. 
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Figure 2. Trypanosoma cruzi Sir2rp1 characterization and inhibition by nicotinamide A) Purity 
analysis of 5 and 10 µg of TcSir2rp1 by SDS-PAGE stained with Coomassie brilliant blue (left panel). 
Western Blot analysis of 100 ng of the hexa-histidine tailed TcSir2rp1 recombinant protein with an 
anti-HisTag antibody. B) TcSir2rp1 deacetylase activity was measured with a fluorimetric kit in the 
presence or absence of NAD+ (+CTRL), and in presence of 1 µM of trichostatin A. Bars represent 
mean + standard deviation. Data of 3 independent experiments. C) Deacetylation reactions for the 
determination of the kinetic constants of Ac-peptide. NAD+ was fixed at 2000 µM while Ac-peptide 
was varied (0.63 to 40 µM). Plots of initial velocities versus [Ac-peptide] were fitted to the Michaelis-
Menten equation, yielding the kinetic constants (see Table 1). D) Deacetylation reactions for the 
determination of the kinetic constants of NAD+. Ac-peptide was fixed at 40 µM while NAD+ was varied 
(15.63 to 2000 µM). Plots of initial velocities versus [NAD+] were fitted to the Michaelis-Menten 
equation, yielding the kinetic constants (see Table 1). Dots and error bars represent mean + standard 
Part IV – Objectives and results 
133 
deviation. C-D) Data of 3 independent experiments. E) Dose-response curve of TcSir2rp1 inhibition 
by nicotinamide. Data represents the average + standard deviation of three independent 
experiments. F) Differential inhibition of TcSir2rp1, TbSir2rp1, LiSir2rp1 and hSIRT1 by a dose of 
200 µM of nicotinamide. Bars represent mean + standard deviation. Data of 2 independent 
experiments. Differences between the experimental groups were considered significant as follows: * 
p<0.05, ** p<0.005, *** p<0.001 and **** p<0.0001. 
 
3.2. Inhibitory activity of BNIP 
derivatives on TcSir2rp1  
We next evaluated the 
enzymatic inhibition of TcSir2rp1 by a 
class of experimental compounds 
previously characterized as inhibitors of 
the orthologue enzyme of L. infantum 
[46] as well as the newly synthetized 
derivatives. BNIP derivatives are 
constituted by two naphthalimidopropyl 
groups separated by a linker that varies 
in length and functional groups, and 
have been characterized as NAD+-
competitive inhibitors of LiSir2rp1 [60]. 
In this study, an additional set of 
compounds was synthetized with the 
objective of improving cellular target 
binding by including heteroatoms in the 
alkyl chain connecting the two 
naphthalimidopropyl groups, as well as 
by introducing cyclic structures in the 
linker (Figure 3). The results are 
summarized in Figure 4 A and indicate 
the percentage of inhibition of the 
NAD+-dependent deacetylase activity 
for a single dose concentration of 10 
µM. Of all the compounds tested, 
compounds 2, 3, 8, 9, 13 and 9a had a 
statistically significant inhibition of the 
enzyme (1-way ANOVA). In order to Figure 3. Chemical structures of the bisnaphtha-
limidopropyl derivatives used in the present s study. 
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verify a concentration dependent effect on enzymatic inhibition, compounds 2, 8, 9 and 9a 
were additionally tested at 50 µM, whereas compound 3 and 13 were tested at 20 µM due 
to low solubility. Inhibition percentages for this higher concentration were 55±4%, 34±11%, 
31±9%, 72±6%, 48±6 and 29±4% for compounds 2, 3, 8, 9, 13 and 9a, respectively (Fig4B). 
Only compound 9 demonstrated a statistically significant dose-dependent increase in 
inhibition (1-way ANOVA, p value <0.05). In fact, compound 9 was one of the most active 
compounds against TcSir2rp1, with a 10 µM dose inhibiting almost 50% of the NAD+-
dependent deacetylase activity, a concentration 45 times lower than the necessary for 
nicotinamide to achieve the same level of inhibition. Compound 9 is a derivative of 
compound 5 by substitution of one of the carbons in the linker chain by a nitrogen atom. 
Since compound 5 was not active against the enzyme, it is possible that the substitution of 
the nitrogen allows the establishment of additional molecular interactions with the enzyme 
and/or modifies the rigidity of the linker chain resulting in higher inhibition. Compound 9a is 
also a derivative from compound 5 with eight atoms in the linker chain separating the two 
naphthalimidopropyl groups, but with two oxygen atoms in substitution of two carbons. This 
modification also seems to increase the inhibitory activity against TcSir2rp1 (28±13%) but 
it is not as marked as for compound 9. Although a clear correlation between the length of 
the linking chain and enzymatic inhibition was established for the L. infantum orthologue 
[46], the same was not verified with TcSir2rp1. Compounds with 5 and 6 carbons in the 
linker chain also displayed some inhibitory activity against the enzyme (compound 2, 
42±13% and 3, 31±8%, respectively), but when tested at a higher concentration, the 
increase was not statistically significant. Compound 3 was only tested at 20 µM due to poor 
solubility. In general, the most active inhibitors of TcSir2rp1 were also selective towards the 
T. cruzi enzyme, as demonstrated by inhibition of a human sirtuin homologue, hSIRT1. In 
addition to hSIRT1 inhibition previously described for compounds 1-11 [46], compounds 12-
9a were also tested at 10 µM against this enzyme (Table S1). Compound 6b was the most 
active against the human homologue enzyme (44±8% of inhibition), but was a weak inhibitor 
of TcSir2rp1 (8±5%) at the same concentration of 10 µM. Compound 13 also had a reduced 
activity against hSIRT1 (15±4%), but was a much stronger inhibitor of the T. cruzi enzyme, 
with an inhibition at least 3-fold higher (50±8%). 
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Figure 4. Enzymatic inhibition of TcSir2rp1 by BNIP derivatives. A-B) The percentage of inhibition 
of the NAD+-dependent deacetylase activity of TcSir2rp1 by BNIP derivatives is represented in the y 
axis. A positive (no drug) and negative (NAM, nicotinamide at 2 mM) controls are represented. Bars 
represent the average + standard deviation of at least two independent experiments. Differences 
between the experimental groups were considered significant as follows: * p<0.05, *** p<0.001 and 
**** p<0.0001.  
 
3.3.  BNIPs are potent in vitro inhibitors of Trypanosoma cruzi intracellular 
amastigotes 
Once demonstrated that the deacetylase enzymatic activity is inhibited by some 
BNIP derivatives, the compounds were also tested against whole parasites with an in vitro 
assay using HCS and the intracellular form of amastigotes (Fig. S1). In this assay, the 
compounds are incubated for 72 hours with cells previously infected with wt trypomastigotes 
for 24 hours. The readout is done by comparing the average number of amastigotes per 
cell that developed by the end of the incubation period. The quality of the assay was 
statistically evaluated by the calculation of the z-factor [61], a calculation that represents the 
reliability of the assay in distinguishing positive controls confidently from negative controls. 
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It varies from 0 to 1, with values higher than 0.5 considered being acceptable for drug 
screening. The z-factor obtained was of 0.68, validating the use of the assay (Fig. S1B). 
The reference drug benznidazole was assayed for quality control and showed an IC50 of 
1.23±0.30 µM, in accordance with previous studies [62]. 
In order to prioritize compounds, all the 
BNIP derivatives were firstly screened 
at a single dose of 2.5 µM (Fig 5A). The 
compounds that presented high anti-
parasitic activity (>40%) and low 
toxicity (high cell ratio, defined as 
[average number of cells for the 
compound / average number of cell for 
the DMSO 0,5% control], >70%), 
represented in a blue box, were 
selected for dose-response curve 
analysis. A set of compounds that was 
not toxic at 2.5 µM (green box) was further tested at 10 µM. Again, the compounds that had 
high anti-parasitic activity and low toxicity were selected for dose-response analysis (blue 
box, Fig. 5B). Compounds 10 and 6c were not tested at 10 µM due to poor solubility. 
Figure 5. In vitro activity of BNIP 
derivatives. A) Primary screening of BNIP 
derivatives by an in vitro assay for 
intracellular T. cruzi amastigotes at a single 
dose of 2.5 µM. Values for both anti-
parasitic activity and cell ratio are 
represented in the dot plot graph. The blue 
square represents the zone of selection for 
active, low toxicity hits to be evaluated by 
dose-response curve analysis. The green 
square represents the zone of selection for 
compounds to be tested at a higher dose. 
B) Primary screening of the compounds 
selected for testing at a higher dose of 10 
µM. Values for both anti-parasitic activity 
and cell ratio are represented in the dot plot 
graph. The blue square represents the 
zone of selection for active, low toxicity hits 
to be evaluated by dose-response curve 
analysis. C) Representation of the 
selectivity indexes of the compounds 
analyzed by dose-response curve analysis, 
with the determined antiparasitic activity 
(IC50) in the y axis, and the cell ratio (CC50) 
in the x axis. Dots represent the average of 
three independent experiments. 
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Compounds 1, 6, 8, 9, 12, 13, 1a, 1b, 6a, 7a and 9a (Fig 5C and Table 2) were assayed by 
dose-response curves in the same conditions of the primary screening. Compound 9, the 
strongest inhibitor of TcSir2rp1 was also active against T. cruzi amastigotes, presenting an 
IC50 of 2.84±0.30 µM, in the range of the reference drug benznidazole (1.23±0.30 µM). In 
addition, it was the least toxic of the compounds analyzed by dose-response curve, with a 
CC50 of 24.47±0.45, resulting in a selectivity of 8.8 units. Compound 9a, an analogue of 9 
with two oxygen atoms in the linking chain instead of one nitrogen atom, was also active 
and presented a similar IC50 of 3.43±0.57 µM. However, it was less selective than compound 
9 (2.1 units). Compound 13, also an inhibitor of TcSir2rp1 (50±8%), was the most active 
compound against T. cruzi amastigotes, with an IC50 of 0.59±0.23 µM. It was not possible 
to calculate the CC50 since the highest concentration tested allowed by the solubility of the 
compound (2.5 µM) did not reduce the cell ratio below 50%, making the selectivity of at 
least 4.2. The second most potent hit, compound 1b, is a derivative of compound 1 where 
a cyclohexane cycle was introduced as a spacer between the naphthalimidopropyl groups. 
The synthesis of this compound was performed with two isomers with a significant 
difference in their antiparasitic activity, where the trans isomer (compound 1b) presents an 
IC50 of 0.78±0.12 µM and the cis isomer (compound 1a) an IC50 of 6.09±0.14 µM. Such 
difference suggests that particular stereoisomeric configurations improve antiparasitic 
activity. Activity of nicotinamide in the amastigote assay was also assessed, but there was 
no activity detected up to a concentration of 2000 µM (data not shown). 
 
Table 2 
Antiparasitic activity, cytotoxicity and selectivity index of BNIP derivatives selected for dose-response curve 
analysis. 
Compound 
Anti-T. cruzi activity 
Amastigotes µM (IC50 ± SD) 
C2C12 cytotoxicity µM 
(CC50 ± SD) 
Selectivity Index* 
1     BNIPDabut 1.71 ± 0.23 2.91 ± 0.94 1.7 
6     BNIPDanon 1.45 ± 0.37 2.35 ± 0.77 1.7 
8     BNIPDadodec 1.43 ± 0.10 1.91 ± 0.06 1.3 
9     BNIPSpd 2.84 ± 0.18 24.47 ± 0.45 8.8 
12   BNIPDmPP 28.74 ± 4.09 > 50 > 1.7 
13   BCNIPP 0.59 ± 0.23 > 2.50 > 4.2 
1a   cis BNIP-1,4-Dacyhex 6.09 ± 0.14 8.74 ± 1.14 1.4 
1b   trans BNIP-1,4-Dacyhex 0.78 ± 0.12 > 2.50 > 3.2 
6a   BNIPDPP 1.45 ± 0.30 2.88 ± 0.12 2.0 
7a   BNIPDapp 13.58 ± 2.90 19.30 ± 5.64 1.4 
9a   BNIPDaoxoct 3.43 ± 0.57 7.37 ± 0.65 2.1 
Benznidazole 1.23 ± 0.30 > 100 > 81.0 
*Selectivity Index = CC50 cell line/IC50 T. cruzi 
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3.4.  BNIPSpd failed in a preclinical mice model for Chagas disease 
Compound 9, BNIPSpd presented high enzymatic inhibition, low IC50 against the 
parasite and also higher selectivity, and based on these parameters was chosen for follow 
up characterization. The compound toxicity was further evaluated against a panel of primary 
cells to determine tissue specific toxic effects. The results of cytotoxicity against neurons, 
hepatocytes and MDCK cells, and the cardiotoxicity determination by hERG predictor 
method are summarized in Table 3. As shown, BNIPSpd presents hepatotoxicity and 
neurotoxicity values very similar to its efficacy concentration (SI 1.1 and 1.4 respectively). 
On the other hand, it seems not to be nephrotoxic (SI 35.2) nor cardiotoxic (hERG channel 
99.6% functional). The toxicity values are higher than the corresponding ones for the C2C12 
cells (Table 2 SI=8.8) but this is not surprising given the fact that the primary cells are usually 
more sensitive. Furthermore, the toxic effects at the cellular level were evaluated and 
quantified by a set of in vitro assays that include mitochondrial dysfunction, membrane 
integrity, DNA damage, apoptosis and neurite outgrowth on hepatocytes and neurons 
(Figure 6). This analysis could not be performed in the MDCK cell line due to the high 
amounts of DMSO to test the required BNIPSpd concentration and that were toxic for the 
cells. 
 
Table 3 
Cytotoxicity and selectivity of BNIPSpd 
Cell type Cytotoxicity Selectivity Index* 
Hepatotoxicity (Hepatocytes) ≥ 3.1 µM 1.1 
Neurotoxicity (Neurons) ≥ 3.9 µM 1.4 
Nephotoxicity (MDCK cells) ≥ 100 µM 35.2 
Cardiotoxicity (hERG predictor) 0.36 ± 0.51 % - 
*Selectivity Index = CC50 cell line / IC50 T. cruzi 
 
Nimesulide, an approved and widely used anti-inflammatory drug was included at a 
concentration of 400 µM as a control of toxicity [63-65]. The results are presented in Fig. 6. 
In summary, the BNIPSpd showed a low injury score for hepatocytes and moderate injury 
score for neurons. These values correspond to the range within the efficacy concentration 
for this compound (2.84 µM). Despite showing a mild injury score for neurons, it should be 
kept in mind that further analysis need to be done in order to determine whether the 
compound is able to cross or not the blood-brain barrier. Indeed, a compound could be very 
neurotoxic but never been able to reach the neurons. 
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Figure 6. In vitro hepatocytes and neurons injury scores for BNIPSpd by HCS. The score was 
calculated as the sum of individual scores obtained from a panel of in vitro cytotoxicity assays that 
include; mitochondrial dysfunction measured by TMRM probe dynamics in cells, membrane integrity 
assayed by lactate dehydrogenase quantification, DNA damage by imaging with H2AX antibody and 
apoptosis by caspase 3/7 activation or neurite outgrowth as imaged with an anti-tubulin III antibody. 
Nimesulide (400 μM), an approved drug with a mild toxicological profile, was included as a toxicity 
control. 
 
Finally, BNIPSpd in vivo activity was characterized with a murine model of T. cruzi 
infection and using bioluminescent imaging. A bioluminescent T. cruzi Y strain was obtained 
like previously described [47] and its in vitro limit of detection in the bioimaging equipment 
IVIS Lumina LT was determined to be of 104 parasites (t-test, p-value < 0.05) (Fig. S2A). 
Different numbers of Luc+ trypomastigotes were tested in order to access which condition 
yielded the best readout (Fig. S2B). When injected intraperitoneally with 104 parasites, the 
mice developed an infection at first mostly located in the site of infection (day 7) but that 
later spreads in the whole body (Fig. S2B). Similar observations were made for 105 and 106 
inocula (data not shown), but 104 parasites yielded a higher and most reproducible increase 
in the bioluminescent signal as measured by the whole body bioluminescent signal in 
average radiance. 
A regimen of 5 mg/kg/day of BNIPSpd was administered intravenously for 4 
consecutive days, while a positive control with a dose of 100 mg/kg/day of benznidazole 
per os and the respective vehicle controls were also performed (Fig. S3A). Unfortunately, 
BNIPSpd did not exhibit any in vivo activity, since bioimaging analysis demonstrates the 
infection progressed like in the animals treated with the vehicles that on average increased 
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the luminescence signal by 40-fold. By comparison, animals treated with benznidazole at 
100 mg/kg/day displayed, on average, a 700-fold reduction in the bioluminescence signal 
compared to vehicle treated mice (Fig. S3A). 
To investigate whether the lack of antiparasitic activity in vivo would be due to 
BNIPSpd pharmacokinetics profile we proceed to compound quantification in the blood over 
the time.  Analysis of the snapshot pharmacokinetics profile (Fig. S3B) may explain the lack 
of in vivo activity of BNIPSpd. For the first 30 minutes after intravenous injection of the 
compound, we verified that it never reaches a concentration equivalent to the in vitro IC50 
for T. cruzi amastigotes. The highest concentration detected in the plasma is 1.70 µM at the 
5 minutes time-point, and the compound is no longer detected after the 3 h time-point and 
up to 72 h post administration (lower limit of quantification is 8.1 nM). This pharmacokinetic 
profile indicates that a concentration of drug able to reach and clear parasitized tissues is 
not achieved in the mice. 
 
 
4. Discussion 
This work sought to explore the potential of inhibitors of TcSir2rp1, as possible 
bioactive compounds against the infection caused by this parasite. Sirtuins have long been 
proposed to be interesting targets to treat parasitic diseases [66, 67], but only recently have 
these proteins been characterized in T. cruzi [44, 45]. Even though the localization, 
expression and some of the important functions of T. cruzi sirtuins have been described, no 
biochemical characterization has been made to date. 
Our results demonstrate that the annotated coding sequence of TcSir2rp1 encodes 
a canonical sirtuin that does not display deacetylation activity in the absence of NAD+ and 
is mostly insensitive to TSA. TSA is usually included in sirtuin deacetylation activity assays 
to exclude the contribution of other histone deacetylases present in a study sample. 
Although in this study 1 µM of TSA resulted in a slightly higher inhibition when compared 
with other orthologue enzymes (see [22] and the hSIRT1 deacetylation activity described in 
the manufacturer’s manual), the lack of activity in the absence of NAD+ excludes the 
possibility of a non-sirtuin source of activity. 
The kinetic data obtained for TcSir2rp1 is highly similar to the values described for 
TbSir2rp1, despite overall sequence similarity being only 61%. However, when the core 
sirtuin Pfam domain of both proteins are aligned, identity level increases to 73%. A close 
analysis to the amino acids adjacent to the essential histidine (H142) at the catalytic site, 
demonstrates a 100% similarity of the four amino acids upstream and four downstream that 
likely participate and/or help shape the catalytic site and thus may explain the similarity 
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observed. Nonetheless, it should be noted that distant amino acids in terms of primary 
structure may have an interference on enzymatic activity, as demonstrated in the case of 
PfSir2 in which the C- and N-terminal removal led to modifications in the enzyme kinetic 
constants and sensitivity to nicotinamide [58]. 
An essential step in the evaluation of a drug target is the proof of druggability. Even 
if a gene product is deemed essential for a given organism, if the activity or function 
mediated by this protein is not amenable to modulation by small molecule inhibitors, then it 
is not considered to be a good drug target. To this end, it was sought to modulate TcSir2rp1 
with a classic inhibitor of this protein family, nicotinamide [68]. The enzymatic activity 
described was indeed inhibited by nicotinamide, although in concentrations higher than 
those previously reported for other members of the family. In particular, the IC50 for LiSir2rp1 
and hSIRT1 is 11 and 4-fold lower, respectively, than the one here reported for TcSir2rp1 
[46]. Another observation that supports the resistance to nicotinamide is the fact that even 
when 2 mM of NAD+ is used in reactions for the determination of the kinetic constants for 
NAD+, there is no decrease in enzymatic activity like previously reported for other enzymes 
[22]. Such inhibition would be expected since nicotinamide is an endogenous product of the 
deacetylation reaction. Nicotinamide binds to a distinct C pocket that appears to be 
conserved among sirtuins that have been structurally elucidated by co-crystallography [57]. 
The study of the presence and conservation of this pocket in TcSir2rp1 may shed some 
light on the resistance for nicotinamide. Although nicotinamide has some anti-parasitic 
activity against Plasmodium [69], Leishmania [70], T. brucei [71] and also T. cruzi [59], no 
confirmation of a sirtuin-mediated mechanism has been clearly established to date. In this 
study, no anti-parasitic activity was detected for nicotinamide in concentrations up to 2 mM. 
The search for additional inhibitors led to the identification of some BNIP derivatives 
as stronger inhibitors of TcSir2rp1. Also inhibitors of LiSir2rp1, this series of compounds 
were, with few exceptions active at 10 µM, with some compounds achieving 50% of 
inhibition. No correlation has been established between the most active compounds for L. 
infantum and T. cruzi enzymes, indicating that both enzymes might be differentially targeted 
by some of the derivatives belonging to this class of compounds [46]. In contrast to LiSir2rp1 
inhibition, no structure-activity relationship regarding the length of the alkyl chain linking the 
two naphthalimidopropyl groups was observed for TcSir2rp1 [60]. Although a linker of eight 
carbon atoms had no activity at 10 µM (compound 5), when some of the carbon atoms were 
substituted by heteroatoms like nitrogen (compound 9) and oxygen (compound 9a), the 
activity towards TcSir2rp1 increased, suggesting that the rigidity and/or the ability to 
establish additional molecular interactions in this part of the molecule may increase 
inhibitory activity. 
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More importantly, some enzymatic inhibitors also demonstrated a strong anti-
parasitic activity against T. cruzi amastigotes, the clinically relevant form responsible for 
infection persistence in humans. Differences observed between the enzymatic inhibition 
and the activity in the parasite may be due to distinct interactions between BNIPs and 
TcSir2rp1, or, possibly, by the contribution of a multi-target mechanism. The majority of the 
compounds demonstrated low selectivity for the parasite and were also toxic for host cells 
as indicated by the selectivity indexes calculated. A possible explanation is the 
characteristic DNA intercalation of BNIP derivatives that were originally developed as anti-
cancer agents [72, 73]. While this might explain some of the toxic effects observed for host 
cells, it should not be excluded that DNA intercalation may be contributing to the anti-
parasitic activity reported, especially since trypanosomes are susceptible to intercalating 
agents [74]. Analysis of TcSir2rp1 by Wregex and cNLS Mapper, bio-computational tools 
that identify nuclear export signals (NES) and nuclear localization signals (NLS), 
respectively, indicate the presence of non-canonical NES/NLS in the sequence of this sirtuin 
[75, 76]. Whether TcSir2rp1 does shuttle to nucleus during specific times of T. cruzi life 
cycle, possibly to perform DNA damage repair like the orthologue from T. brucei, remains 
to be reported. In fact, if TcSir2rp1 also has a role in DNA repair like its T. brucei orthologue 
[42], both sirtuin inhibition and DNA intercalation may be synergistically contributing to the 
activity observed. Activity towards other molecular targets should also no be excluded, 
especially considering that T. cruzi has another sirtuin, TcSir2rp3, that has also been 
described as having important functions in different processes of the parasite life cycle like 
metacyclogenesis, epimastigote growth and host-cell infectivity and replication [44, 45]. 
Since BNIPSpd met some of the biologic criteria recommended for T. cruzi drug discovery 
follow-up, it was decided to further evaluate it as a drug lead [77].  
The toxicity determination showed that although it has low SI values (around 1 for 
hepatocytes and neurons), the toxicity values in the µM range could be considered a 
promising starting point for further optimization in SAR rounds. Moreover, the cardiotoxicity 
evaluation, showed that the cardiomyocytes function seems not to be compromised. On the 
other hand, a more in depth analysis of the toxicity by HCS showed that there is a very 
limited injury to hepatocytes and neurons. The BNIPSpd showed no hepatotoxicity up to 
12.5µM. At 50µM there is a low injury score mainly due to caspase 3/7 activation (although 
the viability -WST8- is also altered). In regards to neurotoxicity, as expected, the neurons 
start to suffer toxicity at lower concentrations; up to 0.7 µM the neurons showed no effects 
but the injury score starts to raise in a dose dependent manner up to 12.5µM. At higher 
concentrations (50µM) the injury score is maintained at high levels. The mechanism of 
toxicity in neurons seems to be the same than the one for hepatocytes, being the caspase 
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3/7 activation the main parameter, followed by membrane integrity and then at higher 
concentrations all the parameters tested were affected. More assays need to be performed 
to evaluate the capacity of the BNIPSpd to cross the blood-brain barrier. In addition, 
BNIPSpd showed decent aqueous solubility (up to 70%) and gastric stability (100%) (data 
not shown). 
Assessment of in vivo efficacy of BNIPSpd by imaging mice infected with 
bioluminescent T. cruzi parasites revealed lack of activity in this mouse model. The results 
may be explained by the pharmacokinetics profile of the compound, that is always in a blood 
concentration bellow the in vitro IC50 for amastigotes and is no longer detected 3 hours after 
administration, even though the drug is administered by intravenous injection, the most 
bioavailable route. An explanation is that most of the compounds is rapidly metabolized in 
the organism to an inactive form. Medicinal chemistry modifications of the compound, as 
well as alternative formulations may improve activity and pharmacokinetics in the host 
organism. 
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Figure S1. Development of the high-content screening assay against intracellular amastigotes of 
Trypanosoma cruzi. A) Representative images of the control conditions used in the assay: infected 
cells, non-infected cells and infected cells treated with 100 μM of benznidazole. B) Statistical 
validation of the screening assay based on the readout of parasites per cell, with a Z value of 0.68. 
C) Dose-response curve against the reference drug benznidazole, demonstrating and IC50 in line 
with previously published values [62]. 
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Figure S2. A) In vitro detection limit of Luc+ trypomastigotes in a 96 well plate incubated with luciferin 
and imaged using the IVIS LUMINA LT. Circles and vertical lines represent the average ± standard 
deviation of the average radiance of quadruplicates. Statistical analysis was performed by standard 
t-test relative to luciferin background with no parasites. Significance is shown in asterisks (*, p-value 
≤ 0.05). B) Comparison of different inocula of Luc+ trypomastigotes (104, 105, 106) tested in BALB/c 
mice infections by quantification of the signal over 5 minutes (average radiance, photons/sec/cm²/sr) 
and representative images of the anesthetized bio-imaged mice at the time-points before and after 
treatment (day 7 and 11 after infection, respectively). 
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Figure S3. In vivo efficacy testing of BNIPSpd. A) Mice were infected with 104 luc+ trypomastigotes 
by intraperitoneal injection. Treatments (BZN, benznidazole at 100 mg/kg/day per os, and BNIPSpd 
5 mg/kg/day by intravenous injection) were initiated 7 days after infection, as well as the respective 
controls (KP, koliphor 20% per os and DMSO 10% by intravenous injection). Imaging of the whole 
mice bioluminescence was done before treatment, at 7 days post-infection and after treatment, at 11 
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days post-infection, using an IVIS LUMINA LT and upon injection of 2.1 mg luciferin. In the lower 
panel, bioluminescence average radiance (photons/sec/cm²/sr) of whole mice was quantified before 
and after treatment. Data representative of two independent experiments. B) Snapshot 
Pharmacokinetics of BNIPSpd in BALB/c mice by quantification of BNIPSpd in the blood of mice by 
UHPLC-MS/MS ESI+ at different time-points after administration of a 5 mg/kg dose by intravenous 
injection. Data is the average + standard deviation of two independent experiments. The dashed line 
represents the value of IC50 for BNIPSpd in the in vitro assay against T .cruzi amastigotes, and the 
dotted line represents the lower limit of quantification of the technique. 
 
 
Table S1 
Enzymatic inhibition of hSIRT1 by newly synthetized 
BNIPs 
Compound 
hSIRT1 inhibition at 10 µM 
 (% ± SD) 
12 n.i. 
13 15 ± 4 
1a 1 ± 1 
1b 3 ± 4 
1c n.i. 
6a 3 ± 4 
6b 44 ± 8 
6c 8 ± 1 
7a n.i. 
9a 3 ± 4 
*n.i. = no inhibition 
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4.2.2.2. Activity of bisnaphthalimidopropyl derivatives against Trypanosoma brucei 
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Objectives of the study: 
 
The potential activity of a set of BNIP derivatives against T. brucei bloodstream 
forms was evaluated in vitro and in vivo. A Sir2rp1-mediated mechanism of action was also 
evaluated. 
 
 
Main results: 
 
→ BNIP derivatives are inhibitors of T. brucei Sir2rp1 enzymatic activity, but it is unlikely 
that such inhibition is a major mechanism of action for the most active compound, 
BNIPDabut. 
 
→ BNIPDabut, the most active compound, demonstrated high activity in vitro against 
bloodstream forms with IC50 in the range of the reference drug pentamidine. 
 
→ Cytotoxicity of BNIPDabut, microsomal metabolic stability and pharmacokinetic profile 
indicate good drug-like properties that warrant in vivo efficacy testing. 
 
→ Despite high trypanocidal activity, BNIPDabut failed to cure a mouse model of acute 
infection. 
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Conclusion: 
 
BNIP derivatives, a class of compounds previously shown to possess antitumoral 
and antiparasitic activity against L. infantum also demonstrated to be highly active against 
the related trypanosomatid T. brucei both in vitro and in vivo. Furthermore, some of these 
compounds described to inhibit the L. infantum Sir2rp1 NAD+-dependent deacetylase 
enzyme also inhibited the T. brucei orthologue. However, the high IC50 observed for 
BNIPDabut against the whole parasite versus the enzyme hints at other mechanisms of 
action taking place. Pharmacokinetic and pharmacodynamic data highlight the possibility of 
further exploiting this scaffold for future lead design.
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5.1. Trypanosomiasis disease control: the missing piece 
 
Despite the efforts of many individuals and organizations over the years, human 
trypanosomiasis remains one of the most neglected diseases in the world. Chagas disease 
in particular, is a leading cause of disease and disability in Latin America, with thousands 
of deaths every year [66]. The negligence is particularly patented by the lack of new drugs. 
Indeed, the available treatment options, benznidazole and nifurtimox, were discovered more 
than 40 years ago. Different strategies have been tried to control the disease, but the most 
impactful so far has been the control of the transmitting vector led by WHO and PAHO. 
Vectorial control has caused the reduction in cases from a staggering 24 million in the 1980s 
to about 6 million nowadays [66, 174], with some countries considered to be free of domestic 
vectorial transmission. Continued and rigorous implementation of the disinfestation 
programs in the remaining zones should decrease even further the global numbers of T. 
cruzi vectorial transmission. Also, the screening of donor blood and transplant organs now 
widely implemented in the endemic regions and other parts of the world have greatly 
reduced the number of cases transmitted by this route. Whereas the global interruption of 
the domestic cycle will be a major breakthrough and reduce to a minimum the number of 
new cases of Chagas disease, complete eradication of the parasite, however, is unlikely to 
be achieved due to the huge natural reservoir of T. cruzi and the many species of 
triatomines capable of transmission in the sylvatic environment [92, 99, 100]. 
What then, stands in the way of disease control for Chagas? First, no major 
technological advances are required to interrupt vectorial transmission responsible for the 
majority of new cases; second, decades of research in the molecular mechanism of T. cruzi 
biology, the particularities of pathogenesis of the disease or the dynamics of immune 
response against the parasite have failed to translate into therapeutic alternatives; and 
finally, vaccination, either preventive or therapeutic, has remained an elusive achievement. 
The answer lies in a new drug. A new, safer, cheap, easy to administer and efficacious drug 
that is able to treat not only new cases, but also the millions of people already affected by 
the chronic stage and indeterminate form of the disease. There is growing evidence that 
chronic manifestations are ultimately related with inflammation resulting from parasite 
persistence [355, 356] and effective treatment of these cases would be highly beneficial to 
stop the development of symptomatology. 
Active drug discovery efforts for Chagas disease have been restricted, until some 
years ago, to just a very limited number of groups, mostly based in academia. As a 
consequence, results have been sporadic, slow, ineffective and highly dependent on 
intermittent funding, failing to deliver an alternative treatment. Chagas disease is as much 
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neglected by the pharmaceutical industry as it is by research funding agencies, whose 
majority of funds are directed to research in diseases affecting developed world populations. 
Only recently has drug discovery for Chagas been met with concerted, focused 
efforts. While still not privately embraced by pharmaceutical companies, public-private 
partnerships have been set up with the objective of bringing together the biology expertise 
from academia and the technical expertise, facilities and resources from pharmaceutical 
industries. One organization that is leading the effort to find new therapies for neglected 
diseases, including human trypanosomiasis, is the DNDi, that has been involved in 
coordinating activities from early drug discovery to the launch and conclusion of clinical 
trials for some candidates like inhibitors of ergosterol biosynthesis of T. cruzi. The Bill and 
Melinda Gates Foundation, a non-governmental organization devoted to human 
development in underdeveloped countries, has recently sign up the challenge of controlling 
neglected diseases by signing The London Declaration on Neglected Diseases together 
with the WHO, the World Bank and 13 leading pharmaceutical industries. The Declaration 
states that by 2020 the signers will achieve, among other ambitious milestones, the 
eradication of Human African trypanosomiasis (HAT) and the control of American 
trypanosomiasis. Since then, other initiatives have been launched with the objective of 
boosting the research in new drugs for trypanosomal diseases, like the European 
Commission Seventh Framework Program (FP7) consortia NMTrypI and KINDReD. The 
recent award of the Nobel Prize in Physiology or Medicine 2015 to William C. Campbell, 
Satoshi Omura and Youyou Tu is a recognition of the importance of drug discovery for 
parasitosis and should further increase the awareness of neglected diseases by the 
international community. 
Even with the recent involvement of new players and an increase of the scarce 
research funding, many challenges remain to what are the most effective strategies and 
models in drug discovery for trypanosomes. This thesis attempted to contribute with some 
insights to these challenges. 
 
 
5.2. Phenotypic-based drug discovery: a viable approach 
 
Pharmaceutical research and drug discovery for infectious disease has historically 
began with what would be classified today as phenotypic assays, and can be traced to the 
pioneering work of Paul Ehrlich in the 19th century while testing the effect of different dyes 
in trypanosomes [357]. Cultures of the microorganism of interest, be they a bacteria or a 
parasite, were incubated with a compound of interest, and the selective staining of the dyes 
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was monitored by microscopy. Products of such “dye therapy” approach were in the origin 
of well-known chemicals like the crystal violet dye, that was used in blood banks of endemic 
areas to kill T. cruzi parasites present in transfusion blood as a way to reduce transmission 
by this route [358]. Another example is trypan blue, that is still widely used as a cell biology 
reagent and that was the starting point for the design of the colorless analogue suramin, a 
drug still in use today for the treatment of HAT [359]. Such early whole cells drug screening 
principles were also central to the development of nifurtimox and benznidazole in the 1960s 
and 1970s, by the pharmaceutical companies Bayer and Roche, respectively [352]. 
With the genomic era there was a dramatic shift in the way new drugs were 
discovered. The past 20 years have witnessed incredible advancements in genomics, 
proteomics, structural biology, computational chemistry and structure based drug-design, 
that coupled with high-throughput screening and combinatorial chemistry have helped 
shape the reductionist mentality “one gene – one protein – one drug” [360]. However, the 
complexity of many diseases and the capacity of adaptation to adverse conditions, like the 
presence of a xenobiotic evidenced by many living cells, have brought the more naïve 
phenotypic whole-cell screening strategies back to the spotlight. With modern phenotypic 
approaches, the effect of a pure molecule in a fully intact whole living organism, bacteria, 
parasites or human-derived cell lines, results in the identification of hit compounds that are 
potentially more useful as scaffolds for medicinal chemistry optimization. 
While early phenotypic screenings for T. cruzi sometimes used the insect specific 
epimastigote stage due to its extracellular nature and easy of culture, the use of reporter 
genes expressed during the clinically relevant stage of the disease, the intracellular 
amastigotes, has met a widespread application. The first of such assays was based on the 
β-galactosidase-expressing parasites that made possible the detection of anti-T. cruzi 
activity by a colorimetric reaction [361]. Later, tdt-tomato and luciferase genes were also 
constitutively expressed in parasites, which allowed the more sensitive measurement of a 
fluorescent or luminescent signal, respectively [362]. 
However, the use of genetically unmodified parasites has always been an attractive 
pursuit, made available only recently due to technologic advancements. One such assay 
was developed by researchers at Institut Pasteur Korea and used in part of this thesis work 
(section 4.2.1.1). This cell-based assay employed the use of wild type parasites of T. cruzi 
infecting a non-modified cell line and the imaging of the resulting infection (in the amastigote 
stage) by high-content analysis (HCA) microscopy. Furthermore, the assay was developed 
in the 384-well format, allowing a high throughput testing of compounds. Preliminary cell 
toxicity is concomitantly determined by quantifying the ratio of host cell nuclei, a clear 
advantage since it reduces the need of an independent assay to access this parameter. 
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Statistical validation demonstrated it as a robust assay suitable for drug screening, as 
assessed by the z-factor of 0.81 [363]. Using this screening assay, a targeted library of 4000 
kinase/phosphatase-like inhibitors was screened and allowed the identification of 11 
compounds with strong antiparasitic activity and selectivity, suitable for follow up hit-to-lead 
optimization. In addition, a complementary assay developed for phenotypic profiling also 
allowed the identification of several compounds that interfered with the development and 
intracellular differentiation of T. cruzi. Compounds that hindered the differentiation from 
trypomastigotes to amastigote and the replication of amastigotes inside host cells are 
among the examples of “phenotypic” hits discovered. Because of the complex genetics and 
still many unknown aspects of T. cruzi biology, this type of compounds has the potential to 
constitute important chemical genomic tools that may help answering questions like: what 
triggers stage differentiation and what are the pathways involved? What factors are 
responsible for parasite persistence? How are amastigotes kept dormant for years to 
decades in host cells, hidden from the immune system? Due to the nature of the chemical 
library, it is likely that the compounds target kinases, of which the T. cruzi genome has 190 
annotated members [19]. T. cruzi and other trypanosomatids have a relatively big kinome 
when compared with other parasites that undergo several stage differentiation and contact 
with distinct environments like Plasmodium spp. [364, 365]. One hypothesis is that while in 
metazoa and yeast the ultimate targets of many signaling cascades are transcriptions 
factors which then trigger the expression of new sets of genes, trypanosomatids have 
constitutive transcription of a majority of genes in large polycistronic units, hinting at a 
greater role of PTMs like phosphorylation. The precise mechanism of action, however, will 
only be evaluated by target deconvolution. Another application of such phenotypic assays 
is the preliminary profiling and evaluation of the mechanism of action for established or 
newly discovered drugs for T. cruzi, for instance, as trypanocidal or trypanostatic agents. 
HCA assays are also valuable for the study of drugs already in use for the treatment 
of T. cruzi, such as nifurtimox (section 4.2.1.2). This drug, effective in the acute stage of the 
disease but possessing many side-effects that often lead to treatment interruption [352], is 
synthetized as a racemic mixture of R- and S-enantiomers. It was hypothesized that one of 
the enantiomers would be majorly contributing or solely responsible for toxicity, activity, or 
other pharmacokinetic and pharmacodynamic property of the medicine that might justify its 
use as a purified isomer. By using this assay on different strains (at least one representative 
of each discrete typing unit - DTU [366]), it was possible to verify that the sensitivity to 
nifurtimox varied among different genotypes, but individual genotypes had the same 
sensitivity to each individualized R- and S-enantiomer, as well as to the racemic mixture 
[367]. This study also allowed to conclude that the enantiomers were similar in what regards 
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to their in vitro cytotoxicity, physicochemical properties, in vitro metabolic stability and in 
vivo efficacy and pharmacokinetics [367]. As such, there is no benefit in separation of the 
racemic mixture. 
Two distinct families of compounds were also evaluated by an equivalent assay 
designed with C2C12 cardiomyocytes as host cells (section 4.2.1.3 and 4.2.1.4). A set of 
newly synthetized 7-aryltioetherthieno[3,2-b]pyridine analogues demonstrated to have 
some antiparasitic activity against trypanosomes, mostly T. brucei bloodstream forms and 
also with some analogues being active against T. cruzi amastigotes. However, cell toxicity 
NOAELs were similar to the dose of demonstrated antiparasitic activity, suggesting 
selectivity was reduced. A group of naphthalimide derivatives was also evaluated for their 
potential antiparasitic activity against T. brucei and T. cruzi. The majority of the compounds 
were inactive towards T. cruzi at 10 µM, with exceptions found in the subset of derivatives 
functionalized with a urea group. T. brucei bloodstream forms were more sensitive to all the 
groups of substituted naphthalimide derivatives, probably a consequence of their 
extracellular nature. Once more, however, host cell cytotoxicity precluded a high selectivity. 
Finally, specifically developed software allows the evaluation of not only compounds 
potency (IC50), but also efficacy (parasite clearance)[368]. A recent study comparing 
efficacy and potency of distinct drugs in use or undergoing clinical trials for Chagas disease 
with strains representative of different DTUs found that nitroheterocyclic compounds like 
benznidazole induced 100% of parasite killing contrary to posaconazole or ravuconazole, 
despite having an IC50 around 1000 times lower [369].   
The major disadvantages related with this screening method are the high costs of 
the technology that are not accessible to all laboratories, and the need of bioinformatics for 
the design and validation of the image analysis software/plugins. 
 
 
5.3. Target-based drug discovery: is Sir2 a potential drug target in Trypanosoma 
cruzi? 
 
Another strategy that can be employed in drug discovery is the target-based 
approach. In this case, the process begins and is centered on a particular molecular target. 
One family of proteins that has gained increased interest as potential drug targets against 
parasitic diseases is that of sirtuins [370, 371]. The hypothesis arose by the time that it was 
demonstrated that sirtuins are life-span regulators in organisms like yeast, flies and worms 
[231, 372, 373]. Many groups promptly investigate whether sirtuin orthologues were present 
in the genome of pathogenic organisms and if they also have important functions that could 
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be exploited for therapeutic applications. A sirtuin form T. brucei was the first trypanosomal 
sirtuin to be described and evaluated as a drug target. Although the protein had a clear 
NAD+-dependent deacetylase activity, in addition to ADP-ribosylation activity, and was 
important for the protection of DNA from damage caused by alkylating agents, RNAi 
experiments did not prove essentiality for T. brucei [317].  Later, another lab studying the 
same protein in bloodstream forms also reported that, in addition to the DNA protective role 
of Sir2rp1 and the participation in telomere gene silencing, the protein was not essential for 
the parasite, as demonstrated by both RNAi and gene knockout experiments [322]. In 
addition, the other two paralogues in T. brucei, TbSir2rp2 and TbSir2rp3 were also not 
essential for parasite survival [322]. Studies in L. infantum Sir2rp1, however, have disclosed 
an important role for the protein in in vitro and in vivo infections of the parasite. Double 
knockouts for the gene were never obtained, and both copies of the endogenous allele were 
only possible to delete when an ectopic copy was provided, thus strongly suggesting 
essentiality of the protein [308]. While L. infantum Sir2rp1 single knockouts did not have 
apparent defects on promastigotes replication, the multiplication of axenic and intracellular 
amastigotes was dramatically affected [308]. Furthermore, single knockouts failed to 
establish an infection in mice like the wild type parasites [308]. Over the course of the 
studies leading to this thesis, two publications reported a role of TcSir2rp1 and TcSir2rp3 in 
the epimastigote replication, metacyclogenesis, infectivity and amastigote replication in T. 
cruzi parasites, mounting up evidence that these proteins have important functions in 
different life-cycle stages [218, 219]. 
One important aspect for the viability of targeting sirtuins in parasites is the 
homology between the protein of interest and other proteins present in the host organisms. 
Although sirtuins are conserved through evolution [194], significant difference at the 
sequence level can be found between trypanosomatid and human homologues. For 
instance, T. cruzi Sir2rp1 shares only 33% identity with mammalian SIRT2, its closest 
homologue (Multi-way protein alignment, BLOSUM 62) [374]. 
Another argument that has led to the consideration of a T. cruzi sirtuin as a drug 
target is that this family of proteins is considered to possess structural properties adequate 
to inhibition by small-molecule compounds. In particular, the catalytic site is located inside 
a hydrophobic channel formed at the interface between the two constituting domains, the 
Rossman fold containing the NAD+ binding domain and the Zn2+ ion binding domain [215]. 
Catalytic pockets buried inside the protein are considered an essential feature for target 
druggability [375]. 
One last fact that prompted the evaluation of TcSir2rp1 as a drug target was the 
previous evidence that a class of experimental compounds preferentially inhibited LiSir2rp1 
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over the human homologue SIRT1 [376]. The synthesis of selective human sirtuin inhibitors 
has been successfully achieved based on structural knowledge of the catalytic site, like it 
has been demonstrated for SIRT2 [377, 378]. 
The first steps of the target-based drug discovery strategy were focused on the 
generation of knockout and overexpressing mutants for the Sir2rp1 gene in T. cruzi (section 
6.1). At the date of writing this thesis, all attempts at obtaining mutant parasites were 
unsuccessful and further efforts to their achievement are currently underway. 
In parallel to the time intensive genetic manipulation of T. cruzi, it was decided to 
proceed with the biochemical characterization of the molecular target. Amplification of the 
gene from CL Brener strain and its heterologous expression in E. coli as a recombinant 
protein produced an active sirtuin with NAD+-dependent deacetylase activity. In addition, it 
is mostly insensitive to TSA inhibition, allowing the classification as a canonical sirtuin 
belonging to the class III histones deacetylases. The kinetic characterization identified 
TcSir2rp1 as a bona fide sirtuin with robust deacetylation activity similar to the founding 
member yeast Sir2 [200]. The kinetic parameters Km and kcat of TcSir2rp1 for NAD+ were 
found to be highly similar to the ones of TbSir2rp1, despite just a 61% identity between 
them, suggesting structure conservation [325]. 
Enzymatic inhibition by small molecule compounds, an essential step in druggability 
assessment of novel therapeutic targets, was evaluated by nicotinamide, a classic non-
competitive inhibitor of sirtuins. TcSir2rp1 was inhibited by nicotinamide, albeit at a relatively 
high IC50 when compared with other sirtuins (4-fold higher for hSIRT1 and 11-fold higher for 
LiSir2rp1) [376]. Different nicotinamide sensitivities are found among distinct sirtuins, and 
may explain the differences described [378]. Nicotinamide inhibits deacetylation by binding 
to a conserved C pocket present in sirtuins that participates in NAD+ binding and catalysis, 
where it promotes a base-exchange reaction at the expense of deacetylation [379]. A 
hypothesis for the high IC50 for nicotinamide in TcSir2rp1 could be related with structural 
characteristics of this conserved C pocket. Structural determination of TcSir2rp1 by X-Ray 
crystallography currently ongoing in our group will certainly highlight these differences. 
Contrary to previous studies [380], we could not observe any antiparasitic activity of 
nicotinamide against T. cruzi amastigotes for up to a concentration of 2 mM. Several studies 
report the activity of nicotinamide against parasitic protozoa [381-383], but to our 
knowledge, none clearly establishes a relation between antiparasitic activity and sirtuin 
inhibition. 
Other biochemical functions and protein interactions have been attributed to Sir2rp1 
in related trypanosomatids, and future experiments should shed light whether it applies to 
TcSir2rp1. One of the biochemical functions that has been characterized for both TbSir2rp1 
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and LiSir2rp1 is ADP-ribosylation. Both orthologous showed to ADP-ribosylate calf thymus 
histones and BSA [317, 384]. Later studies involving TbSir2rp1 demonstrated that this 
biochemical function is dependent on acetylated histones, is coupled to the deacetylase 
activity of the sirtuin but occurs at a much lower rate than the latter [325]. In fact, even 
though ADP-ribosylation has clear functions in both physiological and pathogenic situations 
when catalyzed by other ADP-ribosyltransferases [384, 385], the reaction catalyzed by 
sirtuins is currently challenged to be an unspecific side-reaction [321]. 
Like the human SIRT2, L. infantum Sir2rp1 was also found to be associated with 
tubulin [309], the major component of trypanosomatids cytoskeleton formed by an array of 
subpellicular microtubules that span the whole cell of the parasite [53]. SIRT2 is a tubulin 
deacetylase that displays a higher affinity for tubulin than for histones [193], and has been 
found to be linked to regulation of mitotic progression [247], chromatin condensation [386] 
and cell migration [387]. TcSir2rp1 overexpression in T. cruzi was found to increase the 
deacetylation level of endogenous tubulin [218]. It is interesting to note that Sir2rp1 from T. 
cruzi is a cytoplasmic protein like LiSir2rp1 and not nuclear like T. brucei Sir2rp1. Since T. 
cruzi shares some characteristics with L. infantum like the amastigote intracellular stage, it 
should not be ruled out that Sir2rp1 may have functions in the cytoskeleton remodeling 
necessary for stage differentiation. Several proteins, sirtuins included, have demonstrated 
the ability to shuttle from the nucleus to the cytoplasm and vice-versa [388, 389]. SIRT2, 
the closest sirtuin homologue of mammalian cells, is actively exported to the cytoplasm 
during interphase, but is accumulated in the nucleus from prophase until cytokinesis where 
it co-localizes with important mitotic structures like centrosomes and the mitotic spindle 
[390]. Curiously, analysis of TcSir2rp1 by Wregex and cNLS Mapper, bio-computational 
tools that identify nuclear export signals (NES) and nuclear localization signals (NLS), 
respectively, indicate the presence of non-canonical NES/NLS in the sequence of this sirtuin 
[391, 392]. Whether TcSir2rp1 does shuttle to nucleus during particular moments of T. cruzi 
life cycle, for instance to repair DNA damage like the T. brucei orthologue, remains to be 
reported. 
In conclusion, biological relevance of other biochemical and cellular roles of 
TcSir2rp1 besides deacetylase activity shall be properly elucidated once mutants are 
generated. 
 
 
5.4. Naphthalimide derivatives: sirtuin inhibitors with trypanocidal activity 
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Naphthalimides are a class of compounds that have generated intense interest as 
active molecules with potential to treat a range of conditions [393]. A naphthalene ring linked 
to an imide group that forms a third heterocycle composes the basic chemical structure of 
naphthalimide derivatives. This moiety has a planar nature and is considered to be 
responsible for the pharmacological activities attributed to compounds derived from this 
structure, that can be as distinct as anticancer, antibacterial, antiprotozoal, antiviral, 
analgesic, and anesthetic [393]. Their potential as anticancer compounds has received 
particular attention, mostly because of their DNA intercalating properties and also to their 
reported activity as topoisomerase inhibitors [394-396]. Compounds like amonafide and 
bisnafide have been proposed as anticancer agents and have inclusively reached clinical 
trials in the past [397, 398]. Elinafide is another derivative with two naphathalimide moieties 
that has been evaluated in preclinical studies and demonstrated potential against various 
mouse xenograft models [399]. This last compound was in the origin of the synthesis of the 
first BNIPs that differed in the alkyl chain linking the naphthalimide and amine group - a 
propyl instead of an ethyl chain [400]. These derivatives showed potential activity against 
breast cancer MCF-7 cell line and actively bound DNA as demonstrated by thermal 
denaturation measurements, ethidium bromide displacement and DNA gel mobility [400]. 
Later derivatives that varied in the length of the chain linking the two amines of 
bisnaphthalimidopropyl groups were also evaluated against cancer cell lines and 
promastigotes of the parasite L. infantum [401]. While screening for enzymatic inhibitors of 
the recently characterized LiSir2rp1, BNIPs were identified as inhibitors of its deacetylase 
activity [376]. Furthermore, they were active against intracellular amastigotes, the clinically 
relevant stage of the parasite present in humans, at concentrations in the single micromolar 
range [376]. 
The promising results against L. infantum led to the testing of BNIPs as inhibitors of 
the related trypanosomatid T. brucei and its Sir2rp1 orthologue, TbSir2rp1 (section 4.2.2.1). 
BNIPs revealed to be very potent inhibitors of in vitro parasite growth, with one of the 
compounds, BNIPDabut with an IC50 in the range of the reference drug pentamidine. 
However, when tested against the TbSir2rp1 recombinant enzyme, BNIPDabut had an IC50 
more than 104 times superior to the IC50 against the whole cell parasite, indicating that 
Sir2rp1 inhibition is probably not a major mechanism of action for the compound. Whether 
BNIPDabut inhibits other T. brucei sirtuin enzymes remains to be elucidated. It should be 
noted that RNAi and gene knockout experiments of the three sirtuins did not led to a 
deleterious effect, and unlike LiSir2rp1, there is no indication of essentiality of these proteins 
[317, 322]. The optimal in vitro properties of BNIPDabut led to the testing with an in vivo 
model of trypanosomiasis by bioluminescence imaging. Although BNIPDabut maintained a 
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strong trypanocydal activity in vivo, as assessed by the decrease in bioluminescent signals 
to levels similar to those of the reference drug control pentamidine, it was not sufficient for 
infection clearance, as animals’ parasitaemias relapsed shortly after treatment interruption. 
Nevertheless, BNIPDabut should constitute a scaffold for further consideration in HAT drug 
discovery. 
BNIP derivatives were also tested against TcSir2rp1 and in vitro cultures of T. cruzi 
amastigotes (section 4.2.2.1). BNIPs demonstrated to inhibit the deacetylase activity of this 
enzyme, with BNIPSpd as the most potent compound, showing a dose-dependent effect on 
inhibition. BNIPSpd also proved to be active and selective against amastigotes of T. cruzi 
in a HCS assay. In this work, a new set of derivatives was also synthetized in order to 
improve both solubility and binding to cellular targets, mostly by including cyclic structures 
and heteroatoms in the carbon chain linking the two naphthalimide groups. The most active 
compounds were BCNIPP, also a TcSir2rp1 inhibitor, and trans BNIP-1,4-Dacyhex, a 
derivative of BNIPDabut that weakly inhibited the enzyme. In turn, BNIPDabut had some 
inhibitory activity on T. cruzi amastigotes, with low selectivity, but also didn’t inhibit 
TcSir2rp1 at 10 µM. The activity of BNIPSpd in a mice model of Chagas disease using 
bioluminescent parasites was also determined and found to be inexistent at the doses 
tested. An explanation might be the poor pharmacokinetic profile of the compounds, which 
fails to ever achieve at least the in vitro IC50 against T. cruzi amastigotes. 
Altogether, our data indicate that BNIP derivatives may not be acting entirely by a 
mechanism of Sir2rp1 inhibition, with other targets contributing to the activity detected. 
BNIPs were originally designed and developed as anti-cancer agents [402, 403] by a 
mechanism of DNA intercalation. This property might explain some of the cytotoxic effects 
verified against host cells, but may also be an important mechanism of activity towards the 
parasite, especially since trypanosomes are highly susceptible to intercalating agents [404]. 
The activity of mono naphthalimidopropyl derivatives was also assessed against T. brucei 
and T. cruzi parasites, but they were comparatively less active against the parasites, 
suggesting that a second naphthalimidopropyl group is essential for potency.  
Confirmation of the mechanism of action can be undertaken by appropriate target 
deconvolution experiments [405]. The most common are biochemical methods that employ 
some variation of biochemical affinity purification, where the compounds are immobilized in 
a column, and allowed to contact with protein extracts, preferably previously fractionated. 
After stringent washing steps, the bound proteins are eluted and identified. Such strategy 
has been employed in the identification of small molecule activators of cryptochrome of 
mammalian cells [406]. A disadvantage is that there is a bias towards high affinity ligands, 
and when the target is relatively less abundant or has less affinity, important targets may 
Part V – Discussion and conclusions 
189 
not be detected. Furthermore, the washing steps may eliminate protein complexes that may 
be important for appropriate drug activity. 
Genetic methods can also be valuable for target deconvolution. Gene knockouts 
and RNAi screens can be used to try to phenocopy a compound’s effect [407]. Furthermore, 
if the mutant is hypersensitive to the compound in question, the evidence that the protein 
could be the target for the compounds would be strengthened. The validation of 
trypanothione synthetase and N-myristoyltransferase as drug targets against 
trypananosomes are examples where the differential sensitivity of an inhibitor in wild type, 
overexpression, and knockout mutants is clearly illustrated [408, 409]. An additional genetic 
strategy is based on the generation of resistant cell lines by culturing the parasites in 
increasing sub-lethal drug concentrations that are posteriorly sequenced to find mutated 
genes related to the mechanism of action for the compound [407]. Genetic methods have 
recently been employed in the search of the mechanism of action of oxaboroles [410], a 
class of compounds in development for HAT, but also active against T. cruzi [411, 412]. 
Chemical genomics can also be applied to the discovery of novel drug targets, as 
exemplified by the recent characterization of cytochrome b from T. cruzi. This enzyme was 
demonstrated to be selectively targeted in relation to the human homologue by a hit 
compound coming from a phenotypic screening [413]. 
 
 
5.5. Phenotypic drug discovery versus target-based drug discovery: which strategy 
comes ahead? 
 
Drug discovery and development is a risky, costly and long endeavor [414]. Early 
2000s estimates put the price tag on a new drug around 800 million dollars, but that value 
has since increased at least two-fold [415]. It can take 12 years on average for a new entity 
to enter the market and only about 1 in every 10 compounds that enter clinical trials are 
eventually released [414]. Including the early drug discovery efforts, only 1 in about 50 
programs are successful [414]. Furthermore, despite the fact that neglected tropical 
diseases affect more than 1 billion people worldwide [416], only 0.3% of the funds spent in 
pharmaceutical industry research and development are allocated to these diseases [417]. 
The selection of the early drug discovery strategy is then of the utmost importance, 
especially in an underfunded area. Phenotypic and target-based approaches have long 
been the two main strategies to obtain the early scaffolds (hits and leads) that are the 
starting points of the to-be drug. Each strategy has its advantages and disadvantages, and 
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the focus on one of them will have to be adapted to each particular disease, the tools 
available and the expertise of the team. 
Target-based screening approaches are advantageous in that they are driven by 
specific hypothesis that take advantage of advancements in genome biology and molecular 
tools. The strategy is focused on a certain gene or pathway that has previously been 
characterized and is properly understood. Furthermore, this strategy can directly benefit 
from structural biology and computational screening and drug design as valuable discovery 
tools. Finally, because screening of compounds is most of the times based on enzymatic 
assays, they are amenable to high throughput screening [360]. 
On the other hand, target-based screening can also have some disadvantages, like 
the focus on a relatively small biological environment, reproduced in artificial in vitro 
conditions that neglects the complex intracellular environment and the multitude of 
interactions and interferences that may take place. Also, there are some challenges in what 
regards the translation to an in vivo disease state, where additional complexity may render 
the target irrelevant for modulation. In addition, there is the possibility of in vivo 
compensatory mechanisms that may null the effect of action at a specific target [360]. 
Phenotypic strategies are an un-biased approach, allowing the interrogation of 
complex biological systems as a whole. They have the advantage of being target-free, 
which may translate better into activity in a human disease state. Beneficial drug properties 
like cell permeability and no resistance to efflux pumps ensure that the compound reaches 
its molecular target in the cell. Potential toxicity of the hit compounds can also in principal 
be detected earlier than with hits coming from target-based screenings [360]. Some 
disadvantages of the phenotypic strategies are the unknown mechanism of action of the 
compounds that requires appropriate target deconvolution studies. This aspect may hinder 
lead optimization, which most times rely on some knowledge about the molecular target. 
The optimization may be further complicated by the potential effect of the compound in 
several molecular targets. Since most assays require cell culture, the throughput may be 
potentially lower. However, recent developments in high-throughput technology have 
allowed phenotypic assays to catch up with target-based screening [360]. 
This thesis employed both approaches to the early drug discovery for T. cruzi. The 
target-based approach sought the validation of a protein, TcSir2rp1 by both genetic and 
chemical validation. The genetic validation of targets for T. cruzi has been hindered by the 
particular resistance to genetic manipulation by the parasite [418]. Successful genetic 
validation of a molecular target is affected by a number of characteristic, like the availability 
of inducible and non-inducible expression vectors, the number of drug resistance markers 
characterized and genetic and physiologic properties of the organism in question [419]. 
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Important feature to consider for a successful validation are: the number of gene copies, 
the ploidy of the organism, the ease of transfection and in vitro culture, the susceptibility to 
drug selection and the occurrence of sexual recombination [419]. The molecular toolbox for 
T. cruzi lags beyond what is available for other trypanosomes, like T. brucei, and has been 
slowly enriched overtime with advances like overexpression vectors [420], a tet-regulated 
inducible vector [421], and adaptation to gateway technology [422, 423]. Any information 
regarding the essentiality of a given protein to the biology of T. cruzi has therefore relied in 
time-consuming and inefficient traditional gene knockout methods [418]. These limitations 
were reflected in the difficulties in obtaining gene knockouts undertaken during this thesis. 
One of the examples was the generation of hygromycin resistant parasites when one of the 
Sir2rp1 deletion constructs was transfected as a circular DNA molecule, but not when the 
same construct was transfected as a linear molecule with the objective of gene replacement 
(section 6.1). 
Gene knockouts can be achieved by gene disruption, when the coding sequence is 
interrupted by exogenous DNA and leading to an unnatural transcript and dysfunctional 
protein, or by gene replacement, that is considered a cleaner approach due to the absence 
of partially active or toxic proteins/peptides [424]. When a gene is successfully knocked out, 
care must be taken as to draw the appropriate conclusions: the lack of essentiality must be 
only considered as to that particular stage and particular culturing conditions [419]. This is 
especially true for T. cruzi, since the life-cycle stage commonly genetically manipulated is 
the epimastigote, characteristic of the insect vector and not present in disease context. If a 
strategy fails to achieve or evade gene replacement, then the gene may be considered as 
essential. Events like insertion of the sequence in another part of the genome, increase in 
chromosome number or compensatory genetic mutations have all been described to occur 
in trypanosomatids and are an indication of essentiality [425]. Nevertheless, confirmation 
should be undertaken by nutritional or genetic rescue [426, 427]. Newer technologies like 
CRISPR/Cas9 gene editing have recently been applied to the genetic manipulation of T. 
cruzi, and should bring some advancements in this area [58, 428]. 
On the other hand, chemical validation has been the most exploited target validation 
strategy for Chagas disease. Some examples are the targets cruzain and CYP51 that have 
had inhibitors tested in preclinical and clinical trials [173, 429]. In the basis of this approach 
is the specific inhibition of a target by a small molecule that is later evaluated as to their 
potential in inhibiting the growth or cause the death of the parasite. Using this strategy, the 
compounds selected address some druggability issues, like cell permeability or in vitro 
metabolism. A disadvantage is the possible inexistence of specific inhibitors, or the poor 
translation of in vitro enzymatic assay IC50 to the whole parasite assay IC50. 
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In the present work, the BNIP derivatives were used in the attempt to chemically 
validate TcSir2rp1 as a potential drug target against Chagas disease. Some of the 
derivatives were active against the enzyme, and a significant portion was also active in vitro 
against amastigotes. One of the limitations of the study was the unavailability of a specific 
inhibitor of TcSir2rp1. BNIPSpd was the closest compound that could be considered as 
such, since it strongly inhibited the enzyme in a dose-dependent manner, and also had in 
vitro potency against amastigotes. 
By contrast, the phenotypic strategy employed for T. cruzi was able to find a higher 
number of active inhibitors than the target-based approach, but also inhibitors with a high 
selectivity index for the parasite (section 4.2.1.1). It should be noted, however, that the 
phenotypic approach was started with a much higher number of starting compounds, and 
the chances of finding active hits were higher. Although the exact mechanism of action is 
not known for any of the compounds, this screening strategy presented some advantages: 
all hit compounds already possess adequate cell permeability, selectivity towards the 
parasite and have suitable in vitro drug metabolism and pharmacokinetics. 
But which strategy should be prioritized? Recent data from the pharmaceutical 
industry as a whole indicate the trend. Analysis of the first in class molecular entities 
approved by the American Food and Drug Administration (FDA) in the years 1999 to 2008 
reveal that 28 of those drugs were discovered by employing phenotypic assays in early drug 
discovery, whereas only 17 entities were discovered by target-based approaches [430]. 
The example of drug discovery for tuberculosis, an intracellular bacteria, is a clear 
example in infectious diseases drug discovery: despite the genome being sequenced in 
1988 [431] and many well characterized targets having been reported since then, also with 
good targeting drugs, most of them have failed to advance as clinical leads [432]. By 
contrast, the phenotypic approach has led to the approval of drugs like bedaquiline [433] 
recently approved by the FDA [434], delamanid approved by the European Medicines 
Agency [435], or pretomanid [436] and Q203 [437] that have begun phase II and phase I 
clinical trials, respectively. 
Finally, some lessons can be drawn from compounds that are used currently in the 
therapeutic for neglected tropical diseases and support the preference for phenotypic 
assays: first, they allow the exploitation of non-protein drug targets, like is the case of 
amphotericin B that acts through a mechanism involving the formation of pores at the 
ergosterol-rich membrane of Leishmania [438, 439]; second, they uncover pro-drugs, that 
are compounds that undergo bio-activation in parasite cells as are the examples of 
nitroheterocylces benznidazole and nifurtimox used in Chagas disease [352] or the case of 
allopurinol in leishmaniasis [440]; and finally, they would allow the identification of drugs like 
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arsenical compounds that are active because of selective concentration by trypanosomal 
transporters [441]. Any of this compounds and respective valid drug targets would be 
missed and could not be reliably predicted using current genomic tools extensively applied 
in target-based approaches. 
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6.1. Generation of molecular tools for essentiality evaluation of Sir2 related protein 1 
from Trypanosoma cruzi 
 
 
Data not published 
 
 
Objectives of the study: 
 
The genetic validation of Trypanosoma cruzi Sir2 related protein 1 (TcSir2rp1) is an 
important step in the validation of this protein as a drug target in the parasite. We describe 
the generation of the molecular tools necessary for the knockout of TcSir2rp1 by classic 
gene deletion by homology recombination, as well as the first two attempts at generating 
mutant T. cruzi cell lines. 
 
 
Main results: 
 
→ Two deletion constructs were successfully synthetized by fusion PCR, as well as an 
overexpression plasmid by traditional cloning; 
 
→ In the attempts at generating mutants, although it was possible to obtain resistant 
cultures for some controls, no gene knockout parasites were obtained. 
 
 
Conclusion: 
 
Even though the synthesis of the molecular tools for the genetic manipulation of T. 
cruzi is relatively straightforward, the successful generation of mutant cell lines is difficult 
and time consuming. Additional attempts and the use of newer technologies should 
increase the chances of obtaining the desired genotype.  
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METHODOLOGIES 
 
Parasite culture 
Trypanosoma cruzi epimastigotes from CL Brener or Y strain were grown at 28ºC in 
LIT medium supplemented with 20 mg/L haemin and 10% heat inactivated FBS [442]. 
Cultures were maintained at logarithmic growth by dilution when density reached 1x107 
parasites/mL. 
 
Generation of knockout, overexpression and rescue constructs 
The primers used for the generation of constructs for genetic manipulation were 
synthesized based on the CL Brener Esmeraldo-like sequence of T. cruzi Sir2 related 
protein 1 available in TriTrypDB as a template (Table 1, accession number: XP_818420.1). 
All the constructs’ synthesis accuracy was checked by DNA Sanger sequencing. Sir2rp1 
gene replacement cassettes were generated by fusion PCR as previously described [443] 
(represented in Figure 1). Briefly, a region of DNA comprising the ~600 bp of the 5’-
untranslated region (UTR) and the ~500 bp of the 3’-UTR amplified from genomic DNA 
(primers 10+11/12 and 13/14+15, respectively) were fused by PCR to the ORF of the 
selective markers for drug resistance genes PAC (puromycin N-acetyltransferase) and HYG 
(hygromycin phosphotransferase). The fusion constructs were posteriorly TA cloned into 
pGEM for amplification and cut from the backbone with NotI. The overexpression/rescue 
plasmid was generated by amplifying the coding sequence of TcSir2rp1 (Primer 22+23) 
from genomic DNA and cloned into pTREX with XbaI and XhoI restriction sites [444]. 
 
Table 1. Primers used in the present study. 
Primers Sequence 
LGP010 TGACACATGCGTGCAGTGAG 
LGP011 GGTGAGTTCAGGCTTTTTCATTGGGAAGAAGTAATCCACCTGGC 
LGP012 GTGGGCTTGTACTCGGTCATTGGGAAGAAGTAATCCACCT 
LGP013 GTCCGAGGGCAAAGGAATAGGAGGAAAAGCGGCTGAAATAAAG 
LGP014 GACCCGCAAGCCCGGTGCCTGAGAGGAAAAGCGGCTGAAATAAAG 
LGP015 ATTTATCTTGCCTCTCCCCTCAC 
LGP022 TCTAGAATGAATCAAGATAACGCCAACTTT 
LGP023 CTCGAGTTATTTTCGGTCTGTCTGTGTGTA 
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Figure 1. Schematic of the fusion PCR protocol employed in the 
generation of knockout cassettes for TcSir2rp1. 
 
Parasites transfection and selection  
Transfection of T. cruzi epimastigotes was performed with an Amaxa Nucleofector 
electroporator like described previously [422]. A total quantity of 5-10 µg of DNA was 
transfected into logarithmic growing parasites (1x107 per transfection) suspended in Human 
T-cell Nucleofector solution (100 µl). using the program U-33, V-33 or X-01. Twenty-four 
hours after transfection, selection drugs were added to the cultures of parasites: puromycin 
2 µg/mL, geneticin 100 µg/mL and hygromycin 75-500 µg/mL.  
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RESULTS AND DISCUSSION 
 
The evaluation of essentiality of a gene in T. cruzi, as well as in other pathogens, is 
an essential step in the characterization of the respective protein as a potential drug target. 
The lack of RNAi machinery has greatly hindered the evaluation of new drug targets in T. 
cruzi. Apparently some of its components have been lost or mutated during evolution [445, 
446]. By comparison, in T. brucei, where RNAi is functional, the quantity of potential drug 
targets, as well as the overall understanding of its biology, is much more extensive. As a 
consequence, gene essentiality evaluation in T. cruzi has been relying in traditional 
homology recombination, and has not evolved with other gene editing technologies. 
This work attempted the generation of mutant cell lines of T. cruzi where the gene 
of Sir2rp1 would be removed from the parasite genome. In order to achieve the deletion of 
the endogenous copies of the gene, two cassettes containing the PAC and HYG selection 
marker flanked by UTRs of TcSir2rp1 were synthetized (Figure 1). In addition to the deletion 
constructs, one plasmid for expression of an ectopic copy that could be used for 
overexpression or complementation for facilitated double endogenous allele replacement, 
was synthetized. The experimental approach is represented in Figure 2 A. Although the 
protocol in which the fusion PCR was based [443] reports a high efficiency in the double 
fusion (5’UTR + Selection Marker (SM) + 3’UTR), in this work it was only possible to obtain 
single fusions (5’UTR + (selection marker) SM and SM + 3’UTR) for both constructs. The 
final construct was then obtained by fusion of the two single fusions (5’UTR-SM + SM-
3’UTR). Sequencing of the puromycin knockout cassette revealed no mutations in the 
selection marker, and only occasional indels in the UTRs. However, their frequency was 
considered to not interfere with homologous recombination. The cassette for hygromycin 
included one mutation that resulted in change of aminoacid in the coding sequence of the 
selective marker. However, when the construct was transfected in the circular pGEM vector 
(Figure 2 B), parasites were viable and successfully acquired resistance to hygromycin, 
suggesting that the mutation was not interfering with resistance to the drug.  
In the first transfection experiment (Figure 2 B), 5 µg of HYG cassette both as a 
circular plasmid in pGEM and linearized by NotI was transfected using program U-33 and 
CL Brener strain epimastigotes. After 7 weeks of selection with hygromycin at 500 µg/mL, 
only the circular construct in pGEM-transfected parasites were viable, whereas the 
linearized construct did not produce any viable parasites up to 10 weeks of selection. The 
parasite is able to uptake circular DNA molecules and maintain them as extrachromosomal 
circular elements composed of head-to-tail tandem repeats of the vector [447], but is less 
amenable to gene deletion [422] which might explain the results obtained. 
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In the second transfection experiment (Figure 2 B), a higher quantity of each linearized DNA 
deletion cassette and circular pTREX plasmid was used (10 µg per transfection) in Y strain 
epimastigotes, using the V-33 program. Although by 4 weeks of selection, the negative 
control cultures (epimastigotes transfected without DNA and subject to selection drug) were 
dead, after 8 weeks of selection none of the DNA-transfected cultures had viable parasites, 
including the pTREX overexpression plasmid, indication a likely experimental or biologic 
limitation. 
Additional attempts are recommended for the generation of TcSir2rp1 gene 
knockouts. CRISPR/Cas9 technology has recently been applied to T. cruzi genetics and 
should constitute an advancement over traditional techniques [58]. 
 
 
Figure 2. Transfections of Trypanosoma cruzi. A) Experimental approach for the 
generation of TcSir2rp1 null or facilitated null mutants. B) Transfection attempts 
with the knockout cassettes and overexpression/rescue plasmid. 
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